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Abstract 
Osteoporosis is a condition that results from substantially weakened bone, increasing an 
individual’s risk of fracture. Post-menopausal osteoporosis is the most common form of 
the condition, affecting 30% of post-menopausal women over the age of 50. Following 
the menopause, female oestrogen levels decline and this perturbs bone homeostasis by 
promoting an environment that is biased towards bone erosion. Osteoclasts are the cells 
responsible for eroding bone and are normally inhibited by oestrogen. However, the 
decline in oestrogen production results in increased osteoclast differentiation and 
activity. This rapidly decreases the bone mineral density and results in fracture-prone 
bone. Osteoclasts are derived from mononuclear myeloid progenitors found in the blood 
and bone marrow, which fuse to form large multinucleated cells that reside in the bone 
cavity. These progenitor cells are also responsible for replenishing monocytes, 
macrophages and dendritic cells. One class of receptors present on the surface of these 
cells, which are capable of dictating a cells function, are Fcγ receptors and modulation 
of Fcγ receptors has been shown to inhibit the differentiation of human monocytes to 
osteoclasts. 
This thesis investigates Fcγ receptor modulation on murine osteoclastogenesis and in 
order to stimulate Fcγ receptors, both IgG and IgG complexes were used. IgG complexes 
were generated using Staphylococcus aureus Protein A (SpA) in combination with IgG to 
form SpA-IgG complexes (SIC). We show that IgG and SIC are capable of engaging with 
Fcγ receptors resulting in the inhibition of osteoclast differentiation. Furthermore, both 
IgG and SIC inhibit the transcription of mRNA essential for the fusion of progenitors and 
enzymes for the erosion of bone matrix. Therefore, IgG and SIC are capable of inhibiting 
murine osteoclastogenesis.   
The murine model of osteoporosis was used to further investigate the ability of SIC to 
inhibit murine osteoclast differentiation. Previous studies have shown that when SpA is 
administered in vivo it is capable of binding circulating IgG to form SIC. We used this 
property to test the ability of SpA to bind to the surface of monocytes. SpA was found 
to bind with highest affinity to blood Ly6Chigh monocytes, which are known to 
differentiate in vitro to OCs. IgG and SIC were also able to inhibit the in vitro 
osteoclastogenesis of Ly6Chigh monocytes. It was hypothesised that SpA would co-opt IgG 
and inhibit the in vivo differentiation of progenitors to osteoclasts in the ovariectomy 
model of osteoporosis. To generate this animal model the ovaries were removed from 
the mice in order to simulate the menopause and induce bone loss. To assess the 
percentage of bone present after ovariectomy, we used micro-computer tomography 
and discovered that SpA was unable to prevent bone loss associated with ovariectomy. 
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Therefore, SpA can bind to the surface of osteoclast progenitors but is unable to inhibit 
bone loss in the model of osteoporosis. 
In addition to studying the role of Fcγ receptor modulation of osteoclastogenesis, the 
role of Bcl-3 (a negative regulator of NF-κB) in osteoclast differentiation and bone 
remodelling was also investigated. NF-κB is an essential signalling molecule and 
transcription factor involved in osteoclast differentiation. Previous research has shown 
that in the absence of Bcl-3 (Bcl-3-/-) aberrant cytokine responses to LPS and TNF- 
occur.  Therefore, RANKL stimulation of WT and Bcl-3-/- osteoclast precursors was done 
to determine whether Bcl-3-/- animals responded aberrantly to RANKL. WT and Bcl-3-/- 
animals were able to generate in vitro osteoclasts, which were phenotypically and 
transcriptionally similar. However, comparison of in vivo osteoclast progenitors revealed 
that Bcl-3-/- animals had reduced CD115+ osteoclast progenitors compared to WT 
animals. Examination of the trabecular bone present in the proximal tibia revealed that 
Bcl-3-/- animals had a higher percentage of bone present that WT controls. Therefore, 
Bcl-3 does not effect in vitro osteoclast differentiation but further work needs to be 
done to understand the role of Bcl-3 in bone remodelling. 
This thesis aimed to investigate whether SpA-IgG complexes or Bcl-3 could represent a 
novel avenue of therapeutic intervention in osteoporotic disease. In summation, SpA is 
able to form IgG complexes that can inhibit the differentiation of OCs in vitro; however, 
treatment of osteoporotic animals with SpA was unable to halt bone loss. This suggests 
that SpA-IgG complexes are able to modulate Fcγ receptors in vitro and skew 
progenitors from differentiation into osteoclasts but cannot overcome the prevailing 
pro-osteoclastogenic environment that results from ovariectomy. The presence of 
osteoclast progenitors was also shown to be partially dependent on Bcl-3 and as such 
Bcl-3 may be a novel target for therapeutic agents to target osteoclast progenitors in 
diseases like osteoporosis. However, the role of Bcl-3 in bone remodelling requires 
further investigation.  
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1 Introduction 
1.1 Osteoimmunology 
Osteoimmunology is the study of the interactions between the immune and skeletal 
system1. Many factors produced by cells of the immune system promote immunity as 
well as being essential in the maintenance of bone integrity1. Evidence is growing that 
the interactions between T cells, B cells, Macrophages (MØ), Osteoclasts (OC) and 
Osteoblasts (OB) within the bone marrow (BM) are vital for homeostatic bone 
remodelling1. T and B cells from the adaptive immune system and MØ which bridge the 
innate and adaptive immune system interact with OCs and OBs, which are involved in 
bone modelling and remodelling1. Despite arising from separate lineages, T cells and 
OCs share the same essential transcription factors2, B cells and OBs secrete negative 
regulators of OC differentiation (see section 1.3.4)3 and MØ and OCs share the same 
progenitors prior to terminal differentiation4. However, this intimate link between the 
immune and skeletal system can become perturbed. In diseases like osteoporosis, 
oestrogen deficiency results in dysregulation of immune cells. This causes the 
production of factors which drive the differentiation of OCs, leading to global bone 
loss5. Therefore, establishing the interactions between immune and skeletal cells allows 
for dissection of osteoporotic pathogenesis.     
In bone biology three main cell types remodel bone: OCs, OBs and osteocytes each play 
a vital role in modelling and remodelling the skeletal system. OCs differentiate from 
precursors of the monocyte lineage that are present in blood and reside within the BM4. 
Following the appropriate stimulation, monocytes will express essential 
osteoclastogenic proteins and begin to fuse (see sections 1.3 and 1.4)6,7. Fusion results 
in the formation of a multinucleated OC which attaches onto the surface of the bone 
matrix7. OCs form a tightly sealed zone and a ruffled border creating an isolated section 
of bone matrix directly beneath the OC8. At this point the OC begins to acidify the 
matrix and secrete enzymes such as Tartrate resistant acid phosphatase (TRAP), Matrix 
Metalloproteinase 9 (MMP9) and Cathepsin K to resorb the bone7–12. 
In contrast, OBs differentiate from a mesenchymal origin and secrete organic 
molecules, such as collagen type I, osteocalcin and osteopontin, as they migrate over 
the surface of eroded bone matrix13. These organic molecules, mainly collagen type I, 
bind extracellular calcium ions (Ca2+) which results in mineralisation and bone 
formation14. OBs can remain on the surface of eroded bone and allow themselves to 
become cocooned in the extracellular matrix. OBs which do this are then known as 
osteocytes13. Osteocytes are immobilised but remain connected to other osteocytes by 
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an extensive series of canals15. This shifts their role from bone formation to mechanical 
stress sensing in order to coordinate the bone remodelling process15. 
Together these three cell types regulate bone homeostasis in a system called the basic 
multicellular unit (BMU)16. The BMU involves a coordinated series of events in which OCs 
differentiate and settle on bone, initiating the erosive phase of the BMU. OCs migrate 
across bone matrix and form trenches of eroded bone13. OCs have an average lifespan of 
12 days before they apoptose allowing OBs to begin the lengthy process of secreting 
new organic matrix16. The bone formation phase of BMU can last as long as 3 months, as 
secreted organic matrix slowly binds circulating Ca2+ for mineralisation13. This temporal 
discrepancy in the bone resorption and formation phases of the BMU can become 
perturbed resulting in bone disorders. Despite, the rate at which bone formation and 
resorption occur, the purpose of bone modelling and remodelling is to maintain bone 
integrity16. Bone modelling occurs in order to respond to changes in mechanical load 
resulting in altered structure, size and shape of bones ensuring that the musculoskeletal 
system is able to meet the physical demands17. While, bone remodelling occurs to 
remove damaged bone and is stimulated by osteocyte death15. However, in diseases like 
osteoporosis bone loss exceeds bone formation resulting in pathologically weakened 
bone16. 
1.2 Post-menopausal osteoporosis 
Osteoporosis is a physical state in which there is sufficient bone loss to pose an 
increased risk of fracture. The disease can be categorised into either primary or 
secondary osteoporosis18. Primary osteoporosis is bone loss due to intrinsic factors such 
as menopause, aging or genetic factors19. While secondary osteoporosis occurs usually 
following medical intervention for other conditions such as Cushing’s disease which 
requires long term glucocorticoid treatment resulting in osteoporotic fractures in 
30-50% of patients20. Osteoporotic fractures in the elderly are a major cause of 
disability and can increase mortality rates21. Clinical osteoporosis is diagnosed by 
measuring the percentage of bone present in femoral head by dual-energy x-ray 
absorptiometry (DXA)22. DXA uses x-ray images of the patient’s femoral head and can 
provide insight into the micro-architecture of a patient’s bones. To make a diagnosis, 
the percentage of bone present in the patient’s femoral head is compared to that of a 
healthy sex-matched individual22. If the patient’s percentage of bone is over 2.5 
standard deviations or more below that of a healthy individual then that patient is 
diagnosed with osteoporosis. This method of diagnosis is referred to as the T score and 
this can be used to diagnose osteoporosis in both sexes22. The potential fracture risk 
increases as the mineral density of the bone decreases and studies have shown that the 
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lifetime risk of a female, aged 50 or over, suffering a hip fracture is 15%22. Thus 
diagnosing osteoporosis prior to fracture allows time for treatments to be initiated to 
slow the rate of bone loss and limit hazards which may lead to fractures. 
Post-menopausal osteoporosis (PMO), or Type I osteoporosis, occurs in 30% of 
post-menopausal women and is caused by a decline in the production of oestrogen by 
the ovaries19. The ovaries are small nodular organs located either side of the uterine 
fallopian tubes which are involved in coordination of menstrual cycle. The release of 
follicle-stimulating hormone (FSH) from the pituitary glands induces oestrogen 
production by the ovaries and rising concentrations of oestrogen mark stages of the 
menstrual cycle23. This cycle prepares the uterus for implantation and pregnancy.  
Several hormones are involved in the monthly cycle including gonadotrophin-releasing 
hormone (GnRH), FSH, luteinizing hormone (LH), oestrogen and progesterone (Table 
1-1)24. Rodents experience similar reproductive cycles to humans requiring the 
aforementioned hormones25. However, unlike human menses, rodents reabsorb the 
uterus, rather than shed their menses, at the end of their oestrous cycles which lasts 
approximately 5-6 days for mice and 4-5 days for rats26,27.  
 
 
Figure 1-1: Synthesis of oestrogens from cholesterol. 
Cholesterol is converted to multiple sex steroids depending on the physiological requirements of 
the body. Enzymes involved in producing sex steroids are in blue. Adapted diagram24,28. 
 
Oestrogen plays a pivotal role in both the menstrual and oestrous cycle. It is synthesised 
from cholesterol by thecal cells in the ovaries in response to FSH. However, oestrogen is 
the collective name given to three related hormones; oestrone, oestriol and the most 
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biologically active form oestradiol28. Hereafter, the term oestrogen will be used to 
encompass all isoforms, unless specifically stated. The levels of oestrogen vary 
throughout the female menstrual cycle from 50ng/ml to 250ng/ml29. The biosynthesis of 
oestrogen is a multi-step process in which cholesterol is converted to progesterone and 
the androgen, androsterodione28. Androsterodione is then converted directly to oestrone 
or oestriol by aromatase or converted to testosterone by 17β hydroxysteroid 
dehydrogenase (HSD)28. Testosterone is then finally converted to oestradiol by 
aromatase (Figure 1-1)28.  
 
 
Table 1-1: Hormones involved in human and rodent reproductive cycles. 
Adapted table24. 
 
1.2.1 Therapies for post-menopausal osteoporosis 
The menopause refers to a period in the female reproductive cycle when the final 
oocyte is released by the ovary and the level of oestrogen decreases. The decline in 
oestrogen results in the commencement of menopausal symptoms such as hot flushes, 
neurological problems, weight gain and bone loss30. In order to combat these symptoms 
and reduce the fracture risk hormone replacement therapy (HRT) is given. This supplies 
the body with oestrogen or oestrogen mimetics with or without progesterone 
derivatives31. These therapies are successful in preventing PMO; however, long term 
exposure to oestrogen and progesterone can increase the risk of cancer, cardiovascular 
disease and neurological issues31. Raloxifene, a non-hormonal selective oestrogen 
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receptor modulator has been shown to decrease fracture risk, however, there remained 
the increased risk of side effects including cramps and thromboembolisms32. Another 
group of drugs which is frequently used to treat osteoporosis are bisphosphonates which 
can bind to the bone matrix and upon resorption are ingested by OCs and induce 
apoptosis33. Bisphosphonates effectively eliminate bone resorption. However, these 
drugs can have adverse side effects such as fever, oesophageal irritation, osteonecrosis, 
severely reduced bone remodelling and increased risk of cancer34. Humanised 
monoclonal antibodies which target RANKL and sclerostin have been shown to be safe 
and effective at increasing bone mass in post-menopausal osteoporosis35,36. However, 
these monoclonal antibodies are costly and must be administered in high doses to be 
effective35,36. This has resulted in research focused at generating small peptides with 
the potential to engage the hinge region of RANK, preventing the conformational change 
which results in intracellular signalling, however, preclinical trials have still to be 
undertaken37. Therefore, there is an absence of a safe, efficacious and ultimately cost 
effective therapeutic designed for the treatment of post menopausal osteoporosis. The 
research presented in this thesis will aim to demonstrate novel avenues of investigation. 
1.2.2 Animal models of osteoporosis 
In order to mimic human osteoporosis, animals are ovariectomised (OVX) thus removing 
the predominant source of oestrogen from their system28. The rodent model of 
osteoporosis was first described by Salville in 196938. OVX surgery results in an oestrogen 
deficient system in which rapid trabecular bone loss is observed39. Inducing osteoporotic 
disease by surgical removal of the ovaries has been studied in a range of mammals 
including monkeys, dogs, rats and mice40. Monkeys in particular appear to be a good 
model organism for studying osteoporosis as they naturally undergo age-related bone 
loss and have a natural menopause40. However, these are costly experiments with large 
waiting times before assessment of bone loss40. Dogs are also used to study osteoporosis 
due to bone morphological similarities to humans40. However, only age-related bone loss 
can be studied in dogs, as they are resistant to OVX induced bone loss40. Rodents (rats 
and mice) are frequently used to study osteoporosis due to the rapid bone remodelling, 
reproducibility and ease of use40. Rodents naturally do not develop ‘osteoporosis’ in a 
similar manner to humans; however, both rodents and humans lose bone mass with 
age41. The main difference is that human age and menopausal related bone loss can 
lead to fractures of the vertebrae and femoral head which does not occur in rodents19. 
Despite this difference both the rodent model and human osteoporotic disease results in 
loss of the trabecular structures of the femur, tibia and vertebrae due to over active 
OCs and an inability of OBs to replace eroded bone.    
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1.2.3 Pathogenesis of oestrogen deficiency 
In recent years, and due to the availability of genetically engineered animals, the 
pathways involved in the rodent model of osteoporosis have been examined. In the rat 
model of OVX, early continuous treatment with oestradiol prevented bone loss by 
reducing OC numbers and stabilising the hormone balance42. Combined treatment of 
oestrogen and PTH was effective in the OVX model by preventing bone loss and 
increasing bone formation42. Administration of oestradiol to OVX mice prevents bone 
loss and as a consequence also decreases bone formation highlighting the tightly 
regulated nature of bone remodelling43,44. Interestingly, OVX mice treated with 
oestradiol have reduced weight gain45. These findings mirror results obtained from 
post-menopausal women receiving long term HRT, who had higher bone mineral density 
and decreased weight compared to placebo controls46,47. Oestradiol also induces OPG 
secretion and as such, during PMO insufficient oestrodiol levels result in lower OPG 
levels and increases the risk of developing osteoporosis48. 
The absence of oestrogen can cause systemic effects and one example of this is that 
oestrogen deficiency increases the number of CD25+ T cells present in the spleens of 
OVX animals, which arise in an IFN-γ dependent manner49. MØ taken from OVX animals 
are highly responsive to IFN-γ, producing pro-inflammatory cytokines IL-12 and IL-18, 
which are known to induce T cell proliferation and survival49. This increase in T cell 
numbers and IFN-γ primed MØ results in an activated immune state, with OVX animals 
possessing more than double the number of TNF-α producing T cells in the BM compared 
to controls49. As previously mentioned, T cells are capable of expressing RANKL and 
initiating osteoclastogenesis50. Interestingly, the roles of IFN-γ and IFN-γ Receptor 
(IFN-γR) have not been fully elucidated. IFN-γR-/- C57Bl/6 animals suffer OVX induced 
bone loss while IFN-γR-/- DO11.10 animals are spared from OVX induced bone loss49,51.  
However, Duque et al (2011) went onto show that IFN-γ given therapeutically can 
increase bone mass in sham and OVX operated C57Bl/6 mice51. This suggests that IFN-γ 
may negatively regulate OCs in a strain specific manner and further work must be done 
to fully elucidate IFN-γ’s effects on bone remodelling. 
The importance of T cells in bone remodelling as already been discussed (see section 
1.4.2), however T and B cells contribute to osteoporosis. T and B cell expansion and 
increased IL-7 production are hallmarks of human and OVX induced osteoporosis52,53. IL-7 
is an important regulator of T and B cell maturation produced by stromal cells and OBs. 
The absence of IL-7 results in significantly reduced T and B cell maturation in vivo52. 
Production of IL-7 by stromal cells and OBs is induced following stimulation by IL-1 and 
TNF-α54. This then acts on T cells to increase production of RANKL and TNF-α and drive 
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bone resorption54,55. IL-7 has been shown to directly act via in vivo T cells in order to 
induce bone erosion55,56. However, IL-7-/- animals develop less trabecular bone with 
increased number of OC under steady state conditions and remain susceptible to OVX 
induced bone loss57. The BM from IL-7-/- animals also has an increased propensity to 
differentiate into OCs while treatment of IL-7 inhibits the differentiation of WT OC 
cultures58.  However, IL-7 neutralizing antibodies used in WT OVX animals were able to 
reduce OVX induced bone loss56. Therefore, it would appear that IL-7 can indirectly 
drive OC differentiation and bone loss in osteoporosis. However, IL-7 has a complex role 
in the maintenance of bone remodelling under homeostasis. 
With increasing age, and menopause, there is an increase in the secretion of IL-6, IL-1 
and TNF-α by PBMCs59. The role that IL-6, IL-1 and TNF-α play in OVX induced bone loss 
has been widely studied. Serum concentration of IL-6 positively correlates with serum 
concentrations of IL-1β, TNF-α and the onset of the menopause59. IL-6 is produced by 
stromal cells and OBs, and induces in vitro OC bone erosion60. Interestingly, oestrogen 
effects on IL-6 production occur at a transcriptional level. Oestrogen binds to the 
oestrogen receptor and forms a complex (E/ER) (see section 1.2.4) which is capable of 
interacting with the promoter region of the IL-6 gene at NF-κB and C/EBP regions to 
prevent the binding of p65 and c-Rel61. Thus in a state of oestrogen deficiency this 
transcriptional repression is lost and IL-6 is produced at higher concentrations. The link 
between IL-6 and OVX-induced bone loss was studied in IL-6-/- mice. IL-6-/- mice have a 
normal bone phenotype with faster remodelling than littermate controls, however OVX 
failed to induce bone loss in IL-6-/- animals62. Therefore, IL-6 has a significant role in 
inducing bone loss following OVX.  
As previously mentioned, TNF-α producing T cells are increased following OVX and the 
importance of this has been studied. TNF-α-/- animals have normal bone physiology but 
do not suffer from OVX induced bone loss63. When soluble TNF-α receptor is used to 
treat OVX animals bone loss is limited, however, bone loss is prevented when 
TNF-binding protein (TNF-bp) is used64. Adoptive transfer of WT T cells into TNF-α-/- 
animals resulted in TNF-α-/- animals becoming susceptible to OVX induced bone loss53,63. 
These studies indicate that TNF-α, and TNF-α producing T cells have a central role in 
OVX induced bone loss. Transgenic mice which express human TNF-α spontaneously 
develop arthritis with increased bone loss. This bone loss can be prevented by 
treatment of OPG, suggesting that this bone loss is RANKL dependent65,66. In addition, 
blockade of IL-6 receptor in TNF-transgenic animals was able to reduce the number of 
OC present in inflamed joints, but could not prevent bone erosion67. Under steady state 
conditions treatment with TNF-α increases OC differentiation in the trabecular bone but 
this occurs in an IL-1 dependent manner68.  
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TNF-α induced OC differentiation can be enhanced by treatment with IL-1 which acts on 
OBs to induce a positive feedback and allow secretion of TNF-α to drive 
osteoclastogenesis68. IL-1 also stimulates BM MØ to differentiate into OCs in the 
presence of TNF-α68. In fact, in the BM compartment, oestrogen deficiency in mice 
results in increased secretion of IL-1 and TNF-α by mononuclear cells which acts directly 
on stromal cells increasing their secretion of M-CSF69,70. The concentration of M-CSF 
produced by oestrogen deficient stromal cells positively correlates with the degree of 
ex vivo osteoclastogenesis69. The use of an M-CSF neutralisation antibody prevented OVX 
induced bone loss and inflammatory arthritis induced bone loss71,72. In addition, the 
absence of IL-1 or IL-1 receptor (IL-1R), animals did not suffer OVX induced bone loss73 
and treatment with IL-1R antagonist (IL-1Ra) reduced bone loss after OVX surgery70. 
Oestradiol significantly decreases murine splenic MØ production of TNF-α, IL-6 and IL-1β 
following LPS stimulation by reducing nuclear NF-κB phosphorylation74. In fact, serum 
oestradiol levels are inversely correlated to monocyte TNF-α mRNA transcript and 
oestradiol treatment decreases monocyte secretion of IL-1α and IL-1β75,76. This 
highlights the central role which oestrogen has in maintaining the homeostatic 
production of cytokines which can control bone remodelling. 
1.2.4 Oestrogen inhibits osteoclastogenesis  
Oestrogen can effect a variety of cells; however, it is also capable of directly acting on 
OCs. Interestingly the number of CD14+ monocytes increases during the menopause, 
following a reduction in ER expression, yet this effect was reversed in women using 
HRT77. Thus oestrogen limits the pre-OCs found in the blood limiting the number of 
potential cells which differentiate into OCs. In fact, in vitro experiments using the 
leukemic monocytic cell line, THP-1, showed that treatment with oestradiol decreased 
the anti-apoptotic factor Bcl-2 expression78. Therefore, oestradiol has the ability to 
reduce survival signalling. 
E/ER interactions have genomic and non-genomic function. Oestrogen is able to enter 
the cell and bind intracellular ER where it forms the E/ER complex79. This can then 
translocate to the nucleus for genomic E/ER activity by binding to oestrogen response 
elements (ERE) on the promoters of genes and either activate or inhibit transcription79. 
One notable function of the E/ER complex is its ability to inhibit NF-κB activity. As 
previously mentioned, TNF-α induced NF-κB translocation and IL-6 transcription was 
inhibited by E/ER complex74. As a member of the TNF receptor superfamily, RANK 
signalling via NF-κB is essential in osteoclastogenesis therefore oestrogen may utilise a 
similar mechanism of action and inhibit NF-κB activation. Treatment with oestrogen 
inhibited the activation of p65, RelB, c-Rel and partially blocked p52 in vivo80. However, 
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oestrogen also increases Bcl-3 production which is known to bind and stabilize p50/p52 
dimers on NF-κB sites to modulate transcription80. Treatment of the MCF-7 breast 
cancer cell line with oestrogen increases expression of NF-κB p105 which acts as an IκB 
protein and can block nuclear translocation of NF-κB dimers81. This could be a 
mechanism which oestrogen uses to limit NF-κB activation following RANK mediated 
signalling. 
Oestrogen also exerts non-genomic effects which are due to expression of ERα and ERβ 
on the cell surface82. Ligation of surface ERα results in dimerisation and signalling via 
PI3K/Akt and ERK82, which has been shown to reduce pro-apoptotic factors in 
cardiomyocytes83,84. Oestradiol also has non-genomic effects on OCs by influencing 
potassium (K+) channels, namely the inwardly rectifying K+ channel, and results in the 
depolarisation of the OC membrane within seconds of activation85. Pharmacological 
inhibitors of this channel prevent oestrogen induced depolarisation of the membrane86. 
Oestrogen induced membrane depolarisation may cause the reduction in the secretion 
of H+ by H+ATPase and thus reduce OC activity. In addition, RAW 264.7 cells that were 
treated with oestradiol in RANKL stimulated cultures did not effect the differentiation 
to OCs but inhibited the transcription of Cathepsin K and TRAP, thereby reducing the OC 
capacity to function87.   
In an elegant study, Nakamura et al (2007) used an OC specific ERα KO animal 
(ERαΔOC/ΔOC) to demonstrate that female ERαΔOC/ΔOC had reduced bone volume88. 
Transgenic animals with Cre recombinase under the transcriptional control of 
Cathepsin K where bred with transgenic animals possessing LoxP sites that flanked the 
ERα gene88. This resulted in a transgenic mouse which would only produce the Cre 
recombinase protein in OCs which could ultimately act directly on the LoxP sites to 
remove the ERα DNA from the genome, thus creating an OC specific ERα KO animal88. 
This study demonstrated that oestrogen acts directly on OCs to regulate their in vivo 
function88. Nakamura et al (2007) went onto show that this deficiency did not affect the 
ability of OCs to differentiate in vitro compared to littermate controls, but that 
addition of oestrogen to OC cultures induced the production of Fas Ligand (FasL), which 
could ligate Fas and induce apoptosis88. Therefore, oestrogen is able to directly inhibit 
the function and survival of OCs in vitro and in vivo via production of FasL and induction 
of apoptosis. 
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1.3 Osteoclast differentiation 
1.3.1 Osteoclast progenitors 
Monocytes are typically thought of as the generic precursor of OCs (pre-OC) found in 
both the blood and BM89. However, the view of a homogenous monocyte population has 
changed with recent evidence revealing that the differentiation of monocytes to MØ or 
OCs in health and disease occurs over a series of stages90. Each step of differentiation 
produces a monocyte with a functionally different identity performing a role outlined by 
both the microenvironment and the receptors it expresses91. 
Monocytes arise from haematopoietic stem cells (HSCs) that are self-renewing 
pluripotent progenitors found in the BM90. Depending on the signals received, HSCs can 
differentiate into granulocyte-MØ progenitors (GMPs), common myeloid progenitors 
(CMPs) or MØ/Dendritic cell (DC) progenitors (MDPs)90. However, with each subsequent 
differentiation the stem cell loses pluripotency and becomes more specialised until the 
final cell is terminally differentiated90. In the case of monocytes, MDPs replenish the BM 
with monocytes which can migrate into the periphery to terminally differentiate into 
monocytes/MØ and DCs90. However, prior to terminal differentiation, a number of 
transcription factors control this process. HSCs express high levels of the transcription 
factor promyelocytic leukemia zinc finger (PLZF) which represses myeloid 
differentiation by inhibiting transcription factors involved in stimulating 
monocytopoesis92. However, in response to extracellular stimuli, such as cytokine 
signalling, HSCs can down-regulate PLZF expression allowing the HSC to enter the next 
stage in differentiation92. The repressive activity of PLZF allows HSCs to balance the 
maintenance of progenitors and newly differentiated cells92. Another transcription 
factor which is essential in the differentiation of monocytes, MØ and OCs is PU.1. 
Originally, Scott et al (1994) generated a PU.1 knockout (KO) mouse line and showed 
that PU.1 deletion was embryonic lethal and resulted in abnormal development of 
lymphoid and myeloid compartments93. Tondravi et al (1997) later generated another 
PU.1 transgenic animal with a disrupted gene and demonstrated that PU.1 transgenic 
animals could reach full term but would die of septicaemia within 48 hours. This 
transgenic animal allowed observation of the skeleton which was void of OCs94. These 
results showed that PU.1 was not only vital for the maintenance of the haematopoietic 
compartment but also for the differentiation of OCs. It is believed that this is due to 
PU.1’s ability to control the expression of CD115, which is an essential receptor in 
survival and differentiation of monocytes and OCs (see section 1.3.2)95.    
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The regulation of PLZF and PU.1 allow MDPs to differentiate into monocytes that 
express Ly6C at high levels (Ly6Chigh) prior to their egress, in a CCR2-dependent manner, 
from the BM into the circulation96,97. Ly6Chigh monocytes are known as classical 
monocytes because they are typically involved in inflammatory responses by migrating 
to sites of inflammation and differentiating into MØ to assist the inflammatory 
response98,99. In the absence of inflammatory signals, Ly6Chigh monocytes down-regulate 
Ly6C and become non-classical Ly6Clow monocytes97. Ly6Clow monocytes also 
down-regulate CCR2 and thus lose the capacity to migrate to sites of inflammation97. 
However, Ly6Clow monocytes begin to express high levels of CX3CR1 which enhances 
monocyte survival and promotes Ly6Clow monocyte ‘patrolling’ behaviour100,101. This 
behaviour is thought to allow the surveillance of the vascular system for signs of 
infection and removal of apoptotic cells100. Ly6Clow monocytes are short lived cells and 
they were once believed to migrate into tissue and differentiate into tissue resident 
MØ, however, recently this has been disputed and it is now thought that tissue resident 
MØ are self-renewing and the monocyte compartment does not replenish this MØ 
population97. A third subset of monocyte also exists that has intermediate expression of 
Ly6C (Ly6Cint) and expresses CX3CR1. These cells are believed to be Ly6Chigh monocytes 
which have migrated to the BM and have begun the process of down-regulating Ly6C to 
become Ly6Clow monocytes97. However, there is uncertainty as to whether Ly6Chigh 
monocytes are required to return to the BM for Ly6C down-regulation to occur, as 
intermediary Ly6C monocytes can be found in both the blood and BM97. Human 
monocyte biology is similar to the mouse as classical monocytes are identified by 
CD14bright FcγRIIInegative while non-classical monocytes are CD14+ FcγRIIIbright 99. These cell 
types play similar roles in the human and mice. A similar intermediate monocyte 
population, defined as CD14bright FcγRIII+, is believed to be a classical monocyte 
transitioning to non-classical99. In this manner, Fc γ Receptors (FcγRs) can be used to 
distinguish between human classical and non-classical monocytes and other members of 
the FcγR family are expressed on the surface of monocytes and osteoclast progenitors99.  
An extra layer of complexity is added to the murine system as both Ly6Chigh and Ly6Clow 
monocytes express CD115, the MØ-colony stimulating factor (M-CSF) receptor, which 
promotes monocyte function, survival and is essential in the differentiation of OCs97,102. 
In fact, attempts have been made to determine whether an isolated subset of 
monocytes exist as a defined OC progenitor (OCPs) population and whether these cells 
arise from MDPs. Research by Charles et al (2012) and Jacome-Galarza et al (2013) has 
demonstrated that a separate, but phenotypically similar, cell subset exists in the BM 
which is highly osteoclastogenic when compared to Ly6Chigh and Ly6Clow monocytes 
(Table 1-2)4,103. Charles et al (2013) proposed a novel model for the differentiation of 
OCPs from MDPs based on the expression pattern of receptors essential for MØ and OC 
 
 
26 
 
function (Figure 1-2)103. Subtle differences in surface receptor expression exist between 
monocytes and OCPs which could reflect their in vivo roles.  
Of particular interest is the expression of CD11b, CD117 and CD135. CD11b is an integrin 
which forms as a heterodimer with CD18 known as the complement receptor 3 (CR3)104. 
CR3 is able to bind the complement factor C3b and activate the complement cascade 
and ligate intravascular adhesion molecue-1 (ICAM-1) to mediate phagocytosis, 
chemotaxis and cytotoxicity104. Both Ly6Chigh and Ly6Clow monocytes require high 
expression of CD11b in order to fulfil their role as phagocytes97. Yet, OCPs have no 
immediate requirement for CD11b, as they are not phagocytes and thus do not require 
CD11b expression. CD117 (c-kit) and CD135 (Flt3) are tyrosine kinase receptors 
expressed on BM progenitors105. The ligand for CD117 is stem cell factor (SCF) which 
maintains the differentiation of progeny from progenitors105. The ligand for CD135 is 
Flt3 Ligand (Flt3L) which is believed to promote progenitor viability in the BM and in 
vitro DC differentiation106,107. Down-regulation of CD117 is typically believed to be 
conducive for maturation of haematopoietic cell yet some non-progenitor cells, for 
example, mast cells, retain high expression of CD117105. However, CD117 expression on 
OCPs can identify CD117high and CD117low populations and when isolated CD117high OCPs 
differentiated to OCs at a faster pace than CD117low OCPs4,103. While MDP expression of 
CD117 is known to identify them as a subset it is not possible to delineate CD117 high or 
low expressing populations of MDPs103. Blocking antibodies against CD117 did not, 
however, inhibit the haematopoiesis or differentiation of stem cells to OCs in vitro108. 
The one discerning difference between MDPs and OCPs is that OCPs lack CD135 (Table 
1-2). Flt3L binds CD135 and induces receptor dimerisation and activation promoting cell 
survival106. CD135 is mainly expressed on haematopoietic BM progenitors but is mostly 
involved in lymphocyte development, as CD135-/- animals have regular peripheral blood 
population but altered B cells compartments109,110. Investigation into BM progenitors 
expanded in the presence of Ftl3L in vitro maintain the ability to differentiate into MØ, 
DCs and OCs111. However, the loss of CD135 on the surface of OCPs in vivo suggests that 
OCPs are a distinct cell type from CD135 positive MDPs. 
Interestingly, OCPs have been shown in vitro to differentiate into MØ and DCs under the 
correct conditions, thus retaining a certain degree of plasticity4. It is also worth noting 
that Ly6Chigh monocytes can differentiate into OCs in vitro unlike Ly6Clow monocytes103. 
Monocytes expressing CX3CR1 also migrate through the blood and relocate to BM prior 
to differentiation to OCs112. In the blood and spleen, Ly6Chigh monocytes which express 
high levels of CD115 and CD11b are highly capable of differentiating into OCs and may 
represent the OCP population present in the periphery4. Despite the current research, 
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further work needs to ascertain the exact origin of OCPs. Whether OCPs can be classed 
as a monocyte subset, arise separately or share the same lineage is yet to be 
established. Regardless of progenitor lineage, the differentiation of monocytes and 
OCPs to OC relies on a number of factors in vivo. The most accepted and researched 
factor is Receptor activator of NF-κB ligand (RANKL) mediated OC differentiation (see 
section 1.3.3)113. 
 
Table 1-2: Expression of surface markers on bone marrow subsets.  
Adapted table90,91,103.  
 
1.3.2 Macrophage-colony stimulating factor  
RANK ligand (RANKL) mediated osteoclastogenesis is driven by two factors: M-CSF and 
RANKL113. Although many factors are known to participate in osteoclastogenesis in vivo, 
the activity of M-CSF and RANKL acting on populations of pre-OCs, from the blood or 
BM, from many species results in OC differentiation in vitro3,114,115. Consequently, we 
will explore the ability of RANKL to induce differentiation of OCs.  
For OC differentiation to occur, M-CSF must be a co-stimulator. M-CSF is a cytokine 
released by monocytes, fibroblasts, T cells and B cells which binds to the receptor 
CD115 on the surface of monocytes/MØ and OCPs1,116,117. The importance of M-CSF in 
bone remodelling was first realised when the op/op mouse was generated. op/op 
 
 
28 
 
animals produce a non-functioning form of M-CSF which results in osteopetrosis due to a 
lack of functional OCs resulting in short stature, short tail and no tooth eruption in 
vivo118,119. This phenotype is mirrored in the M-CSF deficient rat which has a mutation in 
the Csf1 gene120. These animals are termed toothless (tl/tl) due to the lack of tooth 
eruption and development of osteopetrosis120. In mice, this osteopetrotic phenotype 
plateaus with age suggesting that other mediators of osteoclastogenesis compensate for 
the lack of M-CSF118. In fact, recently IL-34 was shown to ligate CD115 and successfully 
replace M-CSF in generating mature OCs in the presence of RANKL121. Additionally, IL-34 
is up-regulated in aged op/op animals suggesting that IL-34 is able to rescue 
osteopetrosis in op/op animals122. Kodama et al (1991) found that the bone defect in 
op/op animals could be rescued by the daily injection of recombinant human M-CSF into 
young op/op pups123. Mirroring this finding, Wiktor-Jedrzejczak et al (1990) implanted 
L929 (a murine fibroblast cell line that produces biologically active M-CSF) containing 
capsules intraperitoneally (i.p.) into op/op animals which partially restored OC 
populations and bone homeostasis119.  
The M-CSF receptor CD115 is a tyrosine kinase receptor that dimerises upon ligation 
with M-CSF124. The importance of CD115 in bone remodelling was verified by the 
generation of Csf1r-/- mouse (deficient for CD115) which had severe osteopetrosis and 
altered BM cellularity102. Upon ligation, M-CSF induces CD115 dimerisation and 
auto-phosphorylation of seven tyrosine residues on the cytoplasmic tail of the 
receptor125. These have been shown to interact with up to 150 adaptor proteins in a 
macromolecular protein complex125. The most important mediators of CD115 signalling 
are Phosphoinositide 3-kinase (PI3K) and Extracellular signal-regulated kinases 1/2 
(ERK1/2) (Figure 1-3)125. Both of these signalling molecules are essential for M-CSF 
induced MØ proliferation which leads to phosphorylation of glycogen synthase kinase-3 
beta (GSK3β) resulting in inhibition of cell cycle arrest125,126. CD115 mediated signalling 
also induces the transcription factor PU.1 which is essential for the induction of OCs as 
well as self-regulating the expression of CD1151,95. Another transcription factor which is 
known to be essential for osteoclastogenesis is Microphthalmia-associated transcription 
factor (MITF)127. Genetic knockout of the MITF gene, Mitfmi/mi, are unable to 
differentiate OCs in culture because upon ligation, CD115 activation results in MITF 
phosphorylation which has been shown to induce osteoclastogenesis and increase OC 
activity127. M-CSF has also been shown to maintain nuclear integrity and stimulate 
chemotactic behaviour in mature OCs128. Hodge et al (2011) demonstrated that mature 
OCs treated with RANKL alone could form sealing rings, but addition of M-CSF further 
enhanced this ability129.  Arai et al (1999) found that stimulation of BM mononuclear 
cells with M-CSF increased RANK mRNA within 24 hours which continued to increase for 
up to 72 hours6. In addition, Charles et al (2012) demonstrated that OCPs stimulated 
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with M-CSF for two days resulted in an increase in the surface expression of RANK103. 
Taken together studies suggest that M-CSF induces RANK expression via the combined 
binding of PU.1 and MITF to the promoter region of the RANK gene, inducing 
transcriptional activity130. 
 
Figure 1-2: Differentiation of monocytes and osteoclasts from bone marrow progenitors. 
HSCs present in the BM self renew and parent MDPs. MDPs differentiate further into Ly6Chigh 
monocytes which enter the circulation and migrate to sites of inflammation to terminally 
differentiate into inflammatory MØ. In the absence of inflammation, Ly6Chigh monocytes migrate 
to the BM and down-regulated Ly6C expression becoming Ly6Clow monocytes which patrol the 
vasculature. Ly6Chigh monocytes, but not Ly6Clow monocytes, can differentiate into OCs in vitro. 
OCPs are thought to arise from MDPs and can differentiate into OCs. OCPs are also able to 
differentiate into MØ, as are Ly6Chigh/low monocytes in vitro. Solid arrows indicate in vivo 
differentiation pathways; dashed arrows indicate in vitro differentiation. Adapted 
diagram90,96,97,103. 
 
 
 
30 
 
1.3.3 Receptor activator of NF-κB ligand 
RANKL is a cytokine expressed on the surface of OBs, stromal cells and activated T and 
B cells1,131. RANKL present on the surface of cells interacts with the membrane bound 
receptor RANK on the surface of pre-OCs to stimulate osteoclastogenesis1. However, 
RANKL can be cleaved by MMPs to form a soluble ligand, sRANKL, which has reduced 
efficacy at interacting with RANK and inducing osteoclastogenesis132–134. This reduced 
efficacy may be due to other surface molecules on the OBs interacting with OCs and 
thus enhancing osteoclastogenesis, instead of the difference between membrane 
anchored and soluble protein versions. The role of RANKL in vivo was highlighted by the 
creation of the RANKL deficient animal which was incapable of generating in vivo OCs 
and developed osteopetrosis135. RANKL-/- animals also have altered lymphocyte 
development and lymph node formation demonstrating that RANKL has a wider range of 
functions in vivo135.  
RANK is a transmembrane receptor that is part of the TNF-α receptor super family 
(TNFRSF) found on the surface of haematopoietic cells117,136. RANK deficient animals 
have an inability to form OCs in vivo and also suffer from disturbed lymph node 
formation which demonstrates that RANK is essential in both the skeletal and immune 
systems137. Interaction of RANKL and RANK activates TNF related activation factor 
(TRAF) adaptors138, the most important of these adaptors being TRAF6 which forms a 
complex with c-Src promoting actin re-organisation (Figure 1-3)8,139. Actin 
re-organisation is also mediated by CD115 through stimulation of c-Src which alters the 
cytoskeletal structure in preparation for multinucleation and pit formation8. The 
importance of TRAF6 in RANK signalling is highlighted by the perturbed bone 
remodelling in TRAF6-/- animals140. TRAF6-/- animals also show impaired tooth eruption, 
cytokine signalling and OC function, highlighting TRAF6’s essential role in 
osteoimmunology140.  
In addition to TRAF6, RANK activation stimulates mitogen activated protein kinase (MAP 
kinase) activation through transforming growth factor beta- activated protein 1 (TAK1) 
which activates Activator protein 1 (AP1) and MITF, both of which are essential for OC 
gene transcription1,12. In particular p38, a MAP kinase, is vital for RANKL mediated OC 
differentiation, however, studies using pharmacological inhibitors demonstrated that 
inhibition of p38 does not inhibit mature OC activity141,142. Another member of the MAP 
kinase family, ERK1, has been shown to positively regulate OC differentiation as ERK1 
deletion results in reduced in vitro RANKL mediated osteoclastogenesis143. AP1 is a 
heterodimeric transcription factor essential in osteoclastogenesis. Phosphorylation of 
AP1 family member c-fos is mediated by Nuclear factor-κB (NF-κB) signalling and 
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animals deficient for c-fos suffer from severe osteopetrosis due to a deficit in the OC 
population144,145. The most important transcription factor activated by RANK is nuclear 
factor of activated t cells c1 (NFATc1). NFATc1 transcription is up-regulated a few hours 
following RANKL-RANK engagement initiating the transcription of genes such as 
Cathespin K, as well as auto-regulating its own expression in a positive feedback loop146. 
Deletion of NFATc1 is embroynic lethal but to test the effect of NFATc1 deficiency in 
vivo, NFATc1-/- foetal liver cells were adoptively transferred into c-fos-/- osteopetrotic 
animals147. This adoptive transfer did not resolve the osteopetrosis of c-fos-/- animals 
but when NFATc1+/- cells were adoptively transferred into c-fos-/- animals the 
osteopetrotic phenotype was rescued147. This suggests that during osteoclastogenesis, 
NFATc1 is downstream of c-fos activation as NFATc1 activation could rescue 
osteopetrosis while c-fos deficient animals remained osteopetrotic147. This pathway is 
under the regulation of NF-κB (see section 1.3.5) which is activated before downstream 
c-fos and NFATc1 activation145. Taken together, RANK activates a broad signalling 
cascade with a variety of transcription factors that are responsible for the regulation of 
OC differentiation, survival and activity. 
1.3.4 Osteoprotegrin 
RANKL-RANK interactions are regulated by an endogenous competitive inhibitor known 
as osteoprotegerin (OPG)148. OPG is secreted by OB, stromal cells and B cells in response 
to cytokines such as transforming growth factor (TGF-β) and bone morphogenic proteins 
(BMPs) to regulate the number of differentiating OCs149. In fact, B cells are believed to 
responsible for up to 64% of the OPG production in the BM150. OPG is a soluble decoy 
protein which is released into the extracellular fluid to bind to both sRANKL and 
membrane bound RANKL (Figure 1-3)151. In mice, OPG-/- animals develop osteoporosis 
(bone loss) as the increase in uninterrupted RANKL-RANK signalling results in aberrant 
osteoclastogenesis151. Conversely, mice with artificially high levels of OPG in circulation 
have abnormally dense bone tissue48. The use of OPG-Fc fusion protein decreased OC 
activity in vivo following injection of IL-1, TNF-α, parathyroid hormone (PTH), 
parathyroid-related hormone and Vit D3. This cytokine cocktail was designed to simulate 
a pro-inflammatory environment of arthritic disease and treatment with OPG in this 
model was able to decrease OC differentiation and activity152. This study demonstrated 
that OPG is a negative regulator of osteoclastogenesis. 
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Figure 1-3: Schematic of synergistic effect of cytokines and interactions involved in osteoclast differentiation.  
Each cytokine acts in synergy to stimulate transcription factors associated with osteoclastogenesis initiating differentiation. M-CSF and RANKL produced by OBs 
interacts with CD115 and RANK on the pre-OC surface signalling to promote differentiation. TNF-α, IL-1 and IL-6 produced by a variety of cells can increase OB 
production of RANKL, in turn driving OC differentiation. TNF-α, IL-1 and IL-6 can also interact directly with pre-OCs to enhance differentiation and activity. 
Vitronectin and Collagen Type I present in the bone matrix can stimulate pre-OC attachment and differentiation via Vitronectin receptor and OSCAR-FcRγ. 
DC-STAMP and OC-STAMP are essential for fusion of pre-OCs, however this mechanism remains to be elucidated. Together, these induce the transcription of genes 
which results in the production of enzymes and acidification of the bone matrix for degradation as well as production of actin ring to secure the resorption lacunae. 
Adapted diagram12,125,153–155.  
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1.3.5 NF-κB controls osteoclastogenesis 
NF-κB is the ubiquitous signalling molecule and transcription factor that is vital for a 
variety of cellular processes156. NF-κB is pivotal in cell survival, stress responses and 
cytokine and growth factor signalling157. The role of NF-κB in osteoclastogenesis has 
been widely studied and as the name suggests RANK strongly activates NF-κB by 
inducing gene transcription of proteins essential in the differentiation of OCs145,156. 
NF-κB is a dimer consisting of different combinations of five subunits: p105 (p50), p100 
(p52), p65, RelB and c-Rel158–162. These 5 subunits combine to form up to 15 homo- and 
hetero- dimers each with a specific function. Activated NF-κB dimers can directly 
interact with NF-κB sites on the promoter regions of genes to activate or suppress 
transcription163,164.    
The five NF-κB subunits all contain Rel-homology domains (RHD) which enable 
interaction with NF-κB sites on the DNA165. Rel-B, c-Rel and p65 NF-κB subunits all 
contain a transcriptional activation domain (TAD) which allows dimers containing these 
subunits to induce transcription166. However, p50 and p52 NF-κB subunits lack the TAD 
region and thus homo- and hetero- dimers of p50 and p52 repress transcription167. 
However, p50 or p52 can combine with a TAD containing subunit which can induce 
transcription. Under steady state, p50/p52 dimers occupy NF-κB sites. Activation of 
NF-κB pathway, however, results in nuclear translocation of TAD containing dimers 
which replace p50/p52 dimers allowing the transcription of genes167. 
Inhibitors of κB (IκB) regulate NF-κB signalling to prevent the nuclear translocation of 
NF-κB168. IκB proteins have ankryin repeats which are small protein domains that bind to 
the RHD on NF-κB subunits and block translocation168. The most prominent member of 
the IκB family is IκBα which predominantly sequesters p65:p50 NF-κB dimers in the 
cytoplasm169. The IκB Kinase (IKK) complex regulates this process and initiates NF-κB 
signalling166. Activation of IKK results in phosphorylation of IκBs and targets them for 
degradation by the proteasome, allowing activation of NF-κB and translocation to the 
nucleus166. Rel-B, c-Rel and p65 are produced as active proteins: p50 and p52, however, 
are produced as the precursors p105 and p100, respectively166. The degradation of these 
precursors to active NF-κB subunits is a limiting factor in NF-κB signalling and prevents 
aberrant gene transcription. Interestingly, the NF-κB precursors p105 and p100 contain 
ankyrin repeats and have been shown to sequester NF-κB dimers in the cytoplasm until 
the appropriate stimulation results in their degradation and NF-κB activation166. IκB 
proteins can not only sequester NF-κB in the cytoplasm but can prevent transcriptional 
activation by occupation of NF-κB sites. In the case of Bcl-3, an atypical IκB protein, the 
homo- and hetero- dimers of p50/p52 can be maintained on NF-κB sites preventing 
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transcriptional activity of activatory NF-κB dimers170,171. Bcl-3 selectively binds to these 
p50/p52 dimers and forms a stable complex on NF-κB binding sites167. This 
Bcl-3:p50/p52 complex prevents the ubiquitination of p50/p52 halting its degradation 
and thus inhibiting activatory NF-κB dimer binding167. In the absence of Bcl-3, NF-κB 
activity can become aberrant and uncontrolled167. 
NF-κB activation can result in two distinct signalling pathways; the canonical and 
non-canonical pathways166. The canonical pathway is rapid and occurs over a series of 
minutes to hours, while the non-canonical can require up to 8 to 12 hours following 
stimulation to initiate166. This dual signalling is believed to potentiate stimuli responses 
and the signalling via canonical pathway provides the initiating first response166. Once 
the initial response begins to dissipate the non-canonical pathway begins which results 
in long-term re-enforcement of the initial stimulus166. RANKL stimulation of RANK 
activates both the canonical and non-canonical NF-κB pathways166. The canonical 
pathway relies on TRAF6 mediated signal transduction, rapid proteasomal degradation 
of IκBα by IKK complex mediated ubiquitination and freeing of the p65:p50 NF-κB dimer 
for nuclear translocation and gene transcription172. The non-canonical pathway requires 
degradation of TRAF3 before proteasomal processing of p100 which results in the 
production of the active NF-κB subunit p52160. p52 then forms a dimer with RelB and 
translocates to the nucleus for DNA binding and induction of transcription173. Both 
pathways are essential for RANKL-induced osteoclastogenesis and the importance of 
NF-κB in bone remodelling has been evaluated in numerous KO mice. 
Animals deficient for p50 or p52 have no obvious skeletal abnormalities. Iotsova et al 
(1997), however, generated p50/p52 double KO (p50/p52-/-) animal which were highly 
osteopetrotic and lacked in vivo OCs174. p50/p52-/- animals amassed RANK+ splenocytes 
in vivo, which were unresponsive to RANKL and could not differentiate to OCs in 
vitro175. These studies demonstrated that the p50 and p52 subunits were vital in 
activating c-fos and NFATc1 and their absence resulted in the inhibition of 
osteoclastogenesis145,174. Ablation of the p65 subunit is embryonically lethal and to 
overcome this p65-/-TNFRI-/- animals were generated162. p65-/-TNFRI-/- animals have a 
lifespan of approximately 3 weeks and radiation chimeras were created to study the 
effect of p65 deficiency in the haematopoietic cell compartment in wild type (WT) 
animals162. This revealed that there was no effect on bone volume when p65-/- or p65+/+ 
chimeras were used. However, p65-/- animals had half the number of OCs present in 
vivo162. RelB-/- animals could not produce OCs in vitro but had similar bone architecture 
compared to WT animals176. c-Rel is activated by the canonical NF-κB pathway but does 
not translocate to the nucleus following RANKL stimulation and bone abnormalities have 
not been reported in c-Rel-/- animals177. Highlighting that the NF-κB subunit c-Rel may 
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not be necessary for RANKL mediated osteoclastogenesis. In 2010, Muruyama et al 
generated animals deficient for p100 which has similar bone architecture to littermate 
controls and could differentiate to OCs in vitro160. However, alymphoplasia (aly/aly) 
animals possessing an inactive form of the NF-κB inducing kinase (NIK), which is unable 
to process p100 to p52, had less OCs present in the trabecular micro-architecture as 
well as increased bone volume160. BM cells were also unable to differentiate into OCs in 
response to RANKL. This phenotype, however, could be overcome by transfection of 
aly/aly BM cells with p52 and an active form of NIK160. This is believed to occur because 
p100 accumulates in the cytoplasm and prevents nuclear translocation of p65166. 
Overall, this research demonstrates that NF-κB is essential in bone remodelling and 
RANKL-RANK signalling.  
1.4 Osteoclast maturation 
1.4.1 Co-stimulators of osteoclastogenesis 
RANKL is the main mediator of osteoclastogenesis; however, other cytokines are 
capable of working in synergy with RANKL or even directly initiating osteoclastogenesis. 
One example of this is TNF-α, an inflammatory cytokine that can be produced by a 
variety of cells and has been implicated in a number of diseases. TNF-α and its 
receptors TNFR1 and TNFR2, which are expressed on peripheral blood monocytes 
amongst other cells, belong to a superfamily of cytokines and cytokine receptors which 
includes RANKL/RANK136,178. In osteoclastogenesis, TNF-α can work both in synergy with 
RANKL or independently to stimulate in vitro osteoclastogenesis but TNF-α cannot 
commit monocytes to OCs in RANK-/- mice, therefore, in vivo TNFα cannot replace 
RANKL mediated osteoclastogenesis9,179,180. However, low concentrations of TNF-α used 
alongside RANKL can potently increase in vitro osteoclastogenesis, increase actin ring 
formation and bone erosion179. TNF-α binds to TNFR1 on the surface of M-CSF dependent 
BM cells and signals in synergy with RANKL to stimulate MAP Kinases, AP1, MITF and 
NF-κB (Figure 1-3)179. TNF-α  signals, in a similar manner to RANKL, via TRAF6, TRAF5 
and TRAF2 to activate p50/p52 NF-κB to induce c-fos activation and NFATc1 
transcription for OC differentiation145. However, unlike RANKL, TNF-α only activates the 
canonical NF-κB pathway which results in accumulation of the IκB protein p100 which 
negatively regulates in vitro TNF-α induced osteoclastogenesis, therefore TNF-α 
mediated osteoclastogenesis is self-limiting181. 
The synergistic activation of RANKL and TNF-α may explain certain inflammatory 
pathological diseases where the infiltrating MØ respond to the pro-inflammatory 
environment and produce TNF-α leading to increased OC activity182. In fact, the TNF-α 
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transgenic mouse which over-expresses human TNF-α spontaneously develops a bone 
erosive arthritic phenotype66. These animals also have increased number of actively 
proliferating CD11b+ BM cells, which may help to account for the increased 
osteoclastogenesis183. Treatment of WT animals with TNF-α increased the proliferation 
of a blood CD11b+ CD115+ monocyte population that could be used in vitro to 
differentiate OCs 183. Following treatment with TNF-α, the increase in CD115 expression 
could result in an increase in osteoclastogenesis as CD115 stimulation results in 
up-regulation of RANK183. Anti-TNF-α therapies have proved very effective in treating 
inflammatory diseases and creating a less inflammatory milieu184. An example of this is 
Infliximab (anti-TNF-α antibody) which is clinically used to treat patients with 
Rheumatoid arthritis (RA)185. Removal of TNF-α from patients’ systems results in 
decreased IL-6 and IL-1, decreased T cell responses, tissue destruction to bone and 
cartilage and importantly improved patients’ disease severity185. 
Other cytokines which have been implicated in osteoclastogenesis include the 
Interleukin-1 (IL-1) family members, IL-1α and IL-1β. IL-1α/β are both pro-inflammatory 
cytokines which bind to the IL-1R to induce TRAF6 activation resulting in activation of 
NF-κB, AP1 and MAP Kinase p38 (Figure 1-3)186. TRAF6-/- animals have perturbed bone 
remodelling as well as altered IL-1 activation140. Treatment of MØs with TNF-α can 
differentiate OCs, yet IL-1α is also required to stimulate bone erosion187. IL-1 can 
dose-dependently induce the multinucleation of monocytes and bone erosion via 
p50/p52 NF-κB188–190. IL-1 enhances RANKL mediated OC differentiation and extends the 
lifespan of in vitro mature OCs, in a PI3K and ERK dependent manner191. In vivo, IL-1R 
can indirectly induce osteoclastogenesis; IL-1 activates IL-1R on OBs and stromal cells to 
increase RANKL expression while directly interacting with IL-1R on the surface of BM 
MØs stimulating p38 and enhancing RANKL induced osteoclastogenesis68. As well as 
inducing RANKL production by OBs, IL-1 is also known to induce the production of 
pro-inflammatory cytokines. One important pro-inflammatory cytokine in 
osteoclastogenesis is Interleukin-6 (IL-6). 
IL-6 is a pro-inflammatory cytokine produced by a variety of cells to elicit an immune 
response and initiate inflammation192. IL-6 binds to its receptor IL-6Rα which signals via 
the adaptor protein gp130192. IL-6 activated signalling is mediated by JAK/STAT 
transcription factors as well as PI3K, MAP Kinases and Src activation192. The role of IL-6 
in osteoclastogenesis was realised when IL-6 produced by OBs dose-dependently induced 
OC bone resorption when used along with IL-160. There is an interplay between these 
cytokines, as IL-6 can induce the secretion of IL-1 from human BM cells which results in 
the differentiation of OC-like cells in culture193. Synergistic IL-6 and TNF-α treatment of 
BM MØ can differentiate OCs in the absence of RANKL194. However, direct stimulation of 
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BM MØ with IL-6 can suppress RANK signalling and thus inhibit osteoclastogenesis 
dose-dependently190,195. Therefore, IL-6 alone is unable to induce osteoclastogenesis; 
however, in synergy with other cytokines and in the presence of OBs, IL-6 can strongly 
enhance the differentiation and erosive potential of OCs153.   
1.4.2 The role of T cells in osteoclastogenesis 
During inflammation a number of pleiotropic cytokines are produced which can induce 
the production of pro-OC factors. IL-17 is produced by a subset of T cells called Th17 
cells, which are implicated in the pathogenesis of autoimmune diseases196. IL-17 is a 
recently discovered pro-inflammatory cytokine which induces the expression of TNF-α in 
the synovial membrane and stimulates OBs to express RANKL197,198. Osteoporosis has 
been linked to an increase in the Th17 cell population in the BM as well as an increase 
in serum IL-17199. The presence of IL-17 in the serum can induce the secretion of TNF-α 
and IL-1β from human MØ as well as directly inducing osteoclastogenesis and the 
production of MMP9 and Cathespin K197,200. However, IL-17 appears to have a temporal 
effect on osteoclastogenesis: IL-17 treatment prior to RANKL enhances OC 
differentiation while IL-17 treatment after RANKL inhibits osteoclastogenesis190. 
Therefore, IL-17 needs to be further examined to elucidate its role in bone remodelling. 
Another cytokine which is produced by T cells and has biphasic roles in 
osteoclastogenesis is Interferon-γ (IFN-γ)201. IFN-γ is important in mediating adaptive 
immune responses and priming immune cells to initiate the immune response to 
infection202. IFN-γ exists as a biologically active dimer which binds to its receptors 
IFN-γR1 and IFN-γR2 to stimulate JAK/STAT signalling202. IFN-γ is a negative regulator of 
OC differentiation as it directly inhibits MØ differentiation to OCs by preventing RANKL 
signalling and OC inducible genes201. However, pre-treatment of MØ with RANKL can 
render a cell resistant to IFN-γ and allow OC differentiation201. Yet, IFN-γ indirectly 
enhances osteoclastogenesis via T cells activation50. IFN-γ primed T cells produce TNF-α 
and RANKL which can directly interact with pre-OCs to drive in vivo OC differentiation 
in the BM50.  
Recently a novel T cell derived mediator of osteoclastogenesis was discovered. Secreted 
osteoclastogenic factor of activator of T cells (SOFAT) was discovered when 
fractionated supernatants of T cells, stimulated with CD28/CD3, was used in culture 
with OBs and monocytes203. One fraction of this media was shown to induce IL-6 
production by OBs and increase OC differentiation from human monocytes155. SOFAT was 
found to dose dependently induce osteoclastogenesis independent of RANKL, TNF-α and 
IL-6203. However, TNF-α was able to enhance SOFAT induced osteoclastogenesis203. 
SOFAT was also shown to induce the in vitro differentiation of functional OCs from RAW 
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264.7 cells, and in vivo formation of OCs155,203. As yet, a receptor for SOFAT has not 
been identified nor has its mechanism of action. This novel mechanism highlights the 
wide-ranging interplay between the skeletal and immune system that is yet to be fully 
understood. 
1.4.3 ITAM co-stimulation 
A co-stimulatory immunoreceptor which has been implicated in osteoclastogenesis is OC 
associated receptor (OSCAR). OSCAR is a 282 amino acid long immunoglobulin (Ig)-like 
receptor with an Ig domain, an extracellular N terminal and a transmembrane domain 
containing an arginine residue, which binds to an adaptor protein204. The adaptor 
protein is typically either DNAX activating protein 12 (DAP12) or common γ-chain 
(FcRγ), which rely on immunoreceptor tyrosine-based activation motif (ITAM) signalling 
as OSCAR lacks the capacity to signal205. DAP12 and FcRγ are adaptor proteins typically 
found as a dimer which signal via an ITAM on the intracellular tail206. The ITAM motif 
consists of one tyrosine residue (Y) that is separated from a leucine (L) by two amino 
acids in duplicate (YXXL-YXXL)
206. Upon stimulation, Src family tyrosine kinases 
phosphorylate the tyrosine residues on the ITAM motifs206. This results in activation of 
SYK leading to signalling via MAP Kinases, CREB, NFATc1 and NF-κB (Figure 1-3, see 
section 1.5.1)207. When DAP12 or FcRγ is genetically ablated, OSCAR expression is 
lowered and osteoclastogenesis is altered but not inhibited208. However, when both 
DAP12 and FcRγ are deficient the result is osteopetrosis and a reduction in 
osteoclastogenic gene transcription208. OSCAR is found expressed solely on murine OCs 
but it is more widely distributed on humans monocytes, MØ, OCs and DCs205,209. A murine 
monoclonal antibody generated against OSCAR is capable of inhibiting OB mediated 
osteoclastogenesis, suggesting that OSCAR has a pivotal role in stimulating 
osteoclastogenesis205.  
The ligand for OSCAR has recently been discovered as collagen type II154. OSCAR 
recognises collagen motifs exposed on the bone surface allowing interaction of pre-OCs 
and bone matrix154. Collagen ligation of OSCAR signals through Ca2+ release causing the 
activation of calcineurin and calcium-calmodium kinase IV (CaMKIV). This in turn causes 
a positive feedback loop amplifying NFATc1 and activating cAMP response element 
binding protein (CREB) (Figure 1-3)1. Collagen interaction with OSCAR increases in vitro 
osteoclastogenesis and increased TRAP and Cathespin K mRNA154. OSCAR expression is 
regulated by NFATc1 and is up-regulated by MITF, PU.1 and NF-κB which are induced by 
M-CSF and RANKL stimulation210. Genetic KO of PU.1 and NFATc1 has been shown to 
reduce osteoclastogenesis and prevent the expression of OSCAR94,210. 
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OSCAR has been implicated in the pathogenesis of human diseases like osteoarthritis, 
osteoporosis and RA. Polymorphisms have been discovered in the OSCAR gene leading to 
increased incidence in osteoporosis in post-menopausal women suggesting that the 
genetic variation in the promoter region of the OSCAR gene was a risk factor in the 
development of osteoarthritis211. Interestingly, OSCAR and NFATc1 mRNA transcripts are 
up-regulated in murine BM cells when they were treated with synovial fluid from 
osteoarthritis patients212. In patients suffering from RA the expression level of OSCAR on 
monocytes correlated with the level of C-reactive protein in the serum, which is used as 
a marker of disease severity213.  
DAP12 is also associated with the surface receptor Triggering receptor expressed on 
myeloid cells 2 (TREM2) which is an Ig like receptor which signals via the ITAM on 
DAP12214. TREM2 or DAP12 mutations in humans results in Nasu-Hakola disease which 
leads to brain abnormalities and osteoporotic fractures215. TREM2-/- animals were 
observed to have an osteoporotic phenotype216. Investigation in vitro showed that 
transcription of TREM2 is induced by treatment with M-CSF and RANKL and may help OC 
multinucleation and migration214. However, DAP12-/- BM mononuclear cells failed to 
generate in vitro OCs following M-CSF and RANKL stimulation217. One reason for this is 
that DAP12 associates with CD115 following stimulation by M-CSF218. CD115 dimerisation 
and auto-phosphorylation of tyrosine 559 activates DAP12 phosphorylation and 
recruitment of SYK leading to reorganisation of the cytoskeleton218. Thus, loss of DAP12 
results in augmented in vitro osteoclastogenesis and in vivo DAP12-/- leads to 
osteopetrosis217. However, in vivo TREM2-/- resulted in enhanced osteoclastogenesis due 
to its ability to negatively regulate proliferation in response to M-CSF and thus 
commitment to the OC lineage216.  
ITAM signalling is classically believed to be a co-stimulator in osteoclastogenesis and it 
can enhance late stage osteoclastogenesis219. OSCAR-Ig fusion proteins (antagonist for 
OSCAR) can inhibit in vitro OC differentiation and suggests that OSCAR-FcRγ/DAP12 
ITAM signalling enhances OC differentiation205. The downstream Ca2+ signalling 
associated with ITAM coordinates with M-CSF and RANKL to potentiate 
osteoclastogenesis as well as aiding in reorganisation of the OC cytoskeleton218. 
However, TREM2-/- animals have an increase in OC differentiation and activity that 
provides evidence that TREM2-DAP12 ITAM signalling may be a negative regulator of 
osteoclastogenesis. 
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1.4.4 Multinucleation  
The fusion of mononuclear pre-OCs into multinucleated OCs results in a higher capacity 
for resorption. Without fusion pre-OCs remain functionally viable but have reduced 
activity7. Initially discovered as a receptor on the surface of DCs, DC-specific 
transmembrane protein (DC-STAMP) expression was believed to be a marker of DC 
activation220. DC-STAMP is a 470 amino acid protein with seven transmembrane domains 
expressed on the surface of the cell220. It was later found expressed on the surface of 
OCs and MØs and is essential in fusion as inhibition of DC-STAMP with siRNA inhibited 
multinucleation of RANKL treated RAW-D cells10. Its role in osteoclastogenesis was first 
highlighted when it was discovered to be a RANKL inducible protein under the control of 
NFATc110,221. However, Mensah et al (2009) published that DC-STAMP was constitutively 
expressed on the surface of BM MØ and that that RANKL induced the generation of two 
separate populations of BM MØ; DC-STAMPlow and DC-STAMPhigh7. Hypothesising that 
RANKL induced the internalisation of DC-STAMP in a group of MØ (DC-STAMPlow) which 
would go onto act as the nuclear acceptors for DC-STAMPhigh cells which are 
mononuclear donors7. DC-STAMP has been shown to traffic between RAW-D cells via 
tunnelling nanotubes (TNTs) and interaction via TNTs is essential of osteoclastogenesis 
in murine BM mononuclear cells thus presenting a mechanism by which DC-STAMPhigh/low 
pre-OCs communicate222. The research focusing of DC-STAMP was based mainly in 
murine studies; however, Zeng et al (2009) showed that human RANKL stimulates 
monocytes to increase DC-STAMP mRNA transcription223. The ligand for DC-STAMP is still 
unknown and the mechanism behind internalisation is yet to be elucidated (Figure 1-3).  
Furthermore, OC-stimulatory transmembrane protein (OC-STAMP) was discovered which 
had sequence homology to DC-STAMP224. Yang et al (2008) found that directly blocking 
translation of OC-STAMP using siRNA reduced the number of multinucleated OCs in 
culture but not the number of TRAP positive (TRAP+) cells and provided evidence that 
OC-STAMP was required for multinucleation of OCs224. OC-STAMP was found expressed 
on tissues throughout the body including lung, brain, heart, liver but absent from the 
ovary225. Interestingly, oestrogen inhibited the expression of OC-STAMP and represents a 
possible mechanism for increased osteoclastogenesis and lowered bone density in 
post-menopausal women225. Another interesting observation regarding OC-STAMP and 
DC-STAMP is that in DC-STAMPlow groups OC-STAMP mRNA is up-regulated7. The 
predominant hypothesis regarding fusion of pre-OCs is that OC-STAMP up-regulation is 
dependent on the internalisation of DC-STAMP, allowing the fusion of DC-STAMPlow 
OC-STAMPhigh and DC-STAMPhigh OC-STAMPlow groups via TNTs (Figure 1-3)7,222. 
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1.4.5 Bone resorption 
In order for an OC to mature it must bind to the surface of the bone matrix and secrete 
enzymes onto the bone surface under its ruffled border. OCs bind the bone matrix via 
integrins to form the sealing zone. An important integrin in this process is αvβ3 
(Vitronectin receptor), which is involved in osteoclastogenesis226. OCs express 
Vitronectin receptor which helps the attachment to matrix226. This results in the 
formation of an actin rich ring which seals the edge of the plasma membrane and bone 
interface in order to create the sealed ruffled border226. Interestingly, Vitronectin 
receptor expression is found on microvilli like structures on the leading edge of the cell, 
providing a possible mechanism for OCs migration prior to pit formation227. Inhibition of 
the Vitronectin receptor results in altered OC morphology227. Chin et al (2003) found 
that over expression of αv subunit of Vitronectin receptor stimulated the in vitro 
differentiation of OCs, while Faccio et al (2003) found that β3 deletion decreased OC 
activity228,229. M-CSF is believed to act in synergy with the Vitronectin receptor as they 
share similar MAP kinase pathways and M-CSF treatment can restore β3
-/- deficient OC 
activity229. Therefore, the Vitronectin receptor is responsible for attachment and 
possible migration of OCs on bone matrix.    
After attachment to the bone the formation of the actin ring results in a controlled 
microenvironment between the plasma membrane and the bone matrix. The 
polarisation of OCs allows the targeted secretion of enzymes and acidification into the 
microenvironment. This allows the mineralization of bone by secreted enzymes and the 
subsequent degradation of the organic matrix230. An essential regulator of the 
acidification process is cytosolic carbonic anhydrase (CAII), which hydrates CO2 to form 
H+ and HCO3
- 231. The H+ are then secreted via the vacuolar H+ ATPase proton pump 
(H+ATPase) into the resorption lacunae232. CAII and H+ATPase are both regulated by 
RANKL activated c-Fos and NFATc1 signalling232,233. The acidification of the bone matrix 
is completed by the HCO3
-/Cl- exchanger which provides extracellular Cl- to be 
transported to the resorption lacunae producing HCl with the H+ present231. The 
inhibition of H+ release and CAII activity inhibits osteoclastogenic differentiation and 
activity on dentine slices proving that this acidification process is essential in bone 
erosion232,233.  
Cathepsin K is a cysteine protease enzyme which is involved in the cleavage of collagen, 
osteonectin, elastin and gelatine234. Cathepsin K in the serum of patients with RA 
positively correlates with the clinical disease235. Inhibitors of Cathepsin K activity have 
been shown to effectively treat osteoporosis, as they reduce the degradation of bone 
matrix236. This has been demonstrated in human clinical trials and in animal models of 
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disease234,236. Regulation of Cathepsin K by the MITF is activated by M-CSF and RANKL 
signalling, as MITF-/- mice have reduced Cathepsin K production237. Interestingly, MITF 
also regulates the transcription of TRAP which is an enzyme which works optimally in 
acidic conditions on a variety of substrates ranging from collagen, nucleotides, 
phosphor-proteins but mainly osteopontin in vivo238–240. OCs secrete the precursor TRAP 
5a into the sealing zone which is cleaved by Cathepsins to produce TRAP 5b, the active 
form of the enzyme240. TRAP 5b is known to leach out of the sealing zone and enter the 
systemic circulation and can be used as a serum marker of bone remodelling in 
animals240.  TRAP-/- animals display a mild osteopetrosis with stunted limb growth, while 
over-expression of TRAP typically leads to osteoporosis with increased bone 
turnover241,242. Due to altered bone remodelling, TRAP-/- animals have altered collagen 
cross-linking which consequently results in perturbed Ca2+/Phosphate (PO4
3-) 
homeostasis238. In addition to Cathepsin K and TRAP, MMP9 is also produced by OCs to 
degrade bone matrix and is responsible for the degradation of collagen type IV and V243. 
MMP9 is expressed in many tissue and is typically responsible for tissue remodelling244. It 
is secreted as a pro-protein and cleaved extra-cellularly to an active form of the 
enzyme244,245. These enzymes work in synergy within the acidified microenvironment to 
decalcify and remove organic proteins from areas of damaged bone in order to maintain 
bone integrity. 
1.5 Fcγ receptors interactions 
1.5.1 Fcγ receptors  
Cells of the myeloid lineage, including monocytes, MØ, DCs and OCs express FcγRs and 
FcγRIII expression is able to delineate human monocyte subsets (see section 1.3.1). One 
method that cells of myeloid lineage use to respond to pathogens is by the interaction 
of Immunoglobulin G (IgG) with FcγR. FcγRs are found on phagocytes and function to 
capture the Fc regions of IgG bound to a antigen246. After engagement of FcγR by IgG, 
cells can then release cytotoxic products to kill a pathogen or phagocytose the 
antigen247. Differences exist between human and murine FcγR biology. Human FcγRs can 
be divided into six types; FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB (Table 
1-3)248. However, there are only four members of murine FcγR; FcγRI, FcγRIIB, FcγRIII 
and FcγRIV (Table 1-3)248. Each type of FcγR has a unique signature and can bind IgG 
subclasses with varying affinities (Table 1-3)248. All FcγR have a similar structure in that 
they all have at least two extracellular Ig-like domains responsible for binding to IgG, 
and an intracellular tail, which either maintains the ability to signal or relies on an 
adaptor protein to signal249. However, activation of these receptors can only occur if 
multiple neighbouring FcγRs bind IgG, IgG aggregates or IgG containing immune 
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complexes (IC) simultaneously250. One exception to this rule is FcγRI which has an 
additional extracellular Ig-like domain enabling it to bind with higher affinity to 
monomeric IgG compared to the other FcγRs251.  
 
Figure 1-4: Diagrammatic representation of IgG Fcγ receptor interactions.  
IgG is composed of two regions: F(ab’)2 region which binds antigen and the Fc region which is 
recognised by FcγRs. In mice, four FcγRs exist which have different IgG binding abilities and can 
bind IgG alone, aggregated IgG or IgG in complex with antigen. Activatory FcγRI, FcγRIII and 
FcγRIV signal via ITAM adaptor FcRγ molecule which is phosphorylated upon FcγR ligation. 
Cross-linking and activation of multiple FcγRs induces signalling. Phosphorylated ITAMs signal via 
PI3K, MAP Kinases, and Ca2+ activating effector functions. Inhibitory FcγRIIB contains an 
intracellular ITIM which is phosphorylated to activate phosphatases that remove phosphate 
groups from activated proteins. Thus SHIP is able to regulate SYK, PI3K and MAP Kinase 
activation. Adapted diagram249,252,253. 
FcγRs can be broadly categorised into activatory and inhibitory receptors. Murine 
activatory receptors, FcγRI, FcγRIII and FcγRIV lack the ability to signal and rely on the 
FcRγ ITAM to signal254. As previously mentioned ITAM signalling activates cellular 
responses and can enhance the differentiation of OCs in vivo and in vitro (Figure 1-4, 
see section 1.4.3)206. Unlike activatory FcγRs, FcγRIIB is capable of signalling without 
adaptor molecules250. FcγRIIB does not have the ITAM motif, instead it only has one YXXL 
motif on its intracellular tail, known as an immunoreceptor tyrosine based inhibitory 
motif (ITIM)255. Tyrosine kinases phosphorylate the tyrosine residues on the ITIM motif, 
leading to a signalling cascade which generates phosphatase enzymes like SHP-1, SHP-2 
and SHIP that are able to remove phosphate groups from a large number of proteins 
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involved in cell activation255. In particular, activation of FcγRIIB is capable of inhibiting 
the activation of activatory FcγRs by removal of phosphate groups from ITAM motifs as 
well as inhibiting Ca2+ signalling, SYK and MAP Kinases256. However, recently use of IgG 
and IVIG (see section 1.5.3) have been shown to interact with activatory FcγRIII to 
recruit SHP-1 to the FcRγ resulting in formation of an ‘inhibisome’257,258. This novel 
mechanism has been shown to reduce MØ responsiveness to stimuli, phagocytosis and 
endocytosis and has been termed inhibitory ITAM signalling (ITAMi)257,258. ITAMi signalling 
has also been shown to occur in IgA and FcαRI-FcRγ interactions and is thought to 
dampen the immune response to prevent aberrant inflammatory responses258. It is 
believed that this is a method of maintaining homeostasis as circulating IgG or IC can 
interact with FcγRIII on the surface of monocytes or MØ and induce the recruitment of 
SHPs to the hypo-phosphorylated ITAMs on FcRγ257. It is thought that for ITAMi signalling 
to occur, activatory and inhibitory FcγRs must be in close proximity, however, once the 
concentration of circulating IgG or IC increases ITAMs are fully phosphorylated and 
return to activatory signalling253,257,258.  
In mice, FcγRs are expressed on the surface of many immune cells. FcγRI has been 
shown to be highly expressed on monocytes, MØ and DCs; FcγRIIB is expressed on all 
myeloid cells as well as being the only FcγR present on B cells; FcγRIII is found to be 
expressed on all myeloid cells and on natural killer cells; FcγRIV is only expressed on 
the surface of Ly6Clow monocytes and MØ259,260. Research regarding mature OC 
expression of FcγRs has caused debate. OCs have been shown to express FcγRs on the 
polarised membrane directly interacting with the bone matrix in vivo, while recently 
they have been shown to express activatory FcγRs in vitro261,262. However, OCs in the 
presence of IgG coated red blood cells (RBCs) failed to induce rosette formation, 
suggesting that FcγRs on OCs are non-functional263. OCs are capable of endocytosing 
particles but are not able to phagocytose via an FcγR mediated pathway264. No evidence 
at presence disproves that FcγR interactions influence mature OCs in vivo. Yet, in vivo 
the role of ITAM bearing adaptor proteins, including FcRγ, in bone biology has been 
investigated (see section 1.4.3). Animals deficient of FcRγ developed mild osteopetrosis 
in steady state but remained susceptible to oestrogen deficient bone loss207. FcRγ is 
required for the expression of activatory FcγRs, however, FcRγ is also associated with 
OSCAR and FcRγ-/- animals suffer osteopetrosis which may result from inhibited OSCAR 
signalling209,265.  
Another human and murine Fc receptor which is essential for IgG homeostasis is the Fc 
neonatal receptor (FcnR) which has a similar structure to MHC Class I receptors and is 
associated with a Beta-2-microglobulin (B2m)266. This structure allows the FcnR to 
interact with albumin and IgG in acidic conditions (pH<6.5) but dissociation occurs in 
 
 
45 
 
neutral and alkali conditions267. This feature provides FcnR with its main ability, which 
is to transport IgG across epithelial barriers and prevent IgG degradation267. IgG that is 
pinocytosed by epithelial cells can bind FcnR in internalised vesicle which quickly 
becomes acidified267. This allows bound IgG to be secreted at the basolateral cell 
boundary, this process is particularly important for transferring maternal IgG to the 
foetus268. Binding of IgG to FcnR in this process also prevents IgG degradation in 
lysosomes; therefore, the FcnR can greatly increase the half-life of IgG present in 
serum268. FcnR is also expressed on monocytes, MØ and DCs, but has not been observed 
on OCs269.  
 
Table 1-3: Fcγ receptor subclasses, signalling potential and IgG binding affinities.  
Adapted table248,250. 
 
1.5.2 Immunoglobulin G 
Immunoglobulins (Ig) are proteins produced by B cells and one of the main roles of these 
antibodies is to target epitopes on pathogens to aid in their clearance270. In order for B 
cells to produce Ig a series of cellular interactions must occur to facilitate an 
appropriate immune response270. During an infection, professional antigen presenting 
cells (APCs) such as MØ or DCs phagocytose and degrade microbes/pathogens270. A single 
peptide fragment from the degraded pathogens is then presented at the cell surface in 
a complex with MHC II270. For T cell activation to occur, peptide in the context of MHC II 
presented by APCs is recognized by the the T cell receptor (TCR) and is co-stimulated by 
CD4 and CD28 (ligand for CD80/86 on APCs)270. This interaction induces the clonal 
expansion of T cells specific for the peptide270. Cytokines such as IL-6, IL-12 and TGF-β 
are produced by APCs, with the particular cytokines produced influencing the 
differentiation of helper CD4+ T cells into specific T helper (Th) cell subsets. Each Th 
cell subset has differing roles within the immune response and different Th cell types 
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are induced depending on the type of response required270. B cells are also capable of 
presenting antigen in the context of MHC II, however, B cells can only present antigen 
which their BCR recognises270. B cells which have been exposed to BCR specific antigen 
are able to express peptide in MHC II on their surface but require co-stimulation to 
differentiate and produce antibody270. Helper T cells that have been stimulated by APCs 
and recognise the specific peptide can interact with the B cell by engagement of MHC 
II:peptide/TCR, co-stimulation through CD40/CD40L and cytokine release270. This 
initiates the differentiation of B cells into plasma cells which produce high quantities of 
Ig and also differentiates antigen specific memory B cells which will be easily activated 
upon secondary exposure to antigen270. There are 5 classes of Ig; IgD, IgM, IgA, IgE and 
IgG. Ig contains two highly variable F(ab) regions which are specific for an antigen and 
one constant Fc region which varies between subclass and is responsible for binding 
receptors, tissue distribution and mechanism of action (Figure 1-4)271. The subclass of Ig 
produced is reliant on a number of factors including the type of immune response 
required, the Th cell type produced and the co-stimulation which occurs during the T 
and B cell interaction270.   
IgD is the first Ig produced by B cells and it remains membrane bound to detect antigen 
for B cell differentiation250. IgM is the primary Ig produced in response to infection, it 
has a pentameric structure with the five Fc regions of IgM forming a ring and the F(ab) 
antigen binding sites directed outwards250. IgM is capable of initiating complement 
activation and agglutinating antigen for clearance by phagocytosis250. IgA can be 
produced as a dimer, with two IgA monomers binding at the Fc region250. IgA is secreted 
into mucous membranes and its structure allows it to be trafficked across epithelial 
surfaces250. IgE exists as a monomer and represents only a small fraction of the total Ig 
produced250. However, IgE is essential in allergic reactions and clearance of parasites by 
triggering degranulation of mast cells and basophils250. Finally IgG is the most abundant 
Ig present in circulation and has a similar structure to IgM, but exists as a monomer250. 
IgG is capable of binding antigen with high affinity and engaging Fcγ receptors (FcγRs) 
to initiate complement cascade or phagocytosis250. IgG can be further classified into 
subclasses each with more specific functions, however, species specific differences 
exist in these subclasses. Human IgG can be categorised into IgG1 to IgG4, while murine 
IgG exists as IgG1, IgG2a, IgG2b and IgG3248. Each has very specific abilities to activate 
complement cascade, opsonise pathogen and neutralise antigen248,250. 
IgG exists as approximately a 150kDa protein with two light peptide chains and two 
heavy peptide chains linked by disulphide bonds to form the typical Y shape of an 
antibody (Figure 1-4)272. The light chains consist of two domains, one which varies and 
one which remains constant, while the heavy chain has one variable domain and three 
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constant domains250. The variable domains of the heavy and light chains both recognise 
antigen and are responsible for antibody:antigen binding, this is known as the F(ab’)2 
region250. The constant domains provide the structure for the antibody and provide its 
function250. In humans, the lower hinge region which connects the F(ab) and Fc region is 
of the IgG molecule is involved in receptor engagement248. In particularly, residues 
234-237 in this region have been shown to be essential in receptor binding273. Another 
important factor which affects IgG binding abilities are carbohydrate modifications on 
constant heavy chain (CH2) domain of the Fc region of IgG248,274. These are implicated in 
receptor binding affinity and it is thought that these post translation modifications are 
essential for IgG functions248,274. 
1.5.3 Immune complexes and Fcγ receptors 
IC can be the result of multiple IgG molecules binding to one antigen forming a large 
protein complex with multiple IgG Fc regions exposed275. ICs ligate multiple FcγRs on 
the surface of cells, typically MØ or DCs, resulting in phagocytosis of the IC and  
degradation of bound antigen259. The ability of MØs to phagocytose relies on their 
plastic nature which can change depending on the conditions in which they were 
differentiated276. Treatment of MØ with IFN-γ, TLR4 agonists and TNF-α results in 
classically activated MØ which have strong cell-mediated effects allowing protection 
against microbial pathogens276. Classically activated MØ can secrete high levels of IL-1 
and IL-6 which induces inflammatory damage276. MØ that are exposed to IL-4 tend to 
have wound healing properties by promoting extracellular matrix deposition and 
lowering production of inflammatory cytokines277. The final type of MØ is called the 
regulatory MØ which is believed to have a role in finalising the immune response as it is 
typically generated in the presence of TLR agonists and IC278. It is hypothesised that IC 
stimulation occurs towards the end of the adaptive immune response because high 
levels of antigen specific antibody will be present to engage the remaining antigen. This 
could result in the IC formation which would direct the regulatory MØ to produce high 
amounts of the anti-inflammatory cytokine IL-10 to resolve inflammation278. Unlike 
wound healing MØ, regulatory MØ can produce inflammatory cytokines to stimulate T 
cells, but do not contribute to the extracellular matrix276. However, treatment of MØ 
with variations of these stimulants induces hybrid MØ with mixed phenotypes. 
Engagement of FcγRs on the surface of MØ can therefore have multiple effects 
depending on the context of the stimulation.  
The type of IC can also have an impact on the modulatory effect of FcγR stimulation. IC 
can take many forms, such as multiple antibodies bound to a single antigen, 
agglutinated antigens which are multiple antibodies bound to multiple antigens forming 
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a large mass and antibody aggregates which can form IC without the presence of 
antigen275,279. However, artificially generated heat-aggregated antibodies which form IC 
in a denatured structure is used to test in vitro IC interactions280. The size of the heat 
aggregated IgG depends on the initial concentration of protein which can lead to 
ambiguity regarding whether the production of aggregates is consistent between studies 
if different studies use different concentrations280. Research conducted by Torbinejad et 
al (1979) demonstrated that bone loss could be induced by heat-aggregated human IgG 
when injected into the pulp chamber of feline incisors281. In this case heat-aggregated 
human IgG induced inflammation which resulted in rapid bone loss from 7 to 28 days 
following the injection, this demonstrated that immune complexes were capable of 
modulating in vivo OC activity281. More recently, Kuramoto et al (2012) used LPS in 
complex with rat anti-LPS IgG to induce inflammatory bone loss in rat model of 
periodontal disease282. In this example, LPS would have stimulated TLRs and FcγRs to 
elicit inflammatory immune response in gingival tissue282. The size of these 
antibody:antigen complexes can influence the complex’s ability to bind to FcγRs and 
thus the ratio of antigen and antibody must be carefully controlled279. Both Torbinejad 
et al (1979) and Kuramoto et al (2012) indirectly induced bone loss because MØs would 
be the primary effector cells responding to ICs and thus would promote 
inflammation281,282. Antibody:antigen complexes elicit strong responses in human 
monocyte cultures when a similar ratio of antibody and antigen are used283. This drives 
the production of IL-10 which has an autocrine function down-regulating IL-6, IL-1β and 
TNF-α production283. IL-10 pre-treated MØ reduce the expression of FcγRII following 
treatment with heat-aggregated IgG284. However, Ambarus et al (2012) used 
heat-aggregated human IgG prepared in a similar method to show that treatment of 
human MØ cultured in a variety of conditions did not change the baseline production of 
cytokines, while treatment of IgG alone was enough to skew MØ production of IL-10, 
TNF-α and IL-6284.  
Intravenous immunoglobulin (IVIG) is an effective therapeutic which utilises high dose 
IgG to alter patient’s with autoimmune disorders. IVIG is highly concentrated human 
polyclonal IgG purified from hundreds of donors. IVIG is generally injected directly into 
circulation of patients285. It is an expensive treatment and is given at a dose of up to 
2g/kg to treat diseases like RA, immune thrombocytopenic purpura (ITP) and systemic 
lupus erythematosus286. The mechanism by which IVIG induces its anti-inflammatory 
effect is unknown but research has shown that post-translational modifications on 
around 5% of IgG, known as sialylations, may play a role274. Other studies have shown 
that the inhibitory FcγRIIB is required for IVIG induced protection in murine models of 
ITP287, while IVIG induces FcγRIII mediated ITAMi signalling which is thought to inhibit 
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cellular function257. One general theory of IVIGs mechanism is that IVIG floods the 
system with IgG displacing pathogenic IgG and blocking FcγRs from IC activation. It is 
also thought that IVIG co-opts FcnRs and allows the enhanced clearance of pathogenic 
antibodies from patients system relieving patient symptoms288. This therapy is a strong 
immunomodulator; however, extremely high doses are required to observe effects289. 
Therefore, a more precise and cost effective therapy is required to maximise the 
treatment of these diseases. 
Overall, the experiments which use IC tend to use models which cross-link FcγRs in a 
non-species specific manner and use complexes of unknown conformation. However, 
one particular example of IC formation which can reproducibly generate species specific 
IC of a discreet size are produced the bacterial protein; Staphylococcus aureus Protein 
A.   
1.6 Staphylococcus aureus Protein A 
S. aureus is a gram positive, anaerobic bacteria commonly present as part of the normal 
skin flora and due to the rise in drug resistant has become a widespread virulent 
nosocomial bacterium290. S. aureus invades the host and causes a myriad of diseases 
from minor irritations to serious diseases such as skin infections, cellulitis, impetigo, 
pneumonia and endocarditis291. One mechanism S. aureus has evolved to evade the 
hosts immune system is Protein A (SpA), a 47kDa membrane anchored protein that 
targets both the Fc and F(ab) regions of Ig with high affinity291. In its cell bound form, 
SpA has 5 extracellular IgG binding domains (domains E, D, A, B and C), a 
transmembrane domain and a cell wall binding domain292. Each of the 5 extracellular 
domains are able to bind the Fc region of IgG or F(ab) region in a non-competitive 
manner271,292,293.  
S. aureus, expressing SpA, coats itself with circulating Ig masking its presence as only 
host epitopes are exposed294. It has been hypothesised that the ability of S. aureus to 
co-opt IgG evolved to prevent the activation of complement cascade, inhibit 
opsonisation and prevent FcγR mediated phagocytosis290. However, in the recombinant 
soluble form SpA has been used for decades in the purification and production of 
antibodies. In 1978, Ey and Jenkins published a method which has become 
commonplace, in which SpA was conjugated to sepharose and used to isolate purified 
IgG295. This method demonstrated that fractions of IgG1, IgG2a and IgG2b could be 
isolated from mouse serum by incubation with SpA-sepharose and subsequent washes in 
solutions of decreasing pH295. SpA is able to bind to IgG with varying affinities 
dependent on subclass of Ig and host species296,297. SpA binds to murine IgG2a, IgG2b and 
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IgG3 with higher and equal affinity than IgG1296. Naturally occurring IC are also capable 
of binding SpA, which has been immobilised in silica, with high affinity298.   
 
Figure 1-5: Diagrammatic representation of SpAs interaction with IgG. 
Two molecules of SpA bind the CH2/CH3 region of four IgG molecules when IgG is present in 
excess. R denotes radio-labelled IgG. The continuous formation and dissociation of SpA and IgG in 
SIC is shown in the equation provided. Adapted diagram299–301. 
1.6.1  SpA immunomodulation 
SpA’s IgG binding ability was utilised in apheresis columns, which were clinically used to 
filter patient plasma and remove IgG and ICs302. In a now discontinued model, 200mg of 
SpA was covalently bound to a silica matrix and was used to remove IgG, and some IgA 
and IgM, from circulation302–304. Use of SpA apheresis in patients with RA was highly 
effective despite only removing a small amount of IgG from circulation271,305. However, 
other apheresis columns removed larger quantities of IgG and did not impact on 
patients’ disease as effectively as SpA aphresis271. Interestingly, it was discovered that 
during treatment approximately 200µg of SpA could leach from a column into the 
patient by proteolytic cleavage291. This led researchers to investigate how SpA could be 
interacting with the immune system to resolve inflammation.  
One aspect of SpA’s ability to modulate the immune system is its ability to bind the 
F(ab) region of Ig. This is not an IC mediated pathway as SpA directly interacts with the 
B cell to modulate cellular function. SpA specifically interacts with one variant of the 
F(ab) region produced by the VH3 gene family271. In humans this gene encodes 
approximately 14-50% of B cells, while only 3-5% of murine B cells express the 
variant306,307. SpA specifically interacts with the IgM expressed on the surface of B cells 
(BCR) and induces super-antigenic apoptosis308. Once SpA engages the BCR, there is a 
down-regulation of co-stimulatory molecules CD19 and CD21308. This results in B cell 
activation and within hours there is a decrease in the mitochondria membrane potential 
resulting in the production of pro-apoptotic factor Bim which induces B cell 
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apoptosis308,309. SpA induced cell death can be negated by co-stimulation of B cells using 
IL-4, CD40L and BAFF or even Bcl-2 overexpression309. In diseases such as RA, the 
removal of B cells from circulation via a SpA dependent manner may be beneficial as 
VH3 encoded B cells are implicated in producing auto-antibodies responsible for driving 
inflammation271. In fact, Rituximab is an anti-CD20 monoclonal antibody, used clinically 
to deplete B cells in patients and successfully treat diseases like RA310. Therefore, SpA 
mediated removal of B cells from patients maybe a viable treatment; however, it is not 
SpA’s only method of immunomodulation.  
1.6.2 SpA IgG complex immunomodulation 
SpA has long been known to bind to the Fc region of IgG and form IgG complexes 
consisting of IgG bound to SpA at a 4:2 ratio311. These complexes are distinct from 
typical IC because SpA binds to the IgG Fc region and allows the formation of a distinct 
protein conformation311. While typically, IgG binds to an antigen via the F(ab) region 
and in the correct ratio of antibody:antigen results in either multiple antibodies binding 
to a single antigen or multiple antibodies bind to multiple antigens to form a large 
agglutinated mass275. Both of these forms of IC are distinct from the SpA IgG complexes 
(SIC) because these IgG complexes form without F(ab) binding (Figure 1-5). The 
interaction between SpA and IgG is dependent on molarity, because if SpA is in molar 
excess of IgG the ratio of binding becomes 1:1300. SpA binds the Fc portion of IgG at the 
CH2/CH3 hinge region while the hinge section linking the F(ab) and CH2 regions of IgG 
are important in interact with FcγRs292,312. Deisenhofer (1981) used the B domain of SpA 
and Fc fragment of human IgG and demonstrated that the B domain interacted with the 
CH2/CH3 domains311. Further research demonstrated that mutations in murine IgG Fc 
region resides I253, H310, H433 and H434 were all involved in SpA binding, and this 
region overlapped with FcnR interactions313,314. These four amino acid residues have 
been shown to reside in close proximity to the CH2/CH3 domains interface and thus 
provides different binding site from IgG/FcγRs interactions313,314. Therefore, the use of 
SpA does not cause steric hindrance with the IgG Fc region and FcγRs (see section 
1.5.2). The formation of SIC at a 4:2 occurs almost instantaneously upon 
administration299. In fact, SpA added to serum, purified IgG or Fc fragments can 
generate SIC almost instanteously299,300. Administration of radio-labelled SpA alone or in 
complex with IgG revealed an in vivo half life of approximately 9 hours299. However, 
administration of radio-labelled IgG alone or in complex with SpA revealed a half life of 
approximately 110 hours299. This identified SpA’s promiscuous relationship with IgG, as 
it is proposed that SpA continually dissociates from bound IgG to form complexes with 
fresh IgG which accounts for the discrepancy in half lives299. This led to Dima et al 
(1983) proposing a model of SpA:IgG interactions (Figure 1-5)299. 
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However, more recently the ability of SIC to interact with FcγRs on the surface of 
immune cells to modulate cellular function has received attention315. The use of murine 
SIC (SpA with murine IgG) in mouse MØ cultures was shown to skew the MØ from an 
inflammatory phenotype to a regulatory phenotype316. SIC treated MØs produced high 
levels of IL-10 and decreased IL-12 production, as well as down-regulating MHC II 
expression316. This would suggest that the SIC was capable of producing an 
anti-inflammatory MØ. SpA also demonstrated anti-inflammatory properties when used 
in a murine model of arthritis (collagen-induced arthritis - CIA)316. In the murine model 
of CIA, SpA treatment reduced disease severity as measured by joint inflammation and 
reduced the number of OCs present at the inflamed joint316. It remains unclear whether 
in this model, SpA interacted directly with OCs or pre-OCs to reduce OC numbers or 
whether the reduction in inflammation was responsible for the observed decrease in 
OCs. However, use of SIC generated with human IgG, was shown to inhibit the 
differentiation of human monocytes to OCs316. This demonstrates that FcγR modulation 
in human monocytes can inhibit the differentiation of OCs. 
Recently research using murine cultures has confirmed this observation and shown that 
FcγR modulation on pre-OCs can alter osteoclastogenesis. The use of heat aggregated 
rabbit IgG in cultures of pre-OCs was used to inhibit the in vitro differentiation of 
mature murine OCs 317. This result demonstrates that treatment of pre-OCs with FcγR 
stimulation prior to RANKL stimulation lead to a decrease in the cells ability to 
differentiate317. It was also shown that the cross-linking of activatory FcγRI and IV using 
directed monoclonal antibodies leads to an increase in OC differentiation in pre-OCs 
that had already been cultured with RANKL262. This discrepancy in temporal FcγR 
stimulation and lack of physiologically relevant stimulation has resulted in conflicting 
results. In order to understand the role of FcγRs in osteoclastogenesis, species specific 
interactions are vital in elucidating the complexity of FcγR biology. Therefore, IgG 
complexes derived from SpA and murine IgG will be used to examine the role of FcγRs in 
murine osteoclastogenesis. 
1.7 Hypothesis and aims 
The use of SpA to generate IgG complexes with human IgG can inhibit the 
differentiation of human OCs316. Recently, the participation of FcγRs in murine 
osteoclastogenesis has received attention, however, these studies did not use 
species-specific IgG and thus conflicting results were achieved262,317. To expand on this 
research IgG complexes were generated using murine IgG and SpA alongside murine 
osteoclast cultures. IC interactions with FcγRs have been well studied and are 
commonly used to treat a variety of inflammatory disease286. SpA is able to form IC in 
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vivo with endogenous IgG and engage monocytes and MØ to reduce inflammatory 
disease316. However, the effect of SpA and FcγRs in non-inflammatory diseases has not 
been defined. Oestrogen deficiency induces excessive osteoclastogenesis resulting in 
lowered bone density and osteoporosis - which can be mimicked in vivo by removal of 
the ovaries40. Monocytes and monocyte subsets express FcγRs and can differentiate into 
OCs in vitro and in vivo and play a central role in OVX mouse model of osteoporosis318. 
Therefore, the use of SpA-IgG complexes may have potential in targeting osteoclast 
progenitors, via FcγRs, in osteoporotic diseases. 
The differentiation of OCs relies heavily on RANKL mediated NF-κB activation156. NF-κB 
activation results in nuclear translocation of activatory NF-κB dimers and gene 
transcription164. However, recently Bcl-3 has been discovered as a regulator of cytokine 
stimulated NF-κB induced gene transcription167. Bcl-3 prevents removal of p50/p52 
NF-κB dimers from gene promoters preventing activatory NF-κB dimer gene 
transcription167. As RANKL strongly activates both canonical and non-canonical pathways 
of NF-κB signalling Bcl-3 may regulate of this pathway. Therefore, as a negative 
regulator of NF-κB, Bcl-3 may potentially be a valid target in the search for novel drugs 
to treat osteoporotic diseases via disrupted RANKL signalling. 
Aim: Do SpA-IgG complexes or Bcl-3 represent novel avenues of investigation in 
therapeutic intervention in osteoporotic disease?  
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2 Materials and methods 
2.1 Animals 
C57Bl/6 mice, between the ages of 6-24 weeks old, were either bred by the University 
of Glasgow’s Central Research Facility or purchased from Harlan UK or Charles River UK. 
Bcl-3 deficient (Bcl-3-/-) mice (C57Bl/6 background) between the ages of 6-24 weeks old 
were provided by Dr. Ruaidhri J. Carmody. Bcl-3-/- C57Bl/6 / 129/SV mice originally 
obtained from Jackson Laboratory were backcrossed to C57Bl/6 mice for 12 generation 
and maintained at the University of Glasgow’s Central Research Facility167. Bcl-3-/- were 
generated by selective deletion of the ankyrin repeats in the Bcl-3 genomic DNA of 
129/SV mice which was replaced with a hygromycin resistance gene319. This construct 
was then electroporated into embryonic stem cells before antibiotic selection with 
hygromycin319. Embryonic stem cells with the disrupted bcl-3 gene survived hygromycin 
selection and were injected into C57Bl/6 blastocytes and transferred to surrogate 
C57Bl/6 mice319. Fcγ receptor III deficient (FcγRIII-/-) mice on a C57Bl/6 background 
were purchased from Charles River UK and bred by University of Glasgow’s Central 
Research Facility. FcγRIII-/- mice were generated in a similar manner to Bcl-3-/- animals, 
except the exons encoding the extracellular and transmembrane domains were replaced 
with hydromycin resistance genes320. Mutant mice were then maintained on a C57Bl/6 
background320. All animals were maintained at University of Glasgow’s Central Research 
Facility and procedures were performed according to Home Office Regulations and the 
Animal (Scientific Procedures) Act 1986. 
2.2 Osteoclast differentiation  
2.2.1 RAW 264.7 cell differentiation to osteoclasts 
The murine MØ cell line, RAW 264.7, was kindly provided by Dr. R. Carmody. Cells were 
maintained in complete Dulbeccos Minimum Essential Media (D-MEM, Gibco, Life 
Technologies, UK; see Appendix) at 37oC and 5% CO2 in 75cm
2/mm tissue culture flask 
(BD Biosciences, UK). RAW 264.7 cells were split once 80% confluent. To split RAW 264.7 
cells, a cell scraper (Greiner Bio-one, UK) was used to dislodge adherent cells before 
transfer of non-adherent cells to a 50ml falcon tube and centrifugation at 400g for 5 
minutes. Supernatant was aspirated and cells were re-suspended in 10ml of complete D-
MEM, 1ml of cell suspension was added to 12ml of complete D-MEM and placed in a 
clean 75cm2/mm tissue culture flask.  
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To differentiate RAW 264.7 cells to OCs, RAW 264.7 cells were seeded onto tissue 
culture plates at differing cell densities in complete D-MEM. Cells were then incubated 
with 0, 50 or 100ng/ml RANKL (Peprotech, UK) for varying lengths of time with cultures 
being fed every third day. 
2.2.2 Osteoclast differentiation from murine bone marrow  
Mice were either euthanized by rising concentration of carbon dioxide (CO2) or by 
cervical dislocation, in accordance to Home Office regulations. Reflexes were tested to 
ensure death before the long bones (femurs and tibias) were harvested and/or blood 
was removed via puncture of the exposed vena cava using a 23 gauge (23g) needle and 
20μl of 0.5mM EDTA. Excess flesh was removed from the femurs and tibias. These bones 
were sprayed with 70% ethanol before storing in sterile phosphate buffered saline (PBS). 
In a sterile class II fume cabinet, the epiphysia were dissected and using a 23g needle 
and syringe with complete alpha-Minimum Essential Medium (α-MEM, Gibco, Life 
Technologies, UK; see Appendix), bone marrow (BM) was flushed from the bones into a 
9cm Petri dish. The BM was then aspirated using the needle and syringe to create a 
single cell suspension. The suspension was passed through a 70µm cell strainer (BD 
Bioscience, UK) into a 50ml falcon tube to remove debris. The cell suspension volume 
was increased to 50ml with complete α-MEM and centrifuged at 400g for 5 minutes. 
Medium was removed and the cell pellet re-suspended in 10 ml of complete α-MEM. To 
count the number of cells obtained, 50µl of cell suspension was added to 200µl of 
complete α-MEM. This was further combined with 50µl of trypan blue at a 1:1 ratio. This 
mixture was then loaded onto a haemocytometer and the 16 squares from each of the 
four corners of the haemocytometer were counted and averaged. The value obtained 
was equal to the number of cells x 106 in the 10ml single cell suspension.  
2.2.3 Monocyte enrichment 
BM was prepared as described in Section 2.2.2. To lyse red blood cells (RBCs), 1ml of 
Akt Lysis Buffer (Gibco, Life Technologies, UK) was added to pelleted BM cells and 
incubated at RT for 1 minute. Complete medium was then used to inactivate the lysis 
buffer and cells were centrifuged at 400g for 5 minutes prior to counting with trypan 
blue. With RBCs lysed, BM samples were negatively sorted by magnetic separation using 
Monocyte Enrichment Kit according to manufacturer’s instructions (StemCell 
Technologies, UK).  Briefly, BM cells were counted and re-suspended at a cell density of 
1x108 cells/ml in Separation Media (see Appendix) in a 6ml tube to which 50μl/ml of 
normal rat serum was added. 50μl/ml of mouse monocyte enrichment cocktail was 
added and incubated for 15 minutes at 4oC. Cells were centrifuged at 300g for 10 
 
 
56 
 
minutes and subsequently re-suspended at 1x108 cells/ml. 60μl/ml of Biotin Selection 
Cocktail was added to cells for 15 minutes at 4oC. Cells were vortexed before 150μl/ml 
of magnetic beads were added and incubated for 10 minutes at 4oC. The cell suspension 
volume was increased to 2.5ml and placed inside a magnet for 5 minutes. Unwanted 
cells remained bound in the tube to the magnet, while monocytes were poured off. 
Purity of the total monocyte population was assessed by flow cytometry (described in 
2.9). Purified monocytes were plated out into tissue culture plates at a density of 1x105 
or 1x106 cells/ml in complete α-MEM with 30ng/ml M-CSF (Peprotech, UK) and either 50 
or 100ng/ml RANKL for 10 days, with media refreshed every third day. 
2.2.4 Blood and bone marrow mononuclear cell isolation 
For isolation of mononuclear cells, blood and BM was prepared as previously described 
(Section 2.2.2). Blood and BM cells were combined and this cell suspension was 
centrifuged once with room temperate (RT) PBS at 400g for 5 minutes before 
re-suspending in 1.5ml of PBS. This was layered onto 1.5ml of histopaque and 
centrifuged at 300g for 30 minutes without a centrifuge brake. Following centrifugation, 
the thin white layer (‘buffy coat’), containing mononuclear cells was removed and these 
cells washed with PBS once more before counting using trypan blue and re-suspension at 
1x105 cells/50μl. 50μl of this suspension was added to each well of a 96 well tissue 
culture plate and allowed to adhere for 2 hours before non-adherent cells were gently 
washed off using warm PBS. Adherent cells were cultured with complete α-MEM with 
10ng/ml M-CSF and either 50 or 100ng/ml RANKL for 7 days. 
2.2.5 Isolation of non-adherent bone marrow 
BM was obtained as previously described in Section 2.2.2 and the suspension of murine 
BM cells was re-suspended to a cell density of 1x106 cells/ml in complete α-MEM. 9ml of 
this suspension was cultured overnight at 37oC with 30ng/ml M-CSF in a sterile 9cm non-
tissue cultured treated Petri dish. Non-adherent (NA) BM cells were removed following 
the overnight incubation and these cells were centrifuged at 400g for 5 minutes and the 
cell pellet re-suspended in 10ml of complete α-MEM and counted using trypan blue as 
previously described (Section 2.2.2). The NA BM cells were then re-suspended at a cell 
density of 5x105 cells/ml and 200μl cell suspension containing 1x105 cells were cultured 
at 37oC in 96 well tissue culture plates along with M-CSF and/or RANKL at stated 
concentrations. Complete α-MEM was changed every 3rd day and experiments were 
terminated on various days (see results Section 3.2). In some experiments IL-1β 
(Peprotech, UK) was added to cultures at a concentration of 10ng/ml. 
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L929 cell supernatant which contains M-CSF was used to differentiate OCs. L929 is a 
fibrosarcoma cell line that secretes M-CSF into the cell culture supernatant and this 
supernatant can be used to differentiate MØ321–323. To generate L929 supernatant, L929 
cells were cultured in 100ml of complete Roswell Park Memorial Institute Medium (RPMI, 
Gibco, Life Technologies, UK; see Appendix) until confluent. Cells were cultured for a 
further 4 days to increase the concentration of M-CSF in the supernatant at which point 
supernatants were removed and centrifuged at 400g for 5 minutes to remove cellular 
debris. Supernatant was aliquoted and frozen at -20oC until required. Once thawed, 
L929 cell supernatant was double filtered using a 0.2μm filter (Sartorius Stedim biotech, 
UK) before being diluted in complete α-MEM at a ratio of 2 parts L929 to 8 parts 
complete α-MEM. At this dilution, aliquots of 1x106 cells/ml were plated out in tissue 
culture plates with or without 50 or 100ng/ml RANKL. Cells were cultured till day 7 with 
media refreshed every third day. 
In order to maximise osteoclastogenesis careful screening of FBS was undertaken to 
ensure the terminal differentiation of cells. Ultimately, this involved the use of twice 
filtered FBS using 0.2μm filters in all OC culture media. Additionally, OC differentiation 
in various 96 well flat bottom tissue culture plates (Costar, Corning, UK) was also 
optimised in order to gain maximum OC differentiation.  
2.3 Tartrate resistant acid phosphatase staining 
To assess OC differentiation, cultures were stained for TRAP using Leukocyte Acid 
Phosphatase Kit (Sigma-Aldrich, UK) pre-warmed to RT and following manufacturer’s 
instructions. Briefly, media was removed from cultures and cells were fixed with TRAP 
fixative solution (prepared following manufacturer’s instructions, see Appendix), for 30 
seconds. The fixative was then washed off three times with dH2O at 37
oC. The TRAP 
staining solution was prepared using the reagents provided in the kit (see Appendix) and 
warmed to 37oC. TRAP staining solution was incubated on fixed cells for 1 hour at 37oC. 
After incubation, the staining solution was removed and cultures were counter-stained 
with haematoxylin solution for 1 minute. The stained cells were rinsed in cold running 
water until water ran clear and plates were allowed to air dry. 
2.4 Assessing osteoclastogenesis 
TRAP stained OC cultures were imaged on an Olympus IX51 microscope (Olympus, UK) 
using Olympus TL4 Lamp (Olympus, UK) at 10x magnification. Images were captured 
using Cell^D Software (Olympus, UK) and four random images were taken of each well, 
which were then counted for the number of TRAP positive cells containing 3 or more 
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nuclei. The sum of each well was then averaged from the duplicates/triplicates of each 
condition to assess the level of osteoclastogenesis. ImageJ Analysis software (ImageJ, 
National Institute of Health, USA - http://imagej.nih.gov/ij/) was also used to calculate 
the size of OCs present in each field of view. 
2.5  Bone resorption assay 
NA BM cells were isolated as previously described (Section 2.2.5). NA BM cells were 
cultured in complete α-MEM with 75ng/ml M-CSF and 50ng/ml RANKL in 96 well plates 
on slices of bovine cortical bone (ImmunoDiagnostic Systems plc., UK). Bone slices were 
marked on their underside with pencil prior to culture and incubated at 370C in 
complete α-MEM for an hour to equilibrate the bone.  Cultures were maintained for 10 
or 14 days with media refreshed every 3rd day. On the 10th day, bone slices were 
removed and stained for TRAP as previously described (Section 2.3). On the 14th day, 
media was removed and replaced with tap water for 2 hours at  (RT) to lyse cells. A 
black marker pen was used to dye the non-pencilled side before quickly wiping off ink 
using tissue paper. Areas of erosion remain stained with ink while non-eroded areas 
wipe clean. For bone erosion analysis, five images of the bone slices were taken at 4x 
magnification and analysed using Image J software to calculate the area of erosion per 
bone slice and the area of the slice in the field of vision. The percentage area of erosion 
was then calculated. 
2.6  SpA immunoglobulin complexes 
SpA Immunoglobulin Complexes (SIC) were generated by incubating SpA (recombinant 
Staphylococcus aureus Protein A, rPA-50, RepliGen, USA) with ChromPure Murine IgG 
(Jackson ImmunoResearch, UK), at a molar ratio of 1:4 (37.5μM SpA: 150μM IgG). 
ChromPure Murine IgG is a preparation of whole IgG that has been isolated from 
non-immunised mice and therefore the composition of IgG subclasses present is 
representative of a healthy animal. For 3ml of media, 1.175µl SpA (4mg/ml) and 13.16µl 
Mouse IgG (5.7mg/ml) were incubated at 37oC for 1 hour to allow the formation of SIC 
after which, 15.6μl of PBS was added. SpA or OVA (Chicken Ovalbumin, Sigma, UK) 
alone (1.175µl SpA/OVA and 28.76 µl PBS) were used to control for SpA. OVA with 
polyclonal mouse IgG (1.175µl OVA, 13.16µl Mouse IgG and 15.6µl of PBS) were used as a 
control for SIC. IgG alone was also used as a control which was used at 5.7mg/ml 
(13.16μl) in 16.84μl of PBS. Each treatment was made up to a volume of 30μl in PBS. Of 
which, 10μl was added to 1ml of culture medium which maintained IgG at a constant 
concentration of 25μg/ml. The research presented throughout this thesis utilised SpA in 
all in vivo experiments, while in vitro assays use SIC. IgG was centrifuged at 4000rpm 
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for 5 minutes prior to use to prevent naturally forming IgG aggregates interfering with 
the formation of complexes or interacting with cultures. 
2.6.1 BS3 cross-linking 
SIC was generated as mentioned in Section 2.6. 1.175µl SpA (4mg/ml) and 13.16µl 
Mouse IgG (5.7mg/ml) were incubated at 37oC for 1 hour in an eppendorf tube. This 
allowed sufficient time for complexes to form. At the same time OpIg, IgG, SpA, OVA 
and PBS controls were generated. Following the 1 hour incubation, protein interactions 
were fixed using BS3 cross-linker (ThermoScientific, UK). 1mM of BS3 cross-linker was 
added to each condition and incubated at RT for 30 minutes. 0.5M Tris-HCl was added 
to each condition to terminate the reaction. 
2.6.2 Coomassie stain 
In order to visualise cross-linked proteins, each sample was mixed with 4x LDS sample 
loading buffer (Invitrogen, UK) 15μl was loaded onto a 4-12% Bis-Tris gel (Invitrogen, UK) 
along with 10μl of Pre-stained protein standard (Invitrogen, UK). 1x MOPS running buffer 
(Invitrogen, UK) was added to the central reservoir of an electrophoresis gel tank and 
samples electrophoresed at 200V for 1 hour. Gels were cracked open and washed in 
dH2O before addition of 20ml of Simply Blue SafeStain (Invitrogen, UK) and incubated 
with agitation at RT for 1 hour. Simply Blue SafeStain was washed off with dH2O for 1 
hour to remove background and enhance visualisation. Gels were imaged using an HP 
desktop scanner.    
2.6.3 Size exclusion chromatography 
To show the formation of SIC complexes from SpA and IgG, samples were run through a 
Sephacryl s-400 column (GE Healthcare, UK) using an ÄKTAprime plus (GE Healthcare, 
UK) to discriminate molecules based on size. Filtered PBS was used to wash the 
Sephacryl s-400 column prior to processing. 0.5ml of SIC was generated at 4mg/ml 
following 1 hour incubation at 37oC: 32.5μl SpA and 364μl IgG and loaded onto a column 
under the following conditions; flow rate - 0.2ml/ml; pressure limit – 0.5mPA; fraction 
size – 5ml; equilibrate volume – 120ml; sample injection - 0.5ml; elution volume - 
200ml. The resulting readout shows protein concentration (UV - A280) versus time. OpIg, 
IgG, SpA, OVA and PBS were also run under the same conditions as SIC. Sephacryl s-400 
was cleaned using 20% ethanol in dH2O. Results were visualised using PrimerView (GE 
Healthcare, UK) to establish the concentration and the time at which protein exited the 
column.  
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2.7 Polymerase chain reaction 
2.7.1 RNA isolation 
Murine NA BM derived OCs were differentiated as previously described (Section 2.2.5) 
until day 3. At this time, culture plates were centrifuged at 400g for 5 minutes, cell 
media removed and 700μl QIAzol Lysis Reagent (QIAGEN, UK) was added to each well to 
lyse cells. The lysates were transferred to 1.5ml eppendorfs and either immediately 
using for RNA extraction or stored at -20oC for later purification. RNA was isolated from 
lysates used a miRNeasy Mini Kit (QIAGEN, UK), as per manufacturer’s instructions, 30μl 
of RNase free water was used in the final elution. 
To ensure purified RNA had been isolated the samples were kept on ice and a Nanodrop 
1000 (ThermoScientific) was used to detect the concentration of RNA present in each 
sample. Once the purity and concentration of RNA had been determined the samples 
were stored at -20oC. 
2.7.2  cDNA generation 
Purified RNA was used to generate cDNA using Affinity Script cDNA synthesis kit (Agilent 
Technologies, UK) following manufacturer’s instructions. Using a PCR machine (Applied 
Biosystems 2720 Thermal Cycler, UK), random primers in the Affinity Script cDNA 
synthesis kit transcribed the RNA and generated cDNA. 200ng of RNA was used to 
generate cDNA and this was diluted in 50μl to give 4ng/μl cDNA template and stored 
at -20oC. 
2.7.3 Primer design 
A set of primers (forward and reverse) to generate a PCR product of 100-150 base pairs 
were designed using Primer3 Software (National Institute of Health, USA) and the NCBI 
nucleotide database (National Centre for Biotechnology Information, USA). Primers were 
designed to be between 18-23 base pairs in length have, a 40-60% GC nucleotide 
content, a melting temperature of between 59.5 and 61oC, a maximum self 
complementarity of 2 and a maximum 3’ self complementarity of 1. Once primers had 
been designed and met these specific criteria, Primer BLAST software (National Centre 
for Biotechnology Information, USA) was used to determine their specificity of the 
primers and predict non specific amplification. Once a primer set had met all these 
criteria they were purchased from Integrated DNA Technologies Ltd. (IDT) and tested 
for specificity by end point PCR (Table 2-1). Primers for GM-CSF, Bcl-2 and Bcl-XL were 
obtained from QIAGEN and have been optimised for use with SYBR green. 
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2.7.4  End Point PCR 
To ensure successful generation of cDNA and to test the specificity of primers, end point 
PCR was undertaken. A standard protocol was followed for the generation of a PCR 
master mix; the components of which were 
 Nuclease free water   - 35.5μl 
 5x GoTaq Buffer (Promega)  - 10μl 
 10mM dNTPs (Promega)  - 1μl 
 Primer 1 (Forward)   - 1μl 
 Primer 2 (Reverse)   - 1μl 
 Go Taq Polymerase (Promega) - 0.5μl 
 cDNA (4ng)    - 1μl 
 
 
Each sample was made up in a 0.2ml PCR tube and run on a PCR machine. The following 
thermal cycle was used; an initial 94oC for 5 minutes step followed by 35 cycles of 94oC 
for 10 seconds, 55oC for 30 seconds and 72oC for 30 seconds, terminating the reaction 
with 10 minutes at 72oC before holding at 4oC. After termination of the PCR, the 
samples were loaded into a 2% Agarose gel (see Appendix) with 5μl ethidium bromide 
added prior to pouring the solution onto the flat bed electrophoresis tank. Once the gel 
had cooled and set, 1Kb DNA ladder (Invitrogen, Life Technologies, UK) and PCR samples 
were loaded and the tank attached to a power pack set at 100V for 60 minutes. Gels 
were visualised using a UV light (Alpha Innotech, UK) to detect the presence of PCR 
products at correct molecular weight. 
2.7.5 Quantitative PCR 
For a 96 well qPCR plate (Starlabs, UK), each sample was run in triplicate with a master 
mix comprising of 10.4μl PerfeCTa SYBR Green FastMix (Quanta Bioscience, USA) or 
POWER SYBR Green (Life Technologies, UK), 0.8μl primer mix (0.4μl/primer) and 8.4μl 
nuclease free water per well. 56μl of this reaction mixture was then added to mixing 
wells along with 6μl of appropriate cDNA. This was mixed by pipette 20 times and 19μl 
was added to each of the triplicates. A non-template control (NTC) was used which 
contained nuclease free water in place of cDNA to ensure no contamination of the 
reagents. After loading, the plate was sealed using an adhesive PCR plate cover 
(Starlabs, UK) and centrifuged at 300g for 1 minute. A 9700HT qPCR machine (Applied 
Biosystems) was used to run the samples; the qPCR temperature cycle was 10 minutes 
at 94oC, followed by a 40 cycles of 94oC for 3 seconds and 60oC for 30 seconds. The final 
stage in this process is a dissociation curve which is an incremental increase in 
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temperature from 65oC up to 94oC which is designed to test the specificity of the 
primers in generating only one product. All genes were normalised to housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). ΔCt was measured for each 
sample by subtracting the gene of interest ΔCt of an individual sample from the 
corresponding housekeeping gene ΔCt sample. ΔΔCt was calculated by subtracting the 
ΔCt of a sample of interest from the control sample ΔCt. Fold change was measured by 
inserting the ΔΔCt of a sample into the power equation (2-ΔΔCt).  
Target 
Name 
Direction Tm ( oC) Product Size 
(bp) 
Sequence 
GAPDH F 56.2 100 ACGCAAGGACACTGAGCAAG 
R 53.5 TATTATGGGGGTCTGGGATG 
CD115 F 55 126 TGAAGGTGGCTGTGAAGATG 
R 58.2 AGGCTCCCAAGAGGTTGACT 
RANK F 53.2 102 TTTGTGGTTTTGGCATCCTT 
R 54.3 CTGGCACCTTCATTTTGTCC 
NFATc1 F 54.1 133 ACGCAAGGACACTGAGCAAG 
R 56.1 TATTATGGGGGTCTGGGATG 
DC-STAMP F 56.3 139 TCTGCTGTATCGGCTCATCTC 
R 56.6 ACTCCTTGGGTTCCTTGCTT 
TRAP F 56.4 102 GGTATGTGCTGGCTGGAAAC 
R 59.0 GGTAGTAAGGGCTGGGGAAGTC 
MMP9 F 57.6 128 TCTACTGGGCGTTAGGGACA 
R 58.0 AGGAGTCTGGGGTCTGGTTT 
Cathepsin K F 54.9 122 GGAACGAGAAAGCCCTGAA 
R 56.0 CACACCTCTGCTGTAAAACTGG 
OSCAR F 54.2 109 GTTTTGGGGGTTTGTTCGTT 
R 53.9 TTACCTGGGAGATGGGATTG 
Bcl 3 F 62.9 102 CCGGAGGCCCTTTACTACCA 
R 62.8 GGAGTAGGGGTGAGTAGGCAG 
RANKL F 56.0 100 ATGAAAGGAGGGAGCACG 
R 57.4 AGCAGGGAAGGGTTGGAC 
Primers Ordered from QIAGEN 
Name Product Code 
GM-CSF PPM02990F-200 (csf2) 
Bcl-2 PPM02918F-200 (bcl2) 
Bcl – XL PPM02920F-200 (bcl2l1) 
Table 2-1: List of primers sequences ordered from Integrated DNA Technologies Ltd and 
QIAGEN for qPCR analysis. 
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2.8 Osteoporosis surgical model 
OVX or sham operations were performed on 8 week old anaesthetised female C57Bl/6 
mice by Charles River UK. Mice were laid prone rostro-caudally away from the surgeon. 
The dorso-lumbar region was shaved, and sterilised with 70% ethanol before a ~20mm 
skin incision was made along the vertebral column. Approximately 10mm long incisions 
were made through the muscle wall on either side of the vertebral column and the 
peritoneal cavity exposed. The ovaries, located in a fat pad, were carefully excised. 
Once both ovaries were removed the skin incision was closed using wound clips. If Alzet 
PumpsTM (model 2004) were to be used; Alzet pumpsTM were inserted into the peritoneal 
cavity prior to closing the incision with wound clips. The animals were allowed to 
recover for 7 days and subsequently delivered to the University of Glasgow’s Central 
Research Facility. Sham and OVX animals were used in three treatment regimes. 100μg 
of SpA or OVA was given i.p. to animals in the Therapeutic Treatment Regime starting 
two weeks after surgery. This dose was given every second day up until week 6 when 
the experiment was terminated. The second treatment regime was the Continuous 
Treatment Regime in which 100μg of SpA or OVA was given i.p. to animals from the day 
of surgery until the termination of the experiment at week 6. The final treatment 
regime was the Alzet PumpTM Treatment Regime, in which Alzet PumpsTM containing 
1.4mg of SpA or OVA was inserted into the peritoneal cavity at the point of surgery. 
Alzet PumpsTM secrete SpA/OVA over the course of 4 weeks. All operated mice were 
maintained for 6 weeks after surgery and after which they were euthanized by rising 
concentration of CO2 according to Home Office regulations. 
2.9 Flow cytometry 
Blood and BM were harvested for analysis of cellular populations by flow cytometry. 
200μl of blood was taken using EDTA flushed needles and RBCs lysed using ammonium 
chloride (1 part blood to 9 parts NH4Cl - Stem Cells Technologies, France) on ice for 15 
minutes. BM was prepared and lysed as previously described (Section 2.2.3). Lysis 
buffers were washed off by addition of excess complete media and centrifuged at 400g 
for 5 minutes. Cells were re-suspended in FACs Buffer (See Appendix). Cell numbers 
were determined by either the haemocytometer trypan blue method (Section 2.2.2) or 
by using a MACsQUANT (Miltenyi Biotec, Germany). After counting, 1x106 cells were 
added to each FACs tube in technical duplicates and 1ml of FACS buffer added before 
centrifugation at 400g for 5 minutes. The buffer was aspirated off, tubes vortexed and 
non-specific binding by Fcγ receptors were blocked by using 50μl of 5% normal rat serum 
in FACS Buffer and incubating at 4oC for 15 minutes. Primary antibodies were used at 
stated concentrations and added to a master mix (Table 2-2). 50μl of master mix was 
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then added to each tube and cells stained for 15 minutes at 4oC. Antibody was washed 
off by addition of 1ml of FACS buffer and centrifugation at 400g for 5 minutes. 
Supernatant was aspirated and cell pellets were vortex and re-suspended in 300μl of 
FACS buffer for acquisition on the MACsQUANT (Miltenyi Biotec, Germany) or LSRII (BD 
Bioscience). If a secondary antibody step was required, the cells were stained with 50μl 
of diluted streptavidin conjugated fluorophore in FACS buffer and incubated for 15 
minutes at 4oC, before being washed and re-suspended in 300μl of FACS buffer for 
acquisition. Prior to acquisition, cells were passed through Nitex to prevent cell 
aggregates blocking or interfering with the acquisition and analysis of the cell 
populations. In certain experiments dead cells were excluded from analysis, in order to 
do this, 3μl of DAPI (diluted 1/100 in FACS buffer – Sigma, UK) was added to 300μl of 
cells samples and briefly vortex prior to acquisition. Another method to exclude dead 
cells, which involved staining cells with Live/Dead Aqua Stain (Molecular Probes, 
Invitrogen, UK). Live/Dead Aqua Stain was prepared according to manufacturer’s 
instructions, briefly, 50μl of DMSO was added to lyophilized dye and 1μl/ml of this 
solution was incubated with 1x106cells/ml in PBS for 30 minutes on ice but protected 
from light. Cells were subsequently centrifuged for 5 minutes in excess FACS Buffer and 
re-suspended in FACS Buffer for acquisition. Analysis of FACs data was done using 
FlowJo software (TreeStar Inc., USA). This protocol was also used to examine purity 
following monocyte enrichment (outlined in Section 2.2.3). 
A FACS Aria was also used to sort CX3CR1 GFP+ Ly6Chigh/low monocytes for in vitro 
culturing. Blood and BM were isolated from CX3CR1 GFP animals after which cells were 
prepared for FACS. Dr. J. Montgomery stained and acquired cells on the FACS Aria, after 
which Ly6Chigh and Ly6Clow monocytes were used for culturing. Sorted cells were used in 
an OC assay (as previously described in Section 2.2.5). 
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Table 2-2: List of flow cytometry reagents used. 
 
2.10 ELISA 
IFN-γ, TNF, IL-6, IL-1β, Osteocalcin and CTX-1 ELISAs were performed on mouse plasma. 
Plasma was obtained at the time of culling by exsanguinating the mouse via the vena 
cava using a 23g needle flushed with 0.5M EDTA (see Appendix) and blood was kept on 
ice. Blood was centrifuged at 4,000rpm for 10 minutes and the clear plasma layer 
removed and stored at -20oC.  
IFN-γ, TNF-α, IL-1β and IL-6 ELISA kits (BD Bioscience, UK) were used and 
manufacturer’s instructions were followed. Micro half-well high binding ELISA plates 
(Fisher Scientific) were used to reduce the volume of reagents required. Briefly, ELISA 
plates were coated with specific capture antibody diluted in appropriate coating buffer 
(see Appendix) overnight at 4oC. Plates were washed with PBS 0.05% Tween-20 (Sigma, 
see Appendix) a minimum of 3 times. Plates were then blocked with 5% FBS in PBS 
(Assay Diluent, see Appendix), to reduce non-specific binding, for 1 hour at RT. Plates 
were washed prior to incubation with protein appropriate standards and samples, 
diluted with assay diluents at appropriate dilution, and incubated at RT for 2 hours. 
Plates were washed using PBS 0.05% Tween-20 a minimum of 3 times. A detection 
antibody and a streptavidin-HRP were then used separately or in a working detector 
solution in assay diluents according to manufacturer’s protocol. After 1 hour incubation 
at RT, plates were washed before tetramethylbenzidine (TMB, Kirkegaard & Perry 
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Laboratories, Inc., USA) solution was added to develop the ELISA and the reaction 
stopped using stop solution (2M H2SO4). The plate was read at 450nm using an ELISA 
reader (Sunrise ELISA Reader, Tecan, Switzerland) and a standard curve generated for 
each plate and sample concentrations calculated from the curve. 
Osteocalcin and CTX-1 were both pre-coated ELISA plates purchased from Biomedical 
Technologies Inc., and Immunodiagnostic systems Ltd., respectively. Manufacturer’s 
instructions were followed for both ELISAs. All samples and standards were run in 
duplicate and plasma samples were added at a 1:10 dilution with assay diluents 
provided (Osteocalcin) or added neat (CTX-1) to the appropriate pre coated ELISA 
plates. ELISA plates were read at 450nm on an ELISA plate reader and standard curves 
generated in order to calculate the concentration of protein in each sample. CTX-1 was 
an inverse competitive ELISA and required the use of a 4 way parameter logistic 
standard curve to calculate the sample concentrations of CTX-1. 
2.11 Biomechanical testing 
Left femurs were removed from OVX/Sham mice 6 weeks post surgery. Femurs were 
stored in 70% ethanol and stored at 4oC. Prior to biomechanical testing, femurs were 
rehydrated in PBS overnight and allowed to equilibrate to RT. All tissue was thoroughly 
removed from the femur to ensure that periosteum would not interfere with the 
strength of the bone. Three point bend testing was used as a measure of biomechanical 
integrity of bone using femurs loaded onto an Instron Dynamite hydraulic tester with 
data collected using Bluehill Software. Three point bend testing was performed under 
the supervision of Dr. N. Horwood at the Kennedy Institute of Rheumatology, Imperial 
College London. Femurs were placed ventral side down on two supports and a third 
support was slowly lowered from above to determine the force and time required to 
break the femur. Using this data, Bluehill software calculated Maximum Load 
(Neutrons), Extension at Maximum Load (mm), Load at Break (N), Extension at Break 
(mm), Energy at Break (J) and Modulus (MPa – Mega Pascal’s). 
2.12 Micro-computer tomography 
Tibiae were harvested from 12 week old C57Bl/6 or Bcl-3-/- mice and C57Bl/6 mice 6 
weeks post OVX/Sham surgery. Bones were fixed overnight in 4% formaldehyde in PBS 
(Fisher Chemicals, UK) before being stored in 70% ethanol at 4oC. To assess the 
micro-architecture of the trabecular bone in tibiae and vertebrae, the bones were 
scanned using a micro-computer tomography (μCT) system (Skyscan 1172 X-Ray 
microtomograph or Skyscan 1174 X-Ray microtomography, Aarteselaar, Belgium). μCT 
analysis was performed at the Institute of Genetics and Molecular Medicine, University 
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of Edinburgh, UK under the supervision of Dr. R. Van’t Hof. Scans were obtained with an 
isotropic voxel size of 4.6μm on a Skyscan 1172 or 8.3μm on a Skyscan 1174 (60kV, 
150μA, 0.5mm aluminium filter, 0.5 rotation angle). NReconn software (Skyscan, 
Belgium) was used to reconstruct the X-Ray images into a 3D structure.  
To analyse the trabecular bone of the tibiae, the growth plate of the tibia was used as a 
reference point in all samples. 20 sections below this reference point, 200 further 
sections were selected for analysis in CTAn software (Skyscan, Belgium). Using CTAn the 
trabecular regions underwent thresholding which was set at 80 - 255. The sample 
thresholds were set and analysed using CTAn software. The following parameters were 
analysed; bone volume (BV; μm3), tissue volume (TV; μm3), the percentage of trabecular 
(Bone volume/Tissue Volume; BV/TV; %), tissue surface (μm2), bone surface (μm2), bone 
surface density (BS/TV; μm), trabecular thickness (Tb.Th; μm), trabecular separation 
(Tb.Sp; μm), trabecular number (Tb.No; 1/μm), structural model index (SMI), 
connectivity (Conn.), degree of anisotropy (DA) and connectivity density (1/μm3).        
2.13 Histology 
Following euthanization, C57Bl/6 and Bcl-3-/- animals had hind legs removed for 
histological analysis. Legs were fixed overnight in 4% formaldehyde in PBS and 
subsequently washed in PBS to remove any fixative. 15ml of decalcification solution 
(14% EDTA pH 8, see Appendix) was then added and agitated at 4oC. Decalcification 
solution was changed every week until legs were pliable to touch. Pliable legs were 
subsequently dissected and tibiae then embedded in paraffin wax using Shandan Citadel 
1000 Tissue Processor (Fisher Scientific) and subsequently 20μm sections cut (VWR, UK) 
using a Shandon Finesse 325 Microtome (Fisher Scientific) placed onto super frost glass 
slides. 
2.13.1 Haematoxylin and eosin staining 
Sections of paraffin embedded mouse legs were stained for H&E. Sections were heated 
to 65oC for 1 hour and then de-waxed in two changes of xylene for 3 minutes. Sections 
were then rehydrated in 100%, 90% and 70% ethanol for 5 minutes each, sections were 
subsequently rinsed in cold running tap water. Rehydrated sections were stained with 
haematoxylin for 2 minutes, and washed for 3 minutes in cold running tap water. 
Sections were immersed in 1% acid/alcohol (see Appendix) for a few seconds before 
rinsing in cold running water. Sections were immersed in Scotts Tap Water Substitute 
(see Appendix) for 30 seconds and then stained with 1% Eosin for 2 minutes. Excess stain 
was rinsed off using cold running tap water. Sections were dehydrated through graded 
alcohol (70%, 90% and 100%) for 5 minutes each and then placed in two changes of 
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xylene for 5 minutes each. Sections were mounted with coverslips using DPX (Leica 
Biosystems, UK). Stained sections were imaged on an Olympus IX51 microscope 
(Olympus, UK) using Olympus TL4 Lamp (Olympus, UK).   
2.13.2 Histological TRAP staining 
Coronal sections of the paraffin embedded proximal tibiae were cut and stained to 
determine the presence of OCs in the tibial trabeculae. Slides were heated to 65oC for 1 
hour and de-waxed in Xylene for 10 minutes and re-hydrated in graded ethanol steps 
(100%, 90% and 70% ethanol for 5 minutes) followed by 2 minutes in 37oC dH2O). 
Rehydrated sections were incubated in TRAP staining solution (see Appendix) for 4 
hours. After incubation TRAP stain was rinsed off in 37oC dH2O and counterstained with 
Meyer’s Haematoxylin (CellPath, UK) for 1 minute. The excess haematoxylin was rinsed 
off in dH2O and slides were allowed to air dry, removing excess dH2O, prior to mounting 
in Vectashield mounting medium (Vector Laboratories, UK) and sealed with nail varnish. 
An Olympus IX51 microscope (Olympus, UK) using Olympus TL4 Lamp (Olympus, UK) was 
used to visualise OCs which were stained red/purple. 
2.14  Statistical analysis 
Statistical analysis was performed using GraphPad Prism4 software (GraphPad, USA). 
One Way ANOVA was used to compare more than two groups of data with Bonferroni’s 
post hoc tests used to test for significance. Two Way ANOVAs were used to compare two 
sets of animals within two treatment groups and Bonferroni’s post hoc tests were used 
to determine the significance between groups. Student’s unpaired two-tailed t-tests 
were used to compare the results from two groups of animals. 95% confidence intervals 
were selected and p-values of < 0.05 were deemed significant. The appropriate 
statistical test used is described in the figure legends. 
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3 Fcγ receptor interactions inhibit osteoclastogenesis 
3.1 Introduction 
OCs are large multinucleated cells responsible for eroding the bone during skeletal 
remodelling1. OCs originate from monocytes, MØ and OCPs found in the blood and BM 
and in situ differentiation can be driven by a number of cytokines and interactions1. 
However, in vitro M-CSF and RANKL are known to be sufficient for OC differentiation324. 
M-CSF and RANKL act on their respective receptors, CD115 and RANK, on the surface of 
monocytes, MØ and OCPs to commit these cells to the OC lineage324. Stimulation via 
CD115 results in pro-survival signals128 and increased expression of surface RANK leading 
to an increased potential for RANKL binding and signalling to promote 
osteoclastogenesis6,325.  
A myriad of factors are capable of driving/enhancing OC differentiation. Factors such as 
TNF-α326,327, IL-1328, IL-6329 and the presence of Collagen Type I in the bone matrix acting 
through OSCAR and the FcRγ154,330 are known to enhance the in vitro differentiation of 
OCs. However, RANKL is mainly responsible for the differentiation of OCs through NF-κB 
activation328,331. NF-κB is an umbrella term for five subunits which combine to form a 
combination of homo- and hetero- dimers each with distinct activities332. RANKL 
mediated NF-κB activation results in the p50 and p65 subunits forming a heterodimer 
which rapidly translocates to the nucleus331, signalling the up-regulation of essential 
osteoclastogenic genes and activating NFATc1, which strongly induces 
osteoclastogenesis333. Up-regulated OC specific genes encode proteins like DC-STAMP7, 
OSCAR213, MMP9334, TRAP239,335 and Cathepsin K336,337 which govern OC fusion and enzyme 
production required for the degradation of the bone matrix and bone resorption. 
Monocytes and MØs are known to express FcγR that bind IgG in complex with antigen249. 
Mature murine OCs have also been shown to express all subsets of murine FcγRs: FcγRI, 
FcγRIIB, FcγRIII and FcγRIV259,262.  FcγRI, the high affinity receptor, can bind monomeric 
IgG and signals via the FcRγ251. FcγRIIB, FcγRIII and FcγRIV are only able to bind IgG that 
has formed an IC with several IgGs bound to a single antigen, resulting in cross-linking of 
FcγRs and intracellular signalling338. The effects of these interactions can range from 
phagocytosis of the bound antigen and production to cytokines to enhance the immune 
response339.  
OCs are known to express activatory FcγRI, FcγRIII, FcγRIV and are able to phagocytose 
inert particles264 independently of FcγRs262. Therefore the role of these receptors on 
OCs is unknown. However, recent work by Seeling et al (2013) demonstrated that 
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cross-linking of activatory FcγRI or FcγRIV on RANKL stimulated MØ was able to increase 
differentiation to mature OCs by two fold262. Grevers et al (2012) showed that 
treatment with heat-aggregated rabbit IgG could inhibit the differentiation of murine 
BM into mature OCs in a FcRγ dependent manner340. Seeling and Grevers both 
demonstrated that activatory FcγRs were able to respond differently to ligation. The 
mode of stimulation and differentiation state of the pre-OCs can cause the resulting 
effect to differ markedly262,340.  
In this study, IgG complexes generated by the combination of SpA and IgG will be 
investigated. SpA’s natural ability to form a SIC at a ratio of two SpA to four IgG has 
been widely studied299–301,341–343. Research investigating the potential of SIC to engage 
FcγRs on myeloid cells has shown that SIC can (a) modulate the polarisation state of the 
murine and human MØ, and (b) inhibit the in vitro differentiation of human OCs316. 
Administration of SpA alone, in vivo, was also shown to reduce inflammation in the 
mouse model of CIA, and subsequently reduce the number of OCs in the inflamed 
joint316. These effects are thought to be mediated via FcγRs; in particular, FcγRI. 
MacLellan et al (2011) showed that in the absence of FcγRI, SIC was unable to interact 
with in vitro MØ and pre-OCs316. Thus SIC and heat-aggregated rabbit IgG used by 
Grevers et al (2012) would appear to utilise a similar mechanism of action340. FcγRI is an 
activatory receptor which depends on signal transduction through the FcRγ265. The FcRγ 
and a fellow adaptor protein DAP12 are both activatory ITAM signalling molecules and 
have been shown to regulate the differentiation and activity of OCs in vitro and in 
vivo344. Animals deficient for both the FcRγ and DAP12 become osteopetrotic due to 
deficient OSCAR stimulation154,330. Despite research into the vital role of the FcRγ 
signalling pathways in OC differentiation, the effect of FcγRs has not been greatly 
studied.  
The goal of the research presented in this chapter was to examine the effect of SIC on 
in vitro murine osteoclastogenesis. The principal aims were to: 
1. Determine the optimal conditions for OCs’ differentiation in a murine in 
vitro system. 
2. Examine the effect of SIC on osteoclastogenesis. 
3. Examine whether SIC has an effect on the transcription of OC specific 
genes. 
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3.2  Results 
3.2.1 Optimisation of in vitro osteoclastogenesis 
In order to examine the effect that SIC has on osteoclastogenesis, an in vitro assay had 
to be optimised due to marked variation in existing published data7,69,345. In all 
instances, M-CSF and RANKL are necessary and sufficient to drive osteoclastogenesis324 
but the exact concentrations needed to be empirically determined due to variations in 
published protocols. To define the appropriate amount of RANKL required, studies were 
initiated with a standard assay using immortal murine MØ cell line, RAW 264.7. The 
ability of RAW 264.7 cells to respond to RANKL and differentiate into OCs has been 
widely published346–348. The differentiation of OCs was assessed by the ability of RAW 
264.7 cells to differentiate into large multinucleated OCs (greater than 3 nuclei) which 
stain positive for TRAP349. Stimulation of RAW 264.7 cells at 1x105 cells/ml in a 24 well 
plate while increasing the concentration of RANKL from 50 to 100ng/ml failed to 
differentiate OCs after 5 days of culture (data not shown). In order to further 
investigate RAW 264.7 cells differentiation into OCs, RAW 264.7 cell densities were 
changed from 7x104 up to 1x106 cells/ml while terminating the experiment at different 
time-points. Varying these factors failed to induce full osteoclastogenesis: RAW 264.7 
cells would become TRAP positive but would not fuse and become multinucleated (data 
not shown). Due to the failure of RAW 264.7 cells to respond to RANKL, use of this cell 
line was discontinued to optimise the conditions for osteoclastogenesis using primary 
cells. 
The generation of human OCs relies on the differentiation of purified CD14+ monocytes 
isolated from PBMCs. In contrast to this the published literature regarding murine OCs 
has shown that OCs can be differentiated from BM. Previous work in the lab using OC 
cultures has been conducted on human CD14+ monocytes. Accordingly, to comply with 
previous human studies, purified murine BM monocytes were isolated using negative 
magnetic selection, gaining approximately a 92% pure monocyte population. These 
monocytes were cultured at 1x105 and 1x106 cells/ml in the presence of either 50 or 
100ng/ml RANKL alongside 30ng/ml M-CSF for 10 days. TRAP staining showed 
osteoclastogenesis in this purified population was low and cells did not appear to thrive 
(Figure 3-1). Due to the lack of OCs in the purified BM monocyte population, it was 
decided to isolate circulating murine mononuclear cells in a similar manner to the 
isolation of human CD14+ monocytes from blood. Murine blood was harvested in the 
presence of EDTA and combined with BM samples. The blood and BM mixture was 
subsequently centrifuged on a histopaque layer and the mononuclear cells isolated. 
When 1x105 mononuclear cells were cultured in the presence of 10ng/ml M-CSF and 0, 
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50 and 100ng/ml RANKL for 7 days there was a small degree of osteoclastogenesis 
(Figure 3-2) compared to the monocytes isolated from BM alone (Figure 3-1). However, 
the proportion of OCs that differentiated was minor and the number of mononuclear 
cells isolated from murine blood and BM was minute. This method of OC generation was 
considered unfeasible for the undertaking of larger scale OC assays. Consequently, a 
different method was sought. 
To investigate an alternative method of inducing OC differentiation the literature was 
once again examined. According to Burger et al (1982) the optimal conditions for 
murine osteoclastogenesis involved using murine whole BM as a source of OCs 
progenitors alongside M-CSF and RANKL to stimulate osteoclastogenesis345,350. An initial 
experiment which replicated these conditions was conducted. Murine BM was taken 
from C57Bl/6 animals and flushed from the long bones and cultured overnight at 1x106 
cells/ml with 30ng/ml M-CSF. Following the overnight incubation, non-adherent (NA) BM 
cells were cultured at a cell density of 1x106 cells/ml until day 7 with 30ng/ml M-CSF 
and 50ng/ml RANKL. Assessment by TRAP staining showed very few OCs present in 
RANKL treated cultures (Figure 3-3). Due to the absence of osteoclastogenesis and lack 
of distinction between the RANKL treated positive control cultures and M-CSF alone 
negative control cultures, further investigation into the conditions which differentiate 
murine BM into OCs was needed. 
To investigate these conditions, pro-OC factor IL-1β was used to aid the induction of 
osteoclastogenesis using murine BM. IL-1β is a known activator of OC activity and 
maturation351. This activatory cytokine has been shown to stimulate osteoclastogenesis 
and multinucleation351. NA BM cells were generated as previously described and cells 
were cultured with 30ng/ml M-CSF and 0, 50 or 100ng/ml RANKL, with or without 
10ng/ml IL-1β. The addition of IL-1β in this culture system had no effect on the level of 
osteoclastogenesis (Figure 3-4). Interestingly, it was observed that increasing RANKL 
concentration had no added effect on osteoclastogenesis. Increasing RANKL 
concentration from 50ng/ml to 100ng/ml in cultures of purified monocytes and whole 
BM had no effect on the number of OCs differentiated (Figure 3-1, Figure 3-2 and Figure 
3-4). Hence, RANKL was not the limiting factor in this culture system, so M-CSF was 
investigated to determine whether it could be a limiting factor in osteoclastogenesis. 
Treatment with purified recombinant mouse M-CSF was compared to treatment with 
L929 cell supernatant. L929 is an immortal fibroblast cell line which secretes M-CSF and 
can be used to differentiate MØs in culture321,323,352. Supernatant from these cultures 
was kindly provided by Dr. J. Montgomery. As previously described, murine NA BM at 
1x106 cells/ml were cultured in the presence of L929 supernatant or M-CSF at 30ng/ml 
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with 0, 50 or 100ng/ml RANKL for 7 days. Cells differentiated in the presence of L929 
supernatant did not become OCs and only a small number of OCs differentiated with 
M-CSF at 30ng/ml in both 50 and 100ng/ml of RANKL (Figure 3-5). When 50ng/ml RANKL 
was used, there were, on average, 10 times more OCs present in M-CSF treated cultures 
than L929 cell supernatant cultures. While there were 14 times more OCs present in 
M-CSF treated cultures compared to L929 cell supernatant when used along with 
100ng/ml RANKL. This stark difference indicated that purified recombinant mouse 
M-CSF was superior to L929 cell supernatant for the in vitro differentiation of OCs.  
The generation of OCs in this culture system relied on the use of purified recombinant 
mouse M-CSF and the optimal concentration of M-CSF required for the differentiation of 
OCs was investigated. NA BM cells were cultured at 1x105 cells in 200μl of complete 
α-MEM in 96 well tissue culture plates. Cells were cultured with 50ng/ml RANKL and 
increasing concentrations of M-CSF (30ng/ml, 50ng/ml, 75ng/ml and 100ng/ml) for 5 
days at 37oC. There was a dramatic increase in the size and multinucleation of OCs 
differentiated in 75ng/ml and 100ng/ml M-CSF compared to 30ng/ml and 50ng/ml 
(Figure 3-6A). Interestingly, this huge difference in appearance was not as obviously 
mirrored in the number of OCs enumerated. When compared, there was no difference 
between the M-CSF concentrations used (Figure 3-6B). However, due to the intensely 
TRAP+ multinucleated large OCs present in cultures treated with >75ng/ml M-CSF, this 
concentration of M-CSF in conjunction with 50ng/ml RANKL was chosen as the optimal 
conditions for the generation of OCs and future experiments were modelled on this 
system.  
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Figure 3-1: Enrichment of bone marrow monocytes does not induce the differentiation of 
osteoclasts. 
Murine BM cells were harvested and RBCs were lysed using Akt Lysis Buffer. Monocytes were then 
enriched using EasySep Mouse Monocyte Enrichment Kit. Flow cytometry confirmed a 92.4% 
purity post separation. Purified monocytes (either 1 x105 or 10x105 cells) were cultured with 
30ng/ml M-CSF and either 50 or 100ng/ml RANKL for 10 days in 37oC with media renewed every 
third day. Cultures were stained for the presence of TRAP. A) Representative images of TRAP 
stained cultures. B) TRAP+ OCs with >3 nuclei were counted and the sum total of 8 fields of view 
per condition, in duplicate. Data represents mean ± SD of experimental duplicates. Scale bar; 
200μm. 
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Figure 3-2: Isolated blood and bone marrow monocytes respond to high concentrations of 
RANKL. 
Murine blood was taken using EDTA and BM was taken as previously described. Mononuclear cells 
were isolated using gradient centrifugation on a histopaque layer. The resulting ‘buffy coat’ was 
removed and 1x105 mononuclear cells in 50μl was allowed to adhere to tissue culture plate wells 
at 37oC for 2 hours. Non-adherent cells were gently washed using warm PBS. Complete α-MEM 
with 10ng/ml M-CSF and 0, 50 or 100ng/ml RANKL were added to cultures in duplicate. Cultures 
were maintained at 37oC for 7 days with media refreshed on day 3. Cultures were stained for the 
presence of TRAP. A) Representative images of TRAP stained cultures. B) TRAP+ OCs with >3 
nuclei were counted and the sum total of 4 fields of view per condition, in duplicate. Data 
represents mean ± SD of experimental duplicates. Scale bar; 200μm. 
 
 
76 
 
 
Figure 3-3: 30ng/ml M-CSF and 50ng/ml RANKL is not sufficient to differentiate osteoclasts. 
1x106 murine NA BM cells were cultured with 30ng/ml M-CSF and 50ng/ml RANKL for 7 days in 
37oC with media renewed on day 4. A) Cultures were stained for the presence of TRAP; 
representative images of cultures are shown. B) TRAP+ OCs with >3 nuclei were counted and the 
sum total of 4 fields of view per condition, in duplicate. Data represents mean ± SD of 
experimental duplicates. Scale bar; 200μm.  
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Figure 3-4: Addition of IL-1β does not promote osteoclastogenesis. 
1x106 murine NA BM cells were cultured with 30ng/ml M-CSF and 0, 50 or 100ng/ml RANKL. 
10ng/ml IL-1β was also added to cell media. Cultures were maintained for 7 days in 37oC with 
media renewed every third day. Cultures were stained for the presence of TRAP. A) 
Representative images of TRAP stained cultures. B) TRAP+ OCs with >3 nuclei were counted and 
the sum total of 5 fields of view per condition were used. Data represents mean ± SD of 5 fields 
of view in one experiment. Scale bar; 200μm. 
 
 
78 
 
 
Figure 3-5: Comparison of L929 culture media or M-CSF to differentiate osteoclasts. 
1x106 murine NA BM cells were cultured with either L929 (2 parts L929 to 8 parts media) or 
30ng/ml M-CSF and 0, 50 or 100ng/ml RANKL for 7 days in 37oC with media renewed every third 
day. Cultures were stained for the presence of TRAP. A) Representative images of TRAP staining. 
B) TRAP+ OCs with >3 nuclei were counted and the average number of OCs in 5 fields of view per 
condition. Data represents the mean ± SD of experimental duplicates of one experiment. Scale 
bar; 200μm. 
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Figure 3-6: Increasing concentrations of M-CSF induce osteoclastogenesis.  
1x105 murine NA BM cells were cultured with 30, 50, 75 or 100ng/ml MCSF and either 0 or 
50ng/ml RANKL for 5 days in 37oC with media renewed on day 4. Cultures were stained for the 
presence of TRAP. A) Representative images of TRAP stained cultures. B) TRAP+ OCs with >3 
nuclei were counted and the sum total of 4 fields of view per condition in duplicate were used.  
Data represents mean ± SD of experimental duplicates of one experiment. Scale bar; 200μm. 
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3.2.2 Fcγ receptor mediated inhibition of osteoclastogenesis 
The optimised OC culture system was used to test the affect that SIC could exert on the 
differentiation of OCs. 1x105 NA BM cells in 200μl were cultured with 75ng/ml M-CSF 
and 50ng/ml RANKL for 5 days. In conjunction with the addition of M-CSF and RANKL, 
the cells were treated with SIC or control treatments OpIg and SpA. SIC, OpIg and SpA 
were generated as described in section 2.6 and added to cultures at a concentration 
which reflected 25μg/ml of IgG per condition. A significantly high level of 
osteoclastogenesis was observed in the M-CSF and RANKL treated cultures (mean OCs ± 
SD; 115.6 ± 23.6) compared to the M-CSF alone treated control (0 ± 0; p<0.001) (Figure 
3-7B). The differentiated OCs in the M-CSF and RANKL treated positive control cultures 
were large multinucleated and stained intensely for TRAP (Figure 3-7A). Treatment of 
these cultures with SpA alone did not alter osteoclastogenesis (114.6 ± 14.3) and did not 
affect the appearance of the differentiated OCs. Interestingly, a significant inhibition of 
osteoclastogenesis was observed in cultures treated with OpIg (36 ± 10; p<0.001) and 
SIC (27 ± 8.1; p<0.001) compared to M-CSF and RANKL treated positive controls (Figure 
3-7B). The OCs that differentiated in the presence of OpIg and SIC were not only scarce, 
but smaller in size compared to the M-CSF and RANKL treated positive control (Figure 
3-7A). Thus, in this culture system OpIg and SIC are able to inhibit osteoclastogenesis.     
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Figure 3-7: SIC and OpIg inhibit the differentiation of TRAP+ osteoclasts.  
1x105 murine NA BM cells were cultured with 75ng/ml M-CSF and/or 50ng/ml RANKL for 5 days in 
37oC with media renewed on day 4. Treatment with SpA, OpIg and SIC was given at day 1 and 4 
alongside M-CSF and RANKL. Cultures were stained for the presence of TRAP. A) Representative 
images of TRAP stained cultures. B) TRAP+ OCs with >3 nuclei were counted and the sum total of 
4 fields of view per condition in triplicate. One way ANOVA with Bonferroni’s post tests; p<0.001 
(***). Data represents pooled mean ± SD of three individual experiments. Scale bar; 200μm. 
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3.2.3 Comparison of OpIg and SIC 
OpIg and SIC can both inhibit in vitro osteoclastogenesis. Examination of whether the 
generation of OpIg created IC formation between OVA and IgG in a similar manner to 
SpA generated complexes was conducted. To ensure complexes were generated, protein 
interactions were cross-linked using a BS3 (Bis-sulfosuccinimidyl suberate) cross-linking 
reagent. BS3 contains two amine reactive esters that are able to covalently bind amine 
groups on proteins that are within close proximity353. Samples of SpA, OVA, IgG, OpIg 
and SIC were either cross-linked with BS3 or incubated with PBS. Samples were then 
loaded onto a gel, electrophoresed in non-reducing conditions and coomassie stained. 
All samples that had not been cross-linked migrated through the gel to the same extent 
as their constituent parts (Figure 3-8). OVA (42kDa), SpA (47kDa) and IgG (150kDa), as 
well as the OVA, SpA and IgG within OpIg and SIC samples, all migrated to their 
appropriate protein size as demarked by a protein ladder (Figure 3-8). Without 
cross-linking OpIg and SIC any protein interactions were separated; when the samples 
were cross-linked using the BS3 cross-linking reagent there was a large molecule 
observed at the top of the SIC lane (Figure 3-8). At a predicted size of approximately 
694kDa, SIC was unable to migrate through the gel and remained close to the well at 
the top of the gel (Figure 3-8). However, protein aggregates appear in both cross-linked 
IgG and OpIg samples (Figure 3-8). It is unclear whether these are cross-linked IgG 
aggregates or whether IgG molecules have become cross-linked due to their close 
proximity, both explanations would account for the visible protein smear (Figure 3-8). 
The use of western blots could identify whether OVA and SpA are present in the large 
molecule weight cross-linked proteins present in these samples.  
In order to verify that SpA, and not OVA, is able to form large molecular weight IgG 
complex, samples underwent size exclusion fractionation. OVA, SpA, IgG, OpIg and SIC 
were individually loaded into an ÄKTAprime and processed through a Sephacryl column 
under pressure. When using this method, samples do not require cross-linking as the 
forces used in this process will not separate interacting molecules. This process allows 
for the discrimination of proteins based on molecular weight as indicated by the length 
of time the protein requires to move through the column. Larger molecules are able to 
pass through the column more quickly than smaller molecules which become trapped in 
the column resin. The concentration of protein was measured by UV280 as samples exit 
the column. OVA and SpA are 42 and 47kDa, respectively and required ~400 minutes in 
order to pass through the column, while 150kDa IgG molecules required ~350 minutes to 
exit the column (Figure 3-9). OpIg passed through the column and was observed to exit 
the column between 350-400 minutes (Figure 3-9). This indicates that both IgG and OVA 
exit the column at the same speed as the individual constituents (Figure 3-9). 
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Interestingly, SIC only required 200 minutes for the sample to begin its exit and had 
fully left the column by 400 minutes (Figure 3-9). This demonstrates that SIC can form a 
large molecular weight complex without protein cross-linking, unlike OpIg. However, in 
the SIC sample there is excess IgG which is also present in the OpIg samples (Figure 3-8 
and Figure 3-9). Prior to use, all IgG samples were centrifuged to remove protein 
aggregates, however, the IgG present may still form small molecular weight complexes 
that could interact with cells in culture media. Despite this disparity SIC and OpIg were 
both able to inhibit osteoclastogenesis. 
 
 
Figure 3-8: Cross-linking protein interactions between SpA and IgG results in IgG complex 
formation; OVA and IgG do not form complexes.  
PBS, OVA, SpA, IgG, OpIg and SIC were incubated at 37oC for 1 hour. Protein interactions were 
cross-linked in the samples by addition of 1mM BS3 cross-linker for 30 minutes at RT. The 
reaction was quenched by incubation for 15 minutes in 0.5mM Tris-HCl. Samples that were not 
cross-linked had equivalent volumes of PBS added. 4x LDS sample buffer was added and samples 
were run on a 4-12% Bis-Tris gel with a protein ladder for 2 hours at 200V. Gel was subsequently 
stained using Simply Blue SafeStain and de-stained in dH20. Image represents one experiment.  
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Figure 3-9: Fractionation of SpA, OVA and IgG using Sephacryl chromatography column 
demonstrates that OVA and IgG do not form complexes.  
OVA, SpA, IgG, OpIg and SIC samples were individually processed through a Sephacryl column 
which discriminates protein size into separate fractions for collection – large proteins move more 
quickly through the medium. 2mg of OVA, SpA, IgG, OpIg and SIC in 500μl of PBS were used. 
Graphs represent the concentration of protein, measured by UV (at A280), in each fraction 
collected over time (minutes). Graphs shown are from one experiment.   
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3.2.4 IgG inhibits osteoclastogenesis 
FcγRI has the ability to engage monomeric IgG251, so, it was decided to test whether the 
inhibition associated with SIC and OpIg could be due to the excess IgG present in both of 
these treatments. SpA, IgG, OpIg and SIC were prepared as previously described and 
added to cultures of 1x105 NA BM cells in 200μl alongside 300ng/ml M-CSF and 50ng/ml 
RANKL. Following 5 days of culture, cells were stained for TRAP and it was shown that 
IgG, OpIg and SIC were all able to significantly inhibit osteoclastogenesis (Figure 3-10). 
Despite the supra-physiological concentrations of M-CSF, treatment with IgG was able to 
inhibit osteoclastogenesis by 48.9% (p<0.05), while addition of OpIg could inhibit 
osteoclastogenesis by 68.9% (p<0.01). As previously shown the only constituents of OpIg 
are IgG and OVA which do not interact. Therefore, the difference in inhibition may be 
due the large variation in data spread in IgG treated groups (mean OC number ± SD; 39 
± 24.9) compared to OpIg (23.6 ± 9.0). Consequently, treatment of NA BM with SIC was 
able to significantly inhibit osteoclastogenesis by 80.3% (p<0.001; 15 ± 3.6 - Figure 
3-10). To verify whether the presence of OVA in OpIg was having an effect on 
osteoclastogenesis, NA BM was cultured for differentiation into OCs in the presence of 
SpA, OVA, OpIg and SIC. The presence of OVA in these cultures had no effect on the 
level of osteoclastogenesis, while treatment with OpIg and SIC significantly inhibited 
osteoclastogenesis (Figure 3-10). It remains to be elucidated whether OVA present in 
OpIg can interact with IgG and contribute to OpIg inhibitory capacity; however OVA 
alone cannot alter osteoclastogenesis (Figure 3-10).  
Despite the differences in efficacy of IgG, OpIg and SIC to inhibit osteoclastogenesis, 
the presence of IgG (at 25μg/ml) is able to inhibit osteoclastogenesis. Nevertheless, 
treatment with ICs in the form of SIC was most successful at in vitro OC inhibition. 
Subsequent experiments were undertaken using OpIg as both a control for SIC and also a 
treatment to test the effect of monomeric IgG. 
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Figure 3-10: Murine IgG inhibits the differentiation of TRAP+ osteoclasts. 
A) 1x105 murine NA BM cells were cultured with 300ng/ml M-CSF and 50ng/ml RANKL for 5 days 
in 37oC with media renewed on day 4. Treatment with SpA, IgG, OpIg and SIC was given at day 1 
and 4 alongside M-CSF and RANKL. Cultures were stained for the presence of TRAP. TRAP+ OCs 
with >3 nuclei were counted and the sum total of 4 fields of view per condition, in triplicate. 
One way ANOVA with Bonferroni’s post tests used; p<0.05 (*), p<0.01 (**) p<0.001 (***). Data 
represents mean ± SD of one experiment. B) 1x105 murine NA BM cells were cultured with 
75ng/ml M-CSF and 50ng/ml RANKL for 5 days in 37oC with media renewed on day 4. Treatment 
with OVA, SpA, OpIg and SIC was given at day 1 and 4 alongside M-CSF and RANKL. Cultures were 
stained for the presence of TRAP. TRAP+ OCs with >3 nuclei were counted and the sum total of 4 
fields of view per condition, in triplicate. One way ANOVA with Bonferroni’s post-hoc tests; 
p<0.001 (***). Data represents mean ± SD of three separate experiments.  
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3.2.5 Functional consequence of Fcγ receptor inhibition 
IgG, in the form of OpIg and SIC, has been shown to inhibit the differentiation of OCs 
from murine BM on tissue culture plates. This is a convenient medium to culture cells; 
however, it is an isolated environment in terms of cell growth. Culturing OCs on bone 
discs provides a valid growth platform resembling the physiological microenvironment of 
the bone. Present on the bone surface are stromal factors, among these is Collagen 
Type II which is able to promote osteoclastogenesis via the OSCAR receptor on 
pre-OCs154. Therefore, the effect of OpIg and SIC on the differentiation of OCs on bovine 
bone discs was investigated. NA BM cells were cultured with 75ng/ml M-CSF and 
50ng/ml RANKL with the addition of SpA, OpIg and SIC on bovine bone discs. After 10 
days of culture, bone slices were removed and stained for TRAP (Figure 3-11A). This 
revealed that there was a large variation in the number of OCs present on the surface of 
the bone slices (Figure 3-11C). It also showed that OpIg and SIC were both unable to 
stop the differentiation of OCs cultured on bone discs (Figure 3-11C).  
In parallel with this study, OCs were cultured on bone slices until day 14 in order to 
maximise their erosive capacity. Bone slices were then washed with dH20 to remove any 
cells before areas of erosion were visualised (Figure 3-11B). This showed that the area 
of erosion varied markedly between experimental and biological triplicates, resulting in 
a large data spread. Cells grown in the presence of M-CSF and RANKL alone (mean % of 
erosion ± SD; 14.9 ± 11.2) had similar erosive capacity to cells grown in the presence of 
SpA (12.3 ± 11.2) and OpIg (13.9 ± 11.3) (Figure 3-11D). Interestingly, cells grown in the 
presence of SIC appeared to have a substantial reduction in the percentage of erosion 
(5.4 ± 4.4). However, a comparison of all data sets revealed that there were no 
significant differences in the groups treated with SpA, OpIg and SIC compared to M-CSF 
and RANKL positive control group. However, when a less stringent method of analysis 
was used SIC treated samples have significantly reduced bone erosion ($<0.05) 
compared to positive controls. Further work needs to be done to increase the replicates 
and determine conclusively whether SIC can inhibit in vitro bone erosion. This suggests 
that SIC may limit the activity, but not differentiation, of OCs cultured on bone discs. 
Therefore, SIC may able to overcome the additional stimulation that OCs receive when 
cultured on bone discs that monomeric IgG in OpIg cannot overcome. 
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Figure 3-11: SIC inhibits the activity of osteoclasts on bovine cortical bone slices.  
1x105 murine NA BM cells were cultured on bone slices with 75ng/ml M-CSF and 50ng/ml RANKL 
for 10 to 14 days in 37oC with media refreshed every 3rd day. Treatment with SpA, OpIg and SIC 
was given at day 1 alongside M-CSF and RANKL and upon every media change. A) Representative 
images of TRAP staining on bone slices at day 10 and C) TRAP+ OCs with >3 nuclei were counted 
at day 10 and the sum total of 4 fields of view per condition, in triplicate. One way ANOVA with 
Bonferroni’s post-hoc tests used; p<0.001 (***). B) Representative images of areas of bone 
erosion at day 14. D) 5 images per bone slice were taken and % area of erosion was measured by 
calculating the area of the image over the eroded area per field of view. One way ANOVA with 
Bonferroni’s post-hoc tests; p<0.05 (*). Data represents C) pooled median and range of data of 
three experiments, n=3, and D) pooled median and range of data of three experiments, n=9. 
Scale bar; A) 200μm and B) 500μm. $ represents unpaired two tailed t tests between M+R and SIC 
treated samples; p<0.05. 
 
 
89 
 
3.2.6 The role of FcγRIII in Fcγ receptor mediated inhibition 
To further investigate the differences between OpIg and SIC, their role in inhibiting 
osteoclastogenesis using FcγRIII-/- BM was investigated. NA BM from FcγRIII-/- mice was 
cultured with 75ng/ml M-CSF and 50ng/ml RANKL in the presence of SpA, OpIg and SIC. 
FcγRIII deficiency had no impact on osteoclastogenesis observed in the M-CSF and 
RANKL treated positive control group (mean OCs; 85.3 ± 11.5) (Figure 3-12). Treatment 
of FcγRIII-/- cultures with SpA (95.3 ± 17.4) and, importantly, OpIg (49.6 ± 19.1) had no 
significant effect on osteoclastogenesis, while treatment with SIC (25.3 ± 5.5) was able 
to significantly inhibit osteoclastogenesis (p<0.01). This accounts for a 70.3% inhibition 
of osteoclastogenesis in FcγRIII-/- cultures which is comparable to the 76.6% inhibition of 
osteoclastogenesis observed in WT cultures treated with SIC (Figure 3-10 and Figure 
3-12). FcγRIII is mainly involved in IC interactions249 and the inability of OpIg to inhibit 
osteoclastogenesis in FcγRIII-/- cells suggests that it may be small IgG aggregates present 
in OpIg which are responsible for this inhibition. This also demonstrates that SIC can 
inhibit osteoclastogenesis independently of FcγRIII. It is likely that other FcγRs 
(including FcγRIII) are involved in this inhibitory effect. Without investigation into the 
interaction of other FcγRs this inhibitory effect will not be fully understood. 
 
Figure 3-12: SIC inhibits the differentiation of TRAP+ FcγRIII-/- osteoclasts.  
1x106 murine NA BM cells from FcγRIII-/- mice were cultured with 75ng/ml M-CSF and 50ng/ml 
RANKL for 5 days in 37oC with media renewed on day 4. Treatment with SpA, OpIg and SIC was 
given at day 1 and 4 alongside M-CSF and RANKL. Cultures were stained for the presence of 
TRAP. TRAP+ OCs with >3 nuclei were counted and the sum total of 4 fields of view per condition 
in triplicate used. One way ANOVA with Bonferroni’s post test; p<0.01 (**). Data represents 
pooled mean ± SD of three experiments.  
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3.2.7  Fcγ receptor modulation down-regulates osteoclast essential gene 
transcription 
SIC and OpIg have been shown to inhibit the differentiation of murine BM into OCs. SIC 
limits the activity of OCs when cultured on bone. In order to understand the further 
potential differences between these treatments, OCs were differentiated in the 
presence of these treatments for 3 days and mRNA extracted. cDNA was synthesised 
from the mRNA and the presence of specific target mRNA was examined.  
In order to do this, suitable primers against mRNA were designed. mRNA of genes which 
were of interest to us were located in the NCBI database and Primer 3 software was 
utilised to design primers that could potentially amplify a specific PCR product. Table 
2.1 lists all the primers designed and used in this study. To test the specificity of the 
designed primers, end-point PCR was used to detect a PCR product of known size 
(Figure 3-13). Equal levels of mRNA for CD115, RANK, NFATc1 and Bcl-3 were present in 
MØ (M-CSF treated) and OC (M-CSF and RANKL treated) samples, while mRNA for OC 
specific genes TRAP, Cathepsin K, MMP9, DC-STAMP and OSCAR were only present at 
detectable levels in OC samples as they require RANKL for their induction (Figure 3-13). 
Firstly the genes involved in the induction of osteoclastogenesis were examined. 
Transcription of CD115 and RANK mRNA play vital roles in the differentiation and 
survival of OCs and transcription of these genes was shown to be unaffected by 
treatment with SpA, OpIg and SIC (Figure 3-14).  As mentioned, RANK signals via NF-κB 
and one important inhibitor of NF-κB signalling is Bcl-3167,331. If NF-κB activation is 
inhibited by OpIg or SIC then Bcl-3 transcription may be up-regulated. Following three 
days of RANKL stimulation, Bcl-3 mRNA levels were increased compared to M-CSF alone 
treated samples (p<0.05), however treatment with SpA, OpIg or SIC did not affect Bcl-3 
transcription (Figure 3-14). Another transcription factor of interest is NFATc1 which is 
activated by NF-κB and strongly induces OC differentiation333. Interestingly, the data 
suggests that SIC, and to a small degree OpIg, were able to down-regulate NFATc1 
mRNA compared to M-CSF and RANKL positive control; however this was shown to be not 
significant (Figure 3-14).  
After three days of RANKL stimulation, mRNA transcripts were examined and treatment 
with SIC and OpIg down-regulated the transcription of OC genes. mRNA transcript levels 
of Cathepsin K, TRAP, DC-STAMP and OSCAR were all strongly increased in the M-CSF 
and RANKL treated positive control compared to M-CSF alone (Figure 3-15). This 
induction of mRNA was significantly inhibited when cells were cultured in the presence 
of SIC and OpIg (Figure 3-15). mRNA transcript level for MMP9 appeared to be reduced 
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following treatment with OpIg and SIC, however, this failed to reach significance (Figure 
3-15).  
Therefore, M-CSF and RANKL treatment in cultures committed to the OC lineage 
up-regulate transcription of genes essential for osteoclastogenesis. FcγR modulation 
inhibits this effect preventing the differentiation of mature OCs from murine BM.  
 
Figure 3-13: Primers designed for qPCR are specific for their target gene.  
1x106 murine NA BM cells were cultured with 75ng/ml M-CSF and/or 50ng/ml RANKL for 5 days in 
37oC with media renewed on day 4. Cultures were lysed using QIAzol Lysis Reagent, mRNA was 
extracted using QIAgent miRNEasy mini kit and cDNA generated. cDNA was added to a PCR 
master mix, with specific primer sets, using Go Taq Polymerase and end point PCR was used to 
amplify the PCR product. All odd numbered lanes are M-CSF treated MØ, while even numbered 
lanes are M-CSF and RANKL treated OCs. A) Primer sets used are 1+2) GAPDH, 3+4) CD115, 5+6) 
RANK, 7+8) NFATc1, 9+10) Bcl-3. B) Primer sets used are 1+2) GAPDH, 3+4) TRAP, 5+6) Cathepsin 
K, 7+8) MMP 9, 9+10) DC-STAMP ,11+12) OSCAR.  
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Figure 3-14: Fcγ receptor modulation of transcription in pre-osteoclasts.  
1x106 murine NA BM cells were cultured with 75ng/ml M-CSF and 50ng/ml RANKL for 3 days in 
37oC. Treatment with SpA, OpIg and SIC was given at day 1.  Cultures were lysed on day 3. For 
qPCR, all samples were run in triplicate. GAPDH was used as the housekeeping control and non-
template controls were run for each gene. Fold Change (2(-ΔΔCT)) was measured by normalising 
samples of each primer to the housekeeping control and subsequently normalising all samples to 
M-CSF alone to obtain the ΔΔCT. This was then used to obtain the fold change. One way ANOVAs 
with Bonferroni’s post tests were performed on ΔCT values; p<0.001 (***).  Data represents 
pooled mean ± SD of three experiments.  
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Figure 3-15: IgG inhibits pre-osteoclasts transcript levels of osteoclast specific genes.  
1x106 murine NA BM cells were cultured with 75ng/ml M-CSF and 50ng/ml RANKL for 3 days in 
37oC. Treatment with SpA, OpIg and SIC was given at day 1.  Cultures were lysed on day 3. For 
qPCR, all samples were run in triplicate. GAPDH was used as the housekeeping control and 
non-template controls were run for each gene. Fold Change (2(-ΔΔCT)) was measured as previously 
mentioned. One way ANOVAs with Bonferroni’s post tests were performed on ΔCT values; p<0.01 
(**), p<0.001 (***). Data represents pooled mean ± SD of three experiments.  
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3.3 Discussion  
SIC formed by incubation of SpA with IgG has been shown to inhibit human 
osteoclastogenesis316 and now we show that SIC will inhibit murine osteoclastogenesis. 
Optimisation of an assay to differentiate murine OCs was undertaken and revealed that 
culturing BM with 75ng/ml M-CSF and 50ng/ml RANKL optimal (Figure 3-6). Treatment 
of BM cells with SIC or OpIg, a control treatment, could inhibit the differentiation of 
TRAP+ OCs. While, the generation of SIC produced large protein complexes this did not 
occur with OpIg. Subsequently, IgG was shown to be capable of inhibiting the in vitro 
differentiation of OCs. However, SIC, and not OpIg, inhibited the activity of OCs on 
bone slices. Transcription of OC specific mRNA transcripts (Cathepsin K, DC-STAMP, 
OSCAR and TRAP) were down-regulated following treatment with SIC when compared 
with untreated cultures. Importantly, the effects seen with SIC treatment were also 
observed with OpIg. This indicates that IgG alone could be mediating the observed FcγR 
mediated inhibition. 
In this chapter the ability of SIC to inhibit murine osteoclastogenesis was tested. This 
required the optimisation of an in vitro protocol for the generation of OCs which had 
previously not been done in the lab. Early experiments demonstrated that murine 
osteoclastogenesis was unlike human osteoclastogenesis where MacLellan et al (2011) 
used purified human CD14+ monocytes in the presence of M-CSF and RANKL to 
differentiate OCs316. Murine monocytes purified from BM using a commercially available 
kit (Figure 3-1); monocytes isolated from blood and BM using gradient centrifugation 
and histopaque (Figure 3-2); treatment of NA BM cells with 30ng/ml M-CSF and 
increasing concentrations of RANKL (Figure 3-3); treatment of NA BM cultures with IL-1β 
alongside M-CSF and RANKL (Figure 3-4); culture of NA BM in L929 supernatant and 
RANKL to test the source of M-CSF all failed to induce osteoclastogenesis (Figure 3-5). It 
was not until the concentration of M-CSF added to cultures of NA BM was increased that 
osteoclastogenesis became evident (Figure 3-6).  
The standard protocol that was developed used murine whole BM to derive a population 
of pre-OCs. Treatment of murine BM with 30ng/ml M-CSF overnight was able to induce 
the proliferation of NA mononuclear phagocytes with high OC potential354,355. This 
generated NA BM which could be cultured with 75ng/ml of M-CSF and 50ng/ml RANKL 
for five days to generate OCs. When the concentration of M-CSF was increased from 30 
to 100ng/ml it was shown that higher concentrations of recombinant M-CSF could 
increase osteoclastogenesis and impact on the cells ability to fuse. M-CSF interacts with 
CD115 on the surface of monocytes and without additional stimulation directs the 
monocyte to proliferate and differentiate into a MØ356. A higher concentration of M-CSF 
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may have lead to heightened signalling via CD115 resulting in phosphorylation of the 
transcription factor MITF which is known to increase pre-OC fusion and activity127. In 
op/op mice, a dysfunctional M-CSF protein is produced resulting in decreased in vivo 
monocyte, MØs and OCs numbers119. These op/op mice become osteopetrotic due to a 
lack of OC differentiation123. An increase in M-CSF will result a greater stimulation of 
PU.1, the transcription factor activated by CD115 which can enable the initiation of 
commitment to the OC lineage and has a major role in osteoclastogenesis as PU.1 
deficient animals are osteopetrosis94,357. This is because CD115 signalling through PU.1 
directly interacts with the RANK promoter increasing RANK expression358. The role of 
M-CSF in mature OCs has also been observed as M-CSF is required to increase OC 
motility and prevent apoptosis128,129. Therefore in this culture system M-CSF was the 
limiting factor affecting osteoclastogenesis. 
An optimised OC culture assay allowed the effect of SIC to be investigated. OCs 
differentiated from NA BM in the presence of 75ng/ml M-CSF and 50ng/ml RANKL were 
treated with SIC. This treatment was shown to inhibit of differentiation of OCs (Figure 
3-7). However, treatment of NA BM with OpIg also resulted in inhibition of 
osteoclastogenesis. OpIg consists of IgG and OVA, which is a non-reactive protein of a 
similar molecular weight as SpA. OVA is intended to be a control of the SpA present in 
SIC and should not interact or aggregate with IgG, yet OpIg has the ability to inhibit 
osteoclastogenesis. Therefore, to confirm that OVA was not inducing IgG aggregation in 
the OpIg samples we examined the constituents of OpIg and SIC.  
SpA binds IgG from many mammalian species and forms both soluble and insoluble 
complexes by Fc and Fab mediated interactions294,295,301,343,359. Atkins et al (2008) 
proposed a mechanism of SpA and IgG binding in a 2:4 ratio via the Fc region301. SpA 
bound IgG is still able to interact with FcγRs in the form of this IgG complex that has 
been named SIC316. Cross-linking of protein interactions showed that SIC but not OpIg 
could form large molecular weight complex (Figure 3-8). Another finding observed in 
this experiment, was that cross-linking of IgG and OpIg resulted in proteins larger than 
150kDa. This may indicate that cross-linking has allowed IgG to form protein aggregates. 
Therefore investigation into whether IgG was able to form complexes in these samples 
using size exclusion chromatography was undertaken. By fractionating samples based on 
size it was shown that IgG and OpIg failed to make naturally occurring large molecular 
weight complexes. SIC was able to form a large IgG complex that rapidly exits the 
column (Figure 3-9). Despite the lack of large molecular weight protein aggregates the 
IgG present in OpIg may still interact and form low molecular weight proteins which 
could be responsible for the observed inhibition of osteoclastogenesis. Langone et al 
(1985) used a similar technique to demonstrate that SpA can form large complexes with 
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human purified IgG and serum300. Using both gel electrophoresis and size exclusion 
chromatography it was shown that in the samples of SIC there was an excess amount of 
unbound IgG. This suggests that it is the presence of excess IgG in SIC and OpIg that 
inhibits osteoclastogenesis and that the SIC may not be required for this effect.   
To robustly test whether IgG alone could inhibit murine osteoclastogenesis, OCs were 
differentiated in the presence of IgG, OpIg or SIC. This demonstrated that alone IgG 
could inhibit osteoclastogenesis (Figure 3-10A). IgG, OpIg and SIC all significantly 
inhibited osteoclastogenesis, however, SIC was shown to be superior in this ability. This 
suggests that an IC is able to interact with FcγRs inhibiting osteoclastogenesis to a 
greater extent than IgG alone. Interestingly, investigation into whether OpIg and SIC 
could influence the bone erosion capacity of OCs proved insightful. Neither OpIg or SIC 
were able to prevent the differentiation of OCs when cultured on bone. However, 
importantly only SIC was able to reduce the OCs capacity to erode bone. SIC was able to 
overcome co-stimulatory signals that the OCs were receiving while differentiating on 
bone, which OpIg could not. In a similar experiment, Grevers et al (2012) differentiated 
OCs from murine BM on bone slices and was able to inhibit the erosive capacity of OCs 
using heat-aggregated rabbit IgG while monomeric IgG did not inhibit bone erosion340. 
Thus FcγR modulation is capable of inhibiting murine osteoclastogenesis in an FcRγ 
dependent manner. 
The method used to generate SIC resulted in an IgG complex of defined size and 
conformation in an excess of IgG. Dima et al (1983) demonstrated that SpA was able to 
continually bind and dissociate IgG to form SIC in a dynamic process both in vitro and in 
vivo299. Therefore, SpA requires excess IgG for the formation of SIC. This method of IC 
formation differs from the heat-aggregated rabbit IgG which Grevers et al (2012) 
demonstrated could inhibit osteoclastogenesis340. Heat-aggregated rabbit IgG is a large 
IC with an indefinable conformation340. Heat treatment of IgG is commonly used to 
denature the IgG and allow the individual molecules to interact and form an IC which 
remains able to engage FcγRs360. However, both SIC and heat-aggregated rabbit IgG 
inhibit osteoclastogenesis when BM cultures are treated from initiation of culture340. In 
contrast, Seeling et al (2013) used streptavidin linked biotinylated antibodies specific 
for FcγRI and FcγRIV to bind the FcγRs and induce cross-linking262. This method of IC 
formation resulted in enhanced osteoclastogenesis in cells which had previously been 
stimulated with M-CSF and RANKL262. Could, as Seeling demonstrated, the addition of 
SIC to cells that had previously received M-CSF and RANKL inhibit or enhance 
osteoclastogenesis? Likewise, could cross-linking of activatory FcγRI and FcγRIV from 
initiation of culture inhibit or enhance osteoclastogenesis? As interesting as these 
 
 
97 
 
differences are, the message from both these studies remains constant; activatory 
FcγRs can be used to modulate the differentiation of OCs262,316,340.   
Differences between IgG and SIC interactions with FcγRs exist between human and 
murine monocytes316. OpIg was incapable of inhibiting human CD14+ monocytes from 
differentiating into OCs while SIC inhibits human osteoclastogenesis316. In these human 
studies, SIC and OpIg were generated in the same manner as the murine studies except 
with use of species specific IgG. The reason for the difference observed when OpIg is 
used in human and murine OC studies is most likely due to IgG and FcγR biology 
differences in these species. Human monocytes express activatory FcγRI, FcγRIIA, 
FcγRIIC and FcγRIIIA with an inhibitory FcγRIIB receptor; murine monocytes express 
activatory FcγRI, FcγRIII and FcγRIV with an inhibitory FcγRIIB260. These receptors can 
be further classified by their ability to bind to IgG; in mice and humans FcγRI is the high 
affinity receptor capable of binding monomeric IgG260. The other FcγRs, in mice and 
humans, can only bind IC in conjunction with neighbouring FcγRs260. To further 
complicate this classification, murine and human IgG subclasses are also variable, in 
that murine IgG consists of IgG1, 2a, 2b and 3, while human IgG subclasses include IgG1, 
2, 3 and 4260. In mice IgG2a binds with the highest affinity to FcγRI, while IgG1 fulfils 
this role in the humans260. SpA has been shown to bind to all subclasses of murine and 
human IgG with high affinity296. Thus, depending on the composition of IgG subclasses 
interacting with SpA, the addition of murine IgG to murine monocytes may well have a 
different effect than human IgG with human monocytes. The composition of IgG used is 
dependent on the batch which was purchased. As differences between preparations of 
IgG exist this too may be another reason for the differences observed in human and 
murine OpIg treated samples. 
Another difference that has been observed is that in the absence of FcγRI, fluorescently 
labelled SpA in complex with murine IgG could not bind to monocytes/pre-OCs316. 
Importantly, fluorescently labelled OVA in the presence of IgG could not bind to either 
WT or FcγRI-/- monocytes/pre-OCs316. This marries with the idea that the OVA present in 
the OpIg treatment had no effect on osteoclastogenesis because OVA could not interact 
with the cell surface and again suggests that it is IgG which is interacting with the cells. 
FcγRI is capable of binding monomeric IgG, as well as ICs in conjunction with other 
FcγRs, it can be assumed that the IgG present in OpIg and SIC is interacting with this 
receptor leading to an activatory signal skewing the cell from OC differentiation251. 
Repeating a similar experiment to MacLellan et al (2011) and using fluorescently 
labelled IgG alone, or in the presence of OVA or SpA would allow the identification of 
the monomeric IgG or SIC ability to bind monocytes/pre-OCs316. 
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Studies contained within this chapter also investigated the role of activatory FcγRIII in 
OCs differentiation in the presence of OpIg and SIC. SIC maintained the ability to inhibit 
osteoclastogenesis in FcγRIII-/- cultures, while OpIg could not inhibit osteoclastogenesis, 
highlighting that FcγRIII is not required for SIC’s mechanism of action. Thus suggesting 
that in WT cultures engagement of FcγRIII in conjunction with FcγRI may be sufficient 
for inhibition but is not necessary. This data also demonstrates that OpIg may require 
FcγRIII in order to inhibit OC differentiation. As mentioned, FcγRIII is a low affinity 
receptor for IgG and is only known to ligate ICs339. Therefore, the presence of small IgG 
aggregates could be acting via FcγRIII and thus inhibiting osteoclastogenesis which may 
account for the effects of OpIg.  
In order to elucidate which FcγRs SIC and OpIg require for OC inhibition the use of 
genetic KO or siRNA could be utilised. SIC requires FcγRI to bind to the surface of MØ 
and pre-OCs316, but the differentiation of FcγRI-/- OCs in the presence of SIC is yet to be 
done and therefore it remains to be determined whether SIC requires FcγRI to inhibit 
osteoclastogenesis. Importantly, the use of FcγRI-/- pre-OCs could determine further 
differences between SIC and OpIg’s ability to inhibit osteoclastogenesis. Another 
receptor which is of interest is FcγRIIB, the inhibitory receptor, which negatively 
regulates effector functions, yet, ligation of FcγRIIB was shown to be insufficient for 
inhibiting murine osteoclastogenesis using heat-aggregated rabbit IgG340,361. It would be 
interesting to differentiate FcγRIIB-/- OCs in the presence of OpIg and SIC and determine 
whether murine IgG alone or in the form of SIC could still prevent osteoclastogenesis. 
However, it was not possible to obtain these transgenic animals. The use of FcγRs siRNA 
to elucidate the interactions which underpin SIC’s mechanism of inhibition were the 
next experiments to be undertaken.    
To evaluate the mechanisms of action associated with inhibition of osteoclastogenesis 
via SIC and OpIg we evaluated the effect of mRNA transcription essential for 
osteoclastogenesis. Treatment with IgG in the form of SIC or OpIg was able to 
down-regulate the transcription of DC-STAMP, Cathepsin K, OSCAR and TRAP, all of 
which are necessary for OC function7,154,242,336. Animals which are deficient for TRAP and 
DC-STAMP develop osteopetrosis due to the differentiation of non-functioning OC242,362. 
The down-regulation of mRNA transcripts for DC-STAMP could prevent OC fusion as 
DC-STAMP interacts with OC-STAMP allowing RANKL stimulated mononuclear cells to 
fuse and become multinucleated220,363.  
Recently, it was shown that the ligand for OSCAR is Collagen Type II, as SIC 
down-regulates OSCAR mRNA transcript it is also able to inhibit the erosive capacity of 
OCs on bone154. The data would suggest that SIC is able to interfere with 
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OSCAR/Collagen Type II signalling which is known to aid OC differentiation154. OSCAR 
signals through the FcRγ or DAP12154,330. FcγRI also signals through the FcRγ and is 
required for SIC interaction on monocytes316. This demonstrates that despite the 
similarities between OSCAR and FcγR signalling, SIC may co-opt this pathway and inhibit 
the differentiation of OCs. As the FcRγ is required for the surface expression of 
activatory FcγRI and FcγRIII, an interesting experiment would have been to evaluate the 
effect of SIC on OCs in FcRγ-/- animals. FcRγ-/- animals have normal bone architecture 
and OC function, but would only express the FcγRIIB which would allow investigation 
into whether SIC could inhibit osteoclastogenesis in the absence of activatory FcγRs265. 
The ability of FcγR modulation to inhibit osteoclastogenesis did not affect the 
transcription of CD115, RANK, NFATc1 or Bcl-3 mRNA after three days of culture. 
Previous work demonstrated that human monocytes stimulated with M-CSF and RANKL 
and treated with SIC for 24 hours, down-regulated RANK mRNA (unpublished data). This 
time point may have been too late to observe the effect SIC or OpIg treatment may 
exert on transcription of genes which induce osteoclastogenesis. Earlier time points may 
provide a better representation of how FcγR modulation changes mRNA transcription. As 
shown, SIC and OpIg were unable to influence the expression of CD115. It was not 
expected for SIC or OpIg to influence the expression of this factor greatly as M-CSF 
mediated signalling through CD115 is integral to cell survival128. However, MacLellan et 
al (2011) observed that following 6 hours of treatment SIC the surface expression of 
CD115 was down-regulated in human monocytes stimulated with M-CSF and RANKL316. 
Due to time constraints it was not possible to focus on the earlier time-points and 
surface expression of CD115 on murine cells in order to verify this effect in the mouse. 
As has been previously stated, there are caveats regarding the comparison of human 
and murine cells which are most likely due to species differences FcγR biology. Despite 
the observations in human OCs of CD115 surface expression down-regulation, RANK 
mRNA transcript level down-regulation and inability of OpIg to inhibit 
osteoclastogenesis, a fresh insight has been gained regarding the interaction between 
FcγR modulation and murine OC differentiation.  
A hypothesis which may explain the observations described in this chapter is that in vivo 
monomeric IgG is found in abundance at concentrations of 10mg/ml in the blood299 as 
well as in the extracellular space (Figure 3-16A). The constant interaction between IgG 
and FcγRs on monocytes as well as stimulation within the microenvironment may not 
stimulate monocyte’s differentiation but could contribute to a ‘threshold’ level of 
activation by FcγRs364 (Figure 3-16B). However, removal of cells from this natural 
environment results in a homogeneous population of cells in culture media stimulated 
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only by M-CSF and RANKL (Figure 3-16C-D). In this culture system, the ‘threshold’ for 
FcγR activation may have been lowered. As a result stimulation by monomeric IgG, in 
the form of OpIg (Figure 3-16E) can activate an effector function which can skew the 
monocyte from differentiation into an OC, by preventing transcription of OC essential 
genes. In this system, addition of SIC results in enhanced FcγR activity and further 
inhibition of osteoclastogenesis (Figure 3-16F). Together, the data presented in this 
chapter demonstrates that the presence of IgG alone or in complex is able to inhibit the 
differentiation, activity and mRNA transcription of OCs in an optimised in vitro culture 
system. 
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Figure 3-16: Diagrammatic representation of in vitro osteoclast inhibition. 
A) In vivo, monocytes exist in a microenvironment containing, amongst other factors, IgG, which 
interacts with monocytes constantly. B) In vivo, monocytes are able to bind free IgG which 
creates a high threshold for cellular activation. C) Monocytes removed from animals are used to 
create a homogeneous population of cells in an artificial culture system, which does not 
generally have large amounts of IgG. D) In vitro, the monocytes only exogenous stimuli include 
M-CSF and RANKL in order to differentiate cells to OCs, thus creating a low threshold of 
activation. E) Addition of IgG in the form of OpIg, results in FcγR ligation and due to the low 
threshold of activation results in inhibition of osteoclastogenesis and decreased OC specific 
mRNA production. F) Addition of SIC, further enhances FcγR ligation and in the lower threshold 
of activation state further allows interactions between free and IgG complexes to alter the 
differentiation of monocytes, thus inhibiting osteoclastogenesis. 
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4 SpA treatment in a murine model of bone loss  
4.1 Introduction 
OCs differentiate from circulating monocytes in the blood and BM89. As previously 
mentioned, in vitro stimulation of monocytes/MØ with pro-osteoclastogenic factors 
M-CSF and RANKL differentiates OCs113,324,365,366. However, other factors can act in 
synergy with M-CSF and RANKL to enhance the differentiation of OCs. Cytokines like 
IL-6193, TNF-α187,367, IL-1191, and TGF-β368, produced by a variety of cells, including 
stromal cells found in the BM, can stimulate pre-OCs alongside M-CSF and RANKL to 
drive OC differentiation367. Upon stimulation pre-OCs commit to the OC lineage by 
expressing DC-STAMP and OC-STAMP allowing mononuclear precursor cells to fuse, 
forming large multinucleated bone eroding OCs7,10,220,362.  
Although, blood and BM derived monocytes have the ability to differentiate into OCs, 
they are a heterogeneous population97. Subsets of monocytes have different phenotypes 
and functions depending on their anatomical position and immune status369,370. The 
integrins Ly6C and CD11b can be used to identify Ly6Chigh CD11bhigh classical monocytes 
(hereafter known as Ly6Chigh monocytes); circulating Ly6Chigh monocytes migrate into 
inflamed tissue to resolve infection98,99. However, in the absence of inflammation, 
circulating Ly6Chigh monocytes down-regulate their surface expression of Ly6C371. 
Ly6Chigh monocytes differentiate into Ly6Clow CD11bhigh non-classical monocytes 
(hereafter known as Ly6Clow monocytes) which ‘patrol’ the peripheral vasculature 
before exiting circulation and terminally differentiating into tissue MØs372. These two 
subsets have definable in vivo phenotypes as Ly6Clow monocytes producing higher levels 
of TNF-α than Ly6Chigh monocytes in response to TLR4 stimulation373. Ly6Chigh monocytes 
have also been shown to express higher levels of CCR2 than Ly6Clow monocytes which is 
essential for migration to sites of inflammation96. When Ly6Chigh monocytes 
down-regulate expression of Ly6C to become Ly6Clow monocytes they up-regulate 
expression of CX3CR1100. CX3CR1 is an essential adhesion molecule, not only promoting 
monocyte survival, but also adhesion and rolling on the vascular endothelium101. 
Recently, a third population of monocyte, Ly6Chigh CD11blow, has been shown to be 
highly responsive to M-CSF and RANKL stimulation compared to both Ly6Chigh and Ly6Clow 
BM monocytes4. Interest in identifying a specific monocyte subset as an in vivo OC 
progenitor (OCP) population arose from recent work undertaken by Jacquin et al (2006), 
Jacome-Galarza et al (2013) and Charles et al (2012) which demonstrated that the 
Ly6Chigh CD11blow monocytes present in BM were a definable OCP population capable of 
reconstituting nfatc1Δ/Δ animals with functional OCs4,103,116. This population of OCPs in 
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the BM also express high levels of OC specific proteins like TREM-2, MDL-1 and 
PIR-A/B103. Thus, in the murine system, the Ly6Chigh, Ly6Clow and OCP populations 
represent three potential sources of pre-OC each with distinct properties and 
responsiveness to M-CSF and RANKL stimulation whose role in bone disorders has not 
been fully elucidated. 
Oestrogen is an umbrella term for three related sex steroids which can regulate bone 
remodelling. Normally, oestrogen acts on OBs and OCs to regulate bone integrity; 
increasing OB activity374 and inducing OC apoptosis375. However, in post-menopausal 
women the ovarian production of oestrogen declines, causing a multitude of immune 
factors to become dysregulated leading to bone loss and the development of 
osteoporosis376. The murine model of ovariectomy-induced osteoporosis (OVX) is 
commonly used to interrogate the effect of oestrogen deficiency on bone 
remodelling377. In health, oestrogen enters cells and forms a complex with the oestrogen 
receptor (ER) which translocates to the nucleus allowing for activatory or inhibitory 
genomic effects. In the absence of oestrogen, many systems are perturbed. OBs 
increase production of TNF-α, IL-6, M-CSF, RANKL, and IL-7 while decreasing OPG and 
TGF-β secretion55. T cells respond to IL-7 and produce IFN-γ which stimulates monocytes 
and MØ to increase MHC II expression resulting in co-stimulation of T cells49,378. 
Consequently, there is an increase in circulating TNF-α+/RANKL+ activated T cells and 
activated MØ which produce IL-12, IL-6, IL-1, TNF-α49,54,62,63,378,379. Monocytes of the 
blood and BM become primed by the production of the numerous osteoclastogenic 
cytokines which leads to increase in OC differentiation, survival and bone resorption 
(Figure 4-1). Oestrogen deficiency observed in the OVX model rapidly increases OC 
activity resulting in loss of trabecular bone from the tibia similar to that seen in human 
osteoporosis39. The increase in bone resorption results in decreased bone strength and 
trabecular bone which, in human osteoporosis, leads to an increased risk of fracture380. 
ERs are expressed in myeloid cells of the blood and BM381, yet the effect of oestrogen 
deficiency on monocyte populations has not been well characterised. Menopause has 
been associated with an increase in the number of circulating monocytes which express 
both ERα and ERβ77. In vitro models of oestrogen withdrawal have shown that E/ER 
complex can negatively regulate FcγRIII expression on monocytes and in the absence of 
oestrogen expression of FcγRIII is heightened382. This increase in FcγRIII may allow 
additional interaction with IC. However, as a heterogeneous population, monocyte 
expression of FcγRs varies383. In mice FcγRI, RIIB, RIII and RIV are expressed at varying 
levels on circulating monocytes and OCs259,262. However, expression of FcγRs on the OCP 
population has not been investigated, nor has the effect of oestrogen on the monocyte 
populations.  
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Thus the effect of SpA derived IgG complexes in a model of oestrogen deficiency was 
examined. SpA forms ICs with IgG (SIC) upon injection and has been shown to reduce 
the number of OCs present in the inflamed joints of CIA animals299,316. Previously, SIC 
was shown to inhibit the differentiation of murine BM cells to OC in an FcγRIII 
independent manner, however, SIC may work in concert with multiple FcγRs including 
FcγRIII. This inhibition also resulted in the down-regulation of OC essential genes such 
as DC-STAMP, OSCAR, Cathepsin K and TRAP. Research has also shown that SIC reduces 
MØ responsiveness to IFN-γ and down-regulated surface expression of MHC II, while 
increasing the production of IL-10 compared to IL-12 which is perturbed in the OVX 
model316. SIC down-regulates the surface expression of CD115316 and RANK on human 
pre-OCs and inhibits RANK mediated p38 signalling (unpublished observations) which are 
highly important in oestrogen deficient bone loss. These observations provide evidence 
for the potential of SpA to interfere with OC differentiation in this model. Models of 
inflammatory diseases have been associated with an increased presence of OCPs, yet 
the OCP population has not been studied in the oestrogen deficiency model103,183. 
Likewise, the effect of SpA on pre-OCs has not been examined in a non-inflammatory 
disease, like the oestrogen deficiency model of osteoporosis. 
With a diverse range of potential targets in the OVX induced oestrogen deficiency 
model, the use of SpA focuses on the pool of monocytes in the blood and BM. It is 
hypothesised that treatment with SpA will induce the formation of IC that will interact 
with monocytes in the blood and BM. This will ultimately prevent the differentiation of 
OCs in OVX animals and rescue the bone loss observed in this model (Figure 4-1). The 
research presented in this chapter examines the effect of SpA on murine monocytes and 
monocyte subsets during homeostasis and the OVX mouse model of oestrogen 
deficiency. The principal aims were to: 
1. Determine which monocyte populations SpA interacts with in blood and 
BM. 
2. Investigate whether SpA affects the phenotype of circulating monocytes 
and monocyte subsets in the blood and BM. 
3. Investigate whether SpA can prevent the bone loss observed in the OVX 
mouse model of oestrogen deficiency. 
4. Determine whether oestrogen deficiency and treatment with SpA has an 
effect on circulating populations of monocytes. 
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Figure 4-1: Diagram representing oestrogen deficiency induced bone loss and treatment with 
SpA IgG complexes. 
Following OVX-induced oestrogen deficiency, IL-7 is produced by OBs and stromal cells. This 
induces T cell proliferation leading to MØ activation. The overall effect is the production of IL-6, 
TNF-α, IL-1, M-CSF and RANKL which induce osteoclastogenesis from monocytes leading to 
increased OC activity and thus bone loss. In this microenvironment, it is hypothesised that SIC 
will prevent the differentiation of monocytes to OCs and reduce MØ responiseness to IFN-γ 
stimulation. Overall, SpA treated oestrogen deficient animals should not loss bone mass. 
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4.2 Results 
4.2.1 SpA interacts with blood and bone marrow monocytes 
In order to examine the ability of SpA to bind blood and BM monocyte subsets, a flow 
cytometry gating strategy, based on previous research, was developed. Due to accepted 
nomenclature, a naming system was used which reflected the definition of Ly6Chigh and 
Ly6Clow monocytes, while both expressing high levels of CD11b99. The gating strategy 
isolated monocyte subsets ex vivo which could also identify Ly6Chigh monocytes 
expressing low levels of CD11b4,384; this monocyte subset was termed the OCP after the 
observed functions of the BM population. In the blood, Jacquin et al (2006) 
demonstrated that Ly6Chigh monocytes were more responsive to M-CSF and RANKL 
compared to Ly6Clow monocytes4. However, the osteoclastogenic potential of Ly6Chigh 
CD11blow monocytes found in the blood has not been determined. Despite this, these 
cells were referred to as OCP as demarked by their expression of Ly6C and CD11b, with 
note that in the blood Ly6Chigh monocytes have been shown to differentiate into OCs. 
During the isolation of these monocyte subsets, a Ly6Cnegative CD11bnegative population was 
present, however, Charles et al (2012) showed that this population has no osteogenic 
potential therefore this double negative population was not included in data analysis103. 
This strategy of identification allowed analysis of monocytes free from contamination 
with neutrophils (Ly6G+), T cells (CD3+) or B cells (B220+) in the blood (Figure 4-2A) and 
BM (Figure 4-2B).  
Using this flow cytometry panel, the ability of SpA to bind monocytes in vivo was 
investigated. SpA, or the control protein OVA, was conjugated to the fluorescent dye 
Alexa Fluor 488 (AF488). Fluorescently labelled OVA-488 or SpA-488 was then injected 
i.p. into C57Bl/6 mice, after 2 hours blood and BM was taken and prepared for FACS 
analysis (Figure 4-2A). Injection with SpA-488 resulted in a large percentage of AF488+ 
monocytes in the blood compared to OVA-488 (Figure 4-3A). The absolute number of 
AF488+ monocytes and monocyte subsets in the blood was calculated from the 
percentage of AF488+ monocytes. It was shown that in the blood Ly6Chigh and Ly6Clow 
monocytes were interacting with SpA-488 (Figure 4-4A). However, the average intensity 
of SpA binding in the AF488+ cells remained equal with that of OVA-488 treated animals 
(Figure 4-4C). This suggests that even although there were a higher number of SpA-488+ 
cells, there was a low level of binding to these cells (Figure 4-3 and Figure 4-4). 
Importantly, SpA did not interact with OCP population (Figure 4-4A). However, due to a 
lack of biological replicates in the SpA-488 treatment group statistically analysis of the 
blood could not be done (Figure 4-4A).  
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Treatment with OVA-488 and SpA-488 did not affect percentage of AF488+ monocytes in 
the BM (Figure 4-3). This was reflected in the absolute cell numbers of AF488+ 
monocytes and monocyte subsets of OVA-488 and SpA-488 treated animals (Figure 4-4B). 
Yet, OVA-488 treated animals had significantly increased AF488 MFI on total monocytes 
compared to SpA-488 (Figure 4-4D). This revealed that Ly6Clow and OCP populations 
were responsible for the increased interactions of OVA-488 in the BM (Figure 4-4D). OVA 
protein is inert and thus should not bind to cells. However, resident MØ and phagocytic 
cells in the BM were not excluded from analysis due to exclusion of F4/80 from gating 
strategy. These phagocytic cells may have ingested OVA-488 inorder to clear it from the 
system. While SpA-488 has already been co-opted by circulating monocytes and so will 
not be found at the same concentrations as OVA-488 in the BM. This demonstrates that 
within the total monocyte population, subsets are able to interact with SpA-488 IC and 
OVA-488 within their microenvironment to delineate these populations. Previous work 
done in the lab demonstrated that SpA-488 interacted highly with monocytes in the 
blood and BM 2 hours following i.p treatment316. The present results show a limited 
level of interaction with Ly6Chigh and Ly6Clow monocytes in the blood and BM. However, 
there appeared to be no interaction between OCPs and SpA-488 in this study in the 
blood and BM. 
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Figure 4-2: Gating strategies for the identification of monocytes and monocyte subsets. 
Representative FACS plots of gating strategies employed to distinguish monocytes. A) Blood and 
B) BM cells were isolated from C57Bl/6 mice and FACS stained for CD3, B220, Ly6G, Ly6C and 
CD11b. Doublets were isolated from single cells by exclusion of events which had a non-linear 
relationship with Side Scatter Area versus Side Scatter Height, T and B cells were excluded by 
their expression of CD3 and B220, and Neutrophils were excluded by their expression of Ly6G. 
Total Monocytes (CD3-B220-Ly6G-) and their subsets were analysed by their expression of CD11b 
and Ly6C; Ly6Chigh CD11bhigh (1 – Ly6Chigh Monocytes), Ly6Clow CD11bhigh (2 – Ly6Clow Monocytes) and 
Ly6Chigh CD11blow (3 – OCP population).  
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Figure 4-3: Representative FACS plots of AF488+ monocytes and monocyte subsets. 
SpA and OVA were conjugated to fluorescent dye AF488. 600μg of OVA-488 or SpA-488 in PBS was 
injected i.p. into C57Bl/6 mice. After 2 hours, blood and BM were isolated and prepared for flow 
cytometry. The gating strategy previously shown (Figure 4-2) was used to isolate total monocytes 
and their subsets for analysis of OVA-488 and SpA-488 binding. Representative FACS plots of 
OVA-488+ and SpA-488+ cells in blood and BM monocytes and monocytes subsets is shown from 
one individual experiment.  
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Figure 4-4: Fluorescent SpA binds to Ly6Chigh monocytes in the blood. 
C57Bl/6 mice were injected i.p. with 600μg of OVA-488 or SpA-488 in PBS. After 2 hours, blood 
and BM were isolated and prepared for flow cytometry. Gating strategy previously shown (Figure 
4-2) was used to isolate total monocytes and their subsets for analysis of OVA-488 and SpA-488 
interactions (Figure 4-3). The number of AF488+ cells in A) Blood and B) BM monocytes and 
monocyte subset populations was calculated from the % of AF488+ cells and the total number of 
cells isolated from each animal. C) Blood and D) BM MFI of AF488 in OVA-488 and SpA-488 on 
monocytes and monocytes subsets in treated animals. Two way ANOVA’s with Bonferroni’s 
post-hoc tests used to test BM OVA versus SpA monocyte subsets; p<0.01 (**), p<0.001 (***). Data 
represents mean ± SD, blood OVA-488 (n=2) and SpA-488 (n=3) and BM OVA-488 (n=3) and 
SpA-488 (n=3). Data represents one individual experiment. 
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4.2.2 SpA and monocyte FcγRI 
Due to the documented ability to SpA to interact with FcγRI316, the expression of FcγRI 
was investigated. Following OVA-488 and SpA-488 treatment, the percentage of FcγRI+ 
monocytes and monocyte subsets in the blood and BM was evaluated (Figure 4-5). In the 
blood, SpA treatment had no effect on the number of FcγRI+ cells in total monocytes or 
subsets. Yet, the absolute number of FcγRI+ cells showed that Ly6Chigh monocytes were 
the most abundant FcγRI+ monocyte subset (Figure 4-6A), and upon treatment with 
SpA-488, the expression of FcγRI was reduced (42%) (Figure 4-6C). The expression of 
FcγRI on the surface of Ly6Clow monocytes was also reduced (49%). Interestingly, OCPs 
do not appear to express FcγRI, this may account for the lack of interaction in SpA-488 
binding (Figure 4-4C and Figure 4-6C).  
A similar effect in FcγRI expression was observed in the BM with the number of FcγRI+ 
monocyte population significantly reduced following SpA-488 treatment (37.5%, p<0.01) 
(Figure 4-6B). Upon further examination, Ly6Chigh, Ly6Clow and OCP all had significantly 
reduced FcγRI expression following SpA-488 treatment (38%, p<0.001, 34%, p<0.001 and 
25%, p<0.05, respectively) (Figure 4-6D). The reduction in FcγRI expression on 
monocytes may be a by-product of SpA-488 IgG complexes co-opting FcγRI and thus 
masking the epitope for antibody binding. Therefore, after 2 hours of treatment, SpA 
was able to bind to monocytes in the blood and BM. Down-regulation of FcγRI on the 
surface of all monocyte subsets in the BM suggests that SpA is present in the BM and 
interacting with monocytes despite the obvious presence of SpA-488 binding to these 
cells (Figure 4-3 and Figure 4-4). BM OCPs express FcγRI, while in the blood OCPs don’t 
express FcγRI, demonstrating that these cells are phenotypically different.  
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Figure 4-5: Representative FACS plots of FcγRI expression on monocytes and monocytes 
subsets. 
600μg of OVA-488 or SpA-488 in PBS was injected i.p. into C57Bl/6 mice. After 2 hours, blood and 
BM was isolated and prepared for flow cytometry. Gating Strategy previously shown (Figure 4-2) 
was used to isolate total monocytes and their subsets for analysis of FcγRI expression. 
Representative FACS plots of FcγRI+ cells in blood and BM monocytes and monocytes subsets are 
shown from one individual experiment. 
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Figure 4-6: FcγRI expression is reduced on monocytes and monocyte subsets following SpA 
treatment. 
600μg of OVA-488 or SpA-488 in PBS was injected i.p. into C57Bl/6 mice. After 2 hours, blood and 
BM was isolated and prepared for flow cytometry. Gating strategy shown (Figure 4-2) was used to 
isolate total monocytes and monocyte subsets for analysis of FcγRI (Figure 4-5). The number of 
FcγRI+ cells in A) Blood and B) BM monocytes and monocyte subset populations was calculated 
from the % of FcγRI+ cells and the total number of cells isolated from each animal. C) Blood and 
D) BM MFI of FcγRI in OVA-488 and SpA-488 on monocytes and monocytes subsets in treated 
animals. Two way ANOVA’s with Bonferroni’s post-hoc tests used on BM OVA versus SpA 
monocyte subsets; p<0.05 (*), p<0.01 (**) and p<0.001 (***). Data represents mean ± SD, blood 
OVA-488 (n=2) and SpA-488 (n=3) and BM OVA-488 (n=3) and SpA-488 (n=3). Data represents one 
individual experiment.  
 
 
 
 
 
 
 
 
 
114 
 
4.2.3 SIC inhibits Ly6Chigh monocyte differentiation to osteoclasts 
To investigate the effect of SpA on monocyte populations, Ly6Chigh and Ly6Clow 
monocytes were isolated from blood and BM of CX3CR1-GFP C57Bl/6 animals. Using a 
FACS Aria, monocytes were isolated based on their expression of CX3CR1-GFP, Ly6C, 
Ly6G, CD11b and CD117 (Figure 4-7A). Monocyte sorting on a FACS Aria was performed 
by Dr. J. Montgomery. Single cells which were CD11b+ CD117- Ly6G- CX3CR1+ Ly6Chigh or 
Ly6Clow were sorted. Ly6Chigh and Ly6Clow monocytes were cultured using 75ng/ml M-CSF 
and 50ng/ml RANKL to differentiate cells to OCs. SpA, OpIg and SIC were added to 
Ly6Chigh monocyte cultures in triplicate. Due to the low number of cells isolated, Ly6Clow 
monocytes could only be cultured in duplicate and only with or without SIC treatment. 
Following 5 days of culture, cells were stained for TRAP, revealing that Ly6Chigh 
monocytes cultured in the presence of M-CSF and RANKL could differentiate into OCs 
(Figure 4-7B). Ly6Chigh monocytes differentiation into OC was inhibited by treatment 
with OpIg (96% - p<0.001) and SIC (85% - p<0.001) (Figure 4-7B). Previously, it was 
shown that IgG alone present in the OpIg, as well as IgG complexes in SIC, could inhibit 
osteoclastogenesis. This demonstrates that these cell populations are prevented from 
differentiation to OCs in the presence of M-CSF and RANKL by addition of IgG alone or in 
complex. Treatment of Ly6Chigh monocytes with SpA alone resulted in a slight but 
significant increase osteoclastogenesis (p<0.01). Comparison between Ly6Chigh and 
Ly6Clow monocytes differentiation wasn’t analysed due to a lack of experimental 
replicates (Figure 4-7C). However, the data would suggest that Ly6Clow monocytes are 
far less osteoclastogenic than Ly6Chigh monocytes as there were a third of cells produced 
when differentiated in the same conditions. 
SIC has been used to inhibit the in vitro differentiation of OCs from pre-OCs by 
preventing the transcription of OC specific genes and now has been shown to directly 
prevent Ly6Chigh monocytes from differentiating to OCs. SpA can bind to the surface of 
Ly6Chigh and Ly6Clow monocytes in the blood and reducing the expression of FcγRI in the 
BM. As monocytes are important pre-OCs, the ability of SpA to interact with these cells 
and prevent the in vivo differentiation and function of OCs was examined using a 
murine model of disease.  
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Figure 4-7: Ly6Chigh monocytes are inhibited from differentiating to osteoclasts following Fcγ 
receptor modulation. 
Blood and BM was isolated from CX3CR1 GFP C57Bl/6 mice and prepared for flow cytometry. 
Ly6Chigh and Ly6Clow monocyte subsets were sorted based on their expression of CD11b+ CD117- 
Ly6G-, CX3CR1 GFP. Monocyte cells were isolated by Dr. J. Montgomery. A) Representative FACS 
plots of the monocyte sort on the FACS Aria. B) and C) Isolated Ly6Chigh and Ly6Clow monocytes 
were cultured at 1x105 cells in 200μl of complete α-MEM with 75ng/ml M-CSF and 50ng/ml RANKL 
for 5 days at 37oC with media refreshed on day 4. SIC (and controls) were added on day 1 and 4. 
Cultures were stained for TRAP and TRAP+ cells with >3 nuclei were counted. The sum total of 4 
fields of view per culture well were recorded. Ly6Chigh monocytes were cultured in triplicate and 
Ly6Clow monocytes were cultured in duplicate. One Way ANOVA with Bonferroni’s post-hoc test 
were used on Ly6Chigh monocytes only; p<0.01(**) and p<0.001 (***). Data represents mean ± SD 
from one experiment. Scale bar; 200μm. 
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4.2.4 Murine model of ovariectomy induced bone loss  
The effect of SpA was examined in a non-inflammatory model of bone loss. The OVX 
model of oestrogen deficiency results in an increase in pro-osteoclastogenic factors 
enhancing the differentiation of OCs thus promoting bone loss69. SpA’s ability to alter 
the disease severity in the OVX model was examined.  
Three separate methods of SpA administration were investigated (Figure 4-8). These 
regimes were designed to test the potential of SpA to influence disease progression. The 
Therapeutic Treatment Regime was designed to test the ability of SpA to recover the 
initial bone loss incurred 2 weeks following surgery (Figure 4-8A). The Continuous 
Treatment Regime was considered to be a ‘prophylactic’ regime to test whether SpA 
treatment from initiation of disease could overcome OVX induced bone loss (Figure 
4-8B). The third treatment regime was designed to test the method of administration; 
Alzet PumpsTM (model 2004) with SpA or control protein OVA were inserted i.p at the 
time of surgery thus allowing the secretion of SpA/OVA at a constant rate of 
0.25μl/hour over a 4 week period (Figure 4-8C).  All treatment regimes lasted 6 weeks 
following surgery at which time the experiments were terminated. 
Following surgery, animal’s weights were monitored weekly ensuring that no treatment 
caused detrimental effects beyond those observable in the model (Figure 4-9). The 
weights of all animals steadily increased over the 6 week period. The difference in 
weight (Δ weight change) from the initiation to termination was calculated to evaluate 
weight gain over the treatment course. This revealed that oestrogen deficient animals 
in the Therapeutic and Continuous Treatment Regimes significantly increased weight 
compared to their sham operated counterparts (Figure 4-9C, F). Treatment with SpA 
had no additional effect on the weights observed in these treatment regimes (Figure 
4-9). No difference in weight was observed in animals in the Alzet PumpTM Treatment 
Regime (Figure 4-9I). Following termination of the treatment regimes each animal had 
their uterus removed and weighed. In the event of a successful ovariectomy, oestrogen 
deficiency will cause the uterus to atrophy, as shown in the representative image 
(Figure 4-10A). Uterine weights revealed that the OVX groups had significantly lighter 
uteri when compared to sham operated animals regardless of treatment regime (Figure 
4-10B-D). Treatment with SpA had no additional effect on the weight of the uteri.  
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Figure 4-8: Diagrammatic representation of the OVX treatment regimes. 
All animals were OVX or sham operated at week 0. Disease onset began from point of surgery and 
all animals were sacrificed at week 6. Three treatment regimes were utilised to test the effect 
of SpA on this model. A) Therapeutic Treatment Regime; 100μg of SpA or OVA in 100μl of PBS 
was injected i.p. every 2nd day two weeks after surgery - and the onset of disease - until the end 
of the experiment. B) Continuous Treatment Regime; 100μg of SpA or OVA in 100μl of PBS was 
injected i.p. every 2nd day from the point of surgery until the end of the experiment. C) Alzet 
PumpTM Treatment Regime; Alzet PumpsTM (model 2004) containing 1.4mg of SpA or OVA was 
inserted into the peritoneal cavity at the point of surgery. The Alzet PumpTM secretes at a rate of 
50μg over the course of a day (100μg every 2nd day) for 4 weeks after which point animals were 
allowed to recover prior to the end of the experiment. 
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Figure 4-9: OVX surgery increased animal’s weight. 
Therapeutic Treatment Regime. A) Start weights (g) recorded at the time of surgery. B) Final 
weights of animals recorded 6 weeks after surgery. C) The change in weight (g) from start to the 
end was calculated (Final weight – Start weight = Delta Weight Change). Continuous Treatment 
Regime. D) Start weights (g) recorded at the time of surgery. E) Final weights of animals 
recorded 6 weeks after surgery. F) The change in weight (g) from start to the end was calculated 
(Final weight – Start weight = Delta Weight Change). Alzet PumpTM Treatment Regime. G) Start 
weights (g) recorded at the time of surgery. H) Final weights of animals recorded 6 weeks after 
surgery. I) The change in weight (g) from start to the end was calculated (Final weight – Start 
weight = Delta Weight Change). Two Way ANOVAs with Bonferroni’s post-hoc tests used to 
compare treatment groups; p<0.05 (*) and p<0.01 (**). Data represents means ± SD, n=7-8. 
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Figure 4-10: Oestrogen deficiency decreases uterine weight. 
Six weeks after OVX/sham surgery, uteri were removed from animals. Excess fat and tissue was 
removed from each uterus prior to desiccation overnight. A) Representative image of uterus 
removed from sham and OVX operated animal prior to desiccation. B) Dry weights (mg) of uteri 
from animals in the Therapeutic Treatment Regime. C) Dry weights (mg) of uteri from animals in 
the Continuous Treatment Regime. D) Dry weights (mg) of uteri from animals in the Alzet PumpTM 
Treatment Regime. Two Way ANOVA with Bonferroni’s post-hoc tests used to compare treatment 
groups; p<0.001 (***). Data represents mean ± SD, n=7–8. 
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4.2.5 CTX-1 is a marker of bone resorption 
The effect of SpA treatment on OVX induced bone remodelling was evaluated by 
examining two proteins; Osteocalcin and C-telopeptide fragment of Collagen Type 1 
(CTX-1). Plasma from sham and OVX animals was taken at the termination of treatment 
regimes. OBs secrete Osteocalcin as part of the bone formation process, however, a 
small quanity is leached into circulation as a by-product385. Measurements of 
Osteocalcin concentration by ELISA showed that OVX and treatment with SpA had no 
effect on the rate of bone formation in either the Therapeutic or Alzet PumpTM 
Treatment Regimes (Figure 4-11A, C). Bone resorption was measured by the plasma 
concentration of CTX-1 which is released into circulation as a by-product of bone 
erosion386. The concentration of CTX-1 was measured by ELISA and in the Therapeutic 
and Alzet PumpTM Treatment regimes, oestrogen deficiency increased CTX-1 in plasma 
compared to sham operated animals (Figure 4-11B, D). SpA treatment in both sham and 
OVX animals had no effect on the level of CTX-1 in circulation (Figure 4-11B, D). Due to 
availability of these ELISA reagents, it was not possible to use plasma samples from the 
Continuous Treatment Regime. The detection for pro-OC cytokines TNF-α, IL-6, IL-1β 
and IFN-γ was performed in all treatment regime samples. However, the concentration 
of these cytokines in all samples remained below the limit of detection and thus no 
conclusions could be drawn from these experiments (data not shown). Overall results 
show that in the context of the whole animal bone resorption is increased while the 
bone formation rate remains stable.  
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Figure 4-11: OVX increases the plasma concentration of CTX-1. 
Plasma was collected from animals six weeks after OVX/sham surgery by draining blood from the 
vena cava with a needle and 20μl of 0.5M EDTA. Blood was centrifuged at 4,000rpm for 10 
minutes and the clear plasma layer removed. Plasma concentration of Osteocalcin and CTX-1 
were measured by ELISA. A) Osteocalcin and B) CTX-1 were measured from plasma collected 
from the Therapeutic Treatment Regime and measured by ELISA. C) Osteocalcin and D) CTX-1 
were measured from plasma collected from the Alzet PumpTM Treatment Regime by ELISA. Two 
way ANOVA with Bonferroni’s post-hoc tests were used to compare all treatment groups; p<0.01 
(**) and p<0.001 (***). Data represents mean ± SD, n=5-8. 
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4.2.6 Biomechanical testing of OVX femurs 
Oestrogen deficiency is known to induce bone loss which can result in a decrease in 
bone strength387 and as such the biomechanical properties of OVX animal’s femurs were 
tested. Femurs from the Therapeutic Treatment Regime were taken at termination and 
exposed to three point bend testing. Three point bend testing is used to determine the 
integrity and overall strength of bone as measured by the Maximum Load - the peak 
Newtons of force (N) exerted on the bone before it breaks387–389. This process also 
records the Modulus (MPa – MegaPascals) - a measure of intrinsic stiffness in the bone 
regardless of size; Extension at Max Load (mm - millimetre) – the displacement required 
to reach the peak force necessary to break;  Load at Break (N) – this is the force exerted 
when the bone fractures; Extension at Break (mm) – The displacement required to reach 
the Load to Break; Energy at break (J - Joules) – the energy the bone can absorb prior to 
fracture and is an indication of toughness. These parameters were shown to be 
unchanged following OVX or treatment with SpA (Figure 4-12). Three point bend testing 
is a destructive method to measure bone strength and can only provide limited data 
regarding cortical bone strength. Therefore, another more accurate method of 
measuring the effect of oestrogen deficiency on bone loss was required. 
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Figure 4-12: The effect of OVX and treatment with SpA on bone integrity measured by 
three-point bend testing. 
Femurs were taken from Therapeutic Treatment Regime animals six weeks after OVX/sham 
surgery. Femurs were stripped of flesh and were stored in 70% ethanol at 4oC. The bones then 
underwent three-point bend testing by carefully mounting femurs on an Instron Mechanical 
Testing Stage using a third pressure point lowered slowly to the top of the femur. The force 
exerted on the bone and resistance of the bone were measured and the following parameters 
were calculated by Bluehill software. A) Maximum load (N), B) Extension at Maximum Break 
(mm), C) Load at Break (N), D) Extension at Break (mm), E) Energy at Break (J) and F) Modulus 
(MPa).Two Way ANOVAs with Bonferroni’s post-hoc tests were used to compare all treatment 
groups. Data represents mean ± SD, n=4–6 from one experiment. 
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4.2.7 OVX bone loss measured by micro computer tomography 
The most sensitive method for examining bone micro-architecture is micro computer 
tomography (μCT) which uses a series of X-ray images of a rotated structure to create a 
3 dimensional image that can be manipulated and examined. Using this technology, 
tibias from sham and OVX animals were analysed (Figure 4-13). The trabecular sections 
of the proximal tibias (shown in coronal cross-section) were isolated and analysis was 
focused on a standardised region of interest of trabecular bone shown in the black box 
(Figure 4-13). μCT allows for the analysis of a number of parameters including; 
percentage of trabecular bone, a commonly used parameter to measure the degree of 
osteoporotic disease in this model390. The percentage of trabecular bone examines the 
bone tissue volume (BV) in the trabecular section and normalises it for the overall tissue 
volume (TV) in the section (also known as BV/TV). OVX animals were shown to have 
approximately 30% less trabecular bone present when compared with sham operated 
animals (p<0.001), which treatment with SpA was unable to alter. This was seen in all 
three treatment regimes (Figure 4-14A, E, I). Oestrogen deficiency also induced a 
decrease in bone volume in OVX groups compared to sham operated animals in all 
treatment regimes (Figure 4-14B, F, J).  
Another measure of bone disease in the OVX model is trabecular number, the average 
number of trabeculae present in the trabecular bone section. Increased OC activity 
erodes trabeculae and thus decreases the number of trabeculae. In all treatment 
regimes, the number of trabeculae was significantly decreased in OVX compared to 
sham operated animals and treatment with SpA was unable to rescue this decrease 
(Figure 4-14C, G, K). As trabecular number decreases with OVX disease, the separation 
between each trabeculum increases and this parameter was shown to significantly 
increase by approximately 20% in OVX animals in the three treatment regimes (Figure 
4-14D, H, L). The observed decrease in trabecular bone volume, trabecular number and 
increase in separation between trabeculae all demonstrate that each of the OVX 
surgeries successfully induced bone loss (Figure 4-14). A number of other parameters 
were also measured which all verify that OVX reduced the animals tibial bone volume 
(data not shown). OVX induced oestrogen deficiency resulted in bone loss in the 
proximal tibia that SpA treatment was unable to prevent. 
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Figure 4-13: Representative images of μCT trabecular bone reconstructions from proximal 
tibia of sham and OVX animals. 
The left tibia of each animal was taken six weeks after OVX/sham surgery. Tibias were fixed 
overnight in 4% para-formaldehyde before being stored in 70% ethanol. Bones were scanned using 
a SkyScan 1172 μCT scanner. This generated a series of X-ray images which could be manipulated 
using NReconn software to create a 3D structure of the tibia (shown in the coronal cross-section 
of the proximal tibia). The trabecular bone present in this tibia could be further examined by 
isolating the specific region of interest using CTAn software to create a 3D model of the 
trabecular bone (shown in the dorsal transverse section - black box) which can be processed to 
give a number of measureable parameters. 
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Figure 4-14: μCT analysis of trabecular bone of proximal tibia of sham and OVX animals. 
As described in Figure 4-13, trabecular bone was identified and the properties of which 
quantified by SkyScan CTAn software. The three treatment regimes are shown above. A), E) and 
I) Bone volume / tissue volume (BV/TV); the percentage of trabecular bone present. B), F) and J) 
Bone Volume (μm3) present in the trabecular region. C), G) and K) The number of trabeculae 
present in the trabecular region, normalised to the trabecular volume. D), H) and L) The 
trabecular separation represents the average distance between each trabeculae in the 
trabecular region. Two Way ANOVA with Bonferroni’s post-hoc tests were used to compare all 
treatment groups; p<0.05 (*), p<0.01 (**), p<0.001 (***) Data shown represents mean ± SD, n=7-8. 
 
 
 
 
 
 
 
 
127 
 
4.2.8 Oestrogen, SpA and monocyte composition 
SpA was unable to prevent OVX induced bone loss, however the effect of oestrogen 
deficiency on monocytes was evaluated. FACS analysis was done to analyse the effect 
that oestrogen deficiency exerts on monocytes and their subsets in blood and BM. Blood 
and BM was taken from animals and the total number monocytes was determined by 
flow cytometry (Figure 4-15). Each treatment regime required a slightly altered method 
of gating to isolate monocytes, but, this did not impact on the ability to isolate 
monocytes and their respective subsets within each sample.  
Analysis revealed that the BM monocyte compartment was unaffected by oestrogen 
deficiency in all of the treatment regimes (Figure 4-16B, D, F). Interestingly, circulating 
monocytes from animals in each treatment regime vary. In the Therapeutic Treatment 
Regime, oestrogen deficiency had no effect on the number of total monocytes (Figure 
4-16A). In the Continuous Treatment Regime oestrogen deficiency doubled the number 
of monocytes (p<0.05) (Figure 4-16C), while the Alzet PumpTM Treatment Regime OVX 
groups had a decreased percentage of blood monocytes compared to sham controls 
(Figure 4-16E). In the Alzet PumpTM model, cell counts were not performed on the 
blood, so the total number of monocytes could not be quantified. Beyond the effects 
oestrogen exerts on monocytes, treatment with SpA in all treatment regimes had no 
impact on the number of monocytes in the blood or BM (Figure 4-16). 
To further investigate the effect that oestrogen deficiency has on monocytes the 
composition of subsets was evaluated. Using the gating strategy previously outlined 
(Figure 4-15), monocyte subsets were isolated and the number of cells present within 
each group was quantified. In the Therapeutic Treatment Regime, SpA increased the 
number of Ly6Clow monocytes present in the blood of sham and OVX animals (p<0.05 and 
p<0.001, respectively) and BM of sham operated animals (p<0.001) (Figure 4-17A-B). 
Analysis of the Continuous Treatment Regime demonstrated that oestrogen deficiency 
and treatment with SpA had no effect on blood monocytes, however, both oestrogen 
deficiency and treatment with SpA could increase the number of Ly6Chigh monocytes in 
the BM compared to sham operated animals (p<0.01) (Figure 4-17C-D).  The BM of the 
Alzet PumpTM Treatment Regime showed no change on monocyte subset numbers, while 
oestrogen deficiency decreased the percentage of monocytes in the blood (p<0.05) 
(Figure 4-17E). Overall, oestrogen deficiency did not exert any consistent effect on 
monocyte composition from one predominant cell type to another in any treatment 
regime (Figure 4-17). 
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Figure 4-15: Representative FACS plots of three OVX treatment regimes. 
A) Blood from Therapeutic Treatment Regimes were isolated from C57Bl/6 mice and FACS 
stained for Live/Dead, CD3, B220, Ly6G, Ly6C and CD11b. Representative FACS plots of gating 
strategies employed to distinguish monocytes. Doublets were isolated from single cells, Live 
Cells were selected on low expression of Live/Dead exclusion marker, T and B cells were 
excluded by their expression of CD3+ and B220+, and Neutrophils were excluded by their 
expression of CD3-B220-Ly6G+. Total Monocytes (CD3-B220-Ly6G-) and their subsets were 
analysed by their expression of CD11b and Ly6C. B) Blood from Continuous Treatment Regimes 
were isolated from C57Bl/6 mice and FACS stained for CD3, B220, Ly6G, Ly6C and CD11b. 
Representative FACS plots of gating strategies employed to distinguish monocytes and their 
subsets. C) Blood from Alzet PumpTM Treatment Regimes were isolated from C57Bl/6 mice and 
FACS stained for CD3, B220, Ly6G, Ly6C and CD11b. Representative FACS plots of gating 
strategies employed to distinguish monocytes. Monocyte subset populations were identified as 
described in Figure 4-2.  
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Figure 4-16: Number of total monocytes following OVX and treatment with SpA. 
Blood and BM was isolated from animals six weeks after surgery and prepared from analysis by 
flow cytometry. Red blood cells were lysed using ammonium chloride or Akt Buffer. Cells were 
counted then stained for FACS and a gating strategy previously shown (Figure 4-15) was used to 
isolate the number of total monocytes. The % of monocytes defined by FACS analysis was used to 
calculate the absolute number of monocytes present in both the blood and BM. The number of 
total monocytes from the Therapeutic Treatment Regime in A) Blood and B) BM are shown. The 
number of total monocytes from the Continuous Treatment Regime in C) Blood and D) BM are 
shown. The percentage of and number of total monocytes from the Alzet PumpTM Treatment 
Regime in E) Blood and F) BM are shown. Two Way ANOVAs with Bonferroni’s post-hoc tests were 
used to compare treatment groups; p<0.05 (*). Data represents mean ± SD, n=7–8. 
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Figure 4-17: Monocyte subset cell numbers following OVX and treatment with SpA. 
Continuing on from the data shown in Figure 4-16, the expression profiles of Ly6C and CD11b 
were used to identify monocyte subsets as described in Figure 4-15. The % of cells in each 
monocyte subset was used to calculate the absolute number of monocytes present in both the 
blood and BM. The subsets of interest were Ly6Chigh, Ly6Clow and OCP. The absolute numbers of 
cells constituting these subsets in A) Blood and B) BM for the Therapeutic Treatment Regime is 
shown. The absolute numbers of cells constituting these subsets in C) Blood and D) BM for the 
Continuous Treatment Regime is shown. The percentage of, and absolute number of cells 
constituting these subsets in E) Blood and F) BM for the Alzet PumpTM Treatment Regime is 
shown.  Two Way ANOVAs with Bonferroni’s post-hoc test were used to compare individual 
monocyte subsets across treatment groups; p<0.05 (*), p<0.01 (**) and p<0.001 (***). Data 
represents mean ± SD, n=7–8. 
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4.2.9 Fcγ receptor profiles and oestrogen deficiency  
Previously SpA has been shown to bind the monocytes in vivo (Figure 4-3) mediated by 
FcγRs316. The effect of long term treatment with SpA and the absence of oestrogen 
could impact on the expression of FcγRI or II/III on the surface of monocyte subsets and 
this was examined. 
First, expression of FcγRI on monocytes following OVX was examined. The Therapeutic 
Treatment Regime showed that OVX significantly decreased the expression of FcγRI on 
the surface of total monocytes in the blood (p<0.05), but not on individual subsets 
(Figure 4-18A).  In BM, OCP FcγRI expression was decreased following OVX (Figure 
4-18B). Oestrogen deficiency was shown to have no effect on the expression of FcγRI on 
the surface of monocyte subsets in the blood and BM of Continuous or Alzet PumpTM 
Treatment Regimes (Figure 4-18C-F). This suggests that oestrogen deficiency had no 
overall effect on the expression of FcγRI as there was no consistent result. 
Upon examining the expression pattern of FcγRII/III, OVX was shown to have no effect 
on the expression of FcγRII/III on monocytes in the Therapeutic Treatment Regime 
(Figure 4-19A-B). The Continuous Treatment Regime showed that Ly6Clow blood 
monocytes significantly decreased expression of FcγRII/III (p<0.05) (Figure 4-19C).  
While in the Alzet PumpTM Treatment Regime, Ly6Clow BM monocytes had an increased 
expression of FcγRII/III following OVX (Figure 4-19F). These results show that oestrogen 
deficiency does not have a distinct effect on the expression of FcγRI or FcγRII/III on 
monocyte subsets. The control groups of each treatment regime are similar and 
comparison between OVA treated sham and OVX animals should be identical. Therefore, 
no conclusive effects have been shown.  
Evaluation of SpA treatment showed that it had minimal effects on the expression of 
FcγRs. In particular, the expression of FcγRI and FcγRII/III on monocytes in Alzet 
PumpTM Treatment Regime was unaffected. A minor increase in FcγRII/III expression was 
observed in the Therapeutic Treatment Regime on Ly6Clow blood monocytes following 
treatment with SpA in OVX animals (p<0.05) (Figure 4-20A). In the same treatment 
regime, SpA was able to decrease the surface expression of FcγRI on blood Ly6Clow 
monocytes and both BM Ly6Chigh and Ly6Clow monocytes (Figure 4-20B-C). In the 
Continuous Treatment regime, SpA significantly increased the expression of FcγRII/III on 
BM Ly6Chigh monocytes and OCP (Figure 4-20D). Examination of the expression patterns 
of FcγRI and II/III have shown that oestrogen deficiency does not conclusively alter the 
expression of these receptors on the surface of monocyte subsets and no reproducible 
effect was observed following SpA administration.       
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Figure 4-18: Expression of FcγRI on monocyte subsets in blood and bone marrow following 
OVX. 
Continuing on from Figure 4-16, the expression of FcγRI was examined on the monocyte subsets 
identified (Figure 4-15). The subsets of interest were Ly6Chigh, Ly6Clow and OCP and the 
expression of FcγRI on these subsets was recorded as MFI. The expression of FcγRI on monocyte 
subsets in A) Blood and B) BM for the Therapeutic Treatment Regime is shown. The expression of 
FcγRI on monocyte subsets in C) Blood and D) BM for the Continuous Treatment Regime is shown. 
The expression of FcγRI on monocyte subsets in E) Blood and F) BM for the Alzet PumpTM 
Treatment Regime is shown.  Two Way ANOVAs with Bonferroni’s post-hoc test were used to 
compare the effect of all treatment groups on individual monocyte subsets; p<0.05 (*). Data 
represents mean ± SD, n=7–8. 
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Figure 4-19: Expression of FcγRII/III on monocyte subsets in the blood and bone marrow 
following OVX. 
Continuing on from Figure 4-16, the expression of FcγRII/III was examined on the monocyte 
subsets identified (Figure 4-15). The subsets of interest were Ly6Chigh, Ly6Clow and OCP and the 
expression of FcγRII/III on these subsets was recorded as MFI. The expression of FcγRII/III on 
monocyte subsets in A) Blood and B) BM for the Therapeutic Treatment Regime is shown. The 
expression of FcγRII/III on monocyte subsets in C) Blood and D) BM for the Continuous Treatment 
Regime is shown. The expression of FcγRII/III on monocyte subsets in E) Blood and F) BM for the 
Alzet PumpTM Treatment Regime is shown.  Two Way ANOVAs were used to compare the effect of 
all treatment groups on individual monocyte subsets; p<0.05 (*) and p<0.01 (**). Data represents 
mean ± SD, n=7–8. 
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Figure 4-20: SpA modulates Fcγ receptors on monocytes. 
Continuing on from Figure 4-16, the expression of both FcγRI and FcγRII/III was examined on the 
monocyte subsets identified (Figure 4-15). The subsets of interest were Ly6Chigh, Ly6Clow and OCP 
and the expression of FcγRI and FcγRII/III on these subsets was recorded as MFI. The expression 
of FcγRI on monocyte subsets in A) Blood and B) BM and FcγRII/III in C) Blood in the Therapeutic 
Treatment Regime is shown. The expression of FcγRII/III on monocyte subsets in D) BM for the 
Continuous Treatment Regime is shown.  Two Way ANOVAs were used to compare the effect of 
all treatment groups on individual monocyte subsets; p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
Data represents mean ± SD, n=7–8. 
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4.3 Discussion 
Osteoporosis is a pathology associated with the menopause and is an accumulation of 
multiple factors resulting in weakened bone integrity and increased risk of fracture380. 
PMO occurs in 30% of post-menopausal women and is a major cause of femoral head and 
vertebral fractures in the elderly391. Animal models used to study PMO involve removal 
of the ovaries to simulate the oestrogen deficiency in humans40. In the present study, 
the C57Bl/6 mouse model of osteoporosis was used as this strain is prone to oestrogen 
deficient bone loss39. The mouse model of osteoporosis results in the rapid resorption of 
trabecular bone from the femur, tibia and vertebrae but does not resemble human 
disease because mice do not become prone to fractures40. In mice, increasing age 
increases trabecular bone resorption and is more prominent in females than males due 
to an alteration in the pre-OC pool41,392,393. However, as a model system, the OVX mouse 
model allows for the identification of potential drug targets to inhibit the rapid bone 
erosion in a non-inflammatory environment. As SpA has previously been shown to 
decrease the number of OCs in inflamed joints316, it was hypothesised that SpA could 
reproduce this effect in the OVX model. 
Monocytes are of particular interest as the different monocyte subsets have different 
roles during homeostasis and, when stimulated, are a potential pool of pre-OCs89. 
Ablation of the monocyte lineage by clodronate has also been shown to halt 
osteoporotic disease in OVX animal models, highlighting not only that OCs are central to 
this disease pathology but also highlighting monocytes as a reservoir of pre-OCs318. 
Research has already shown that the OCP population in the BM is a subset of monocytes 
which can repopulate OC deficient animals with mature functional OCs4. While in the 
blood, the same role was undertaken by Ly6Chigh monocytes4. In the present study, we 
observed the effect of oestrogen on the regulation of these populations. It was also of 
interest to examine whether SpA could alter these pre-OC populations and prevent them 
from differentiation into OCs. 
SpA is able to enter both the blood and BM following i.p. injection and interact with 
monocytes, possibly via FcγRI316. Previously, SpA has been shown to bind highly to 
monocytes in the blood and BM and the low level of binding observed in this study may 
be due to a number of reasons. One particular example is that the conjugation of SpA 
and OVA to AF488 may have been unequal. A conjugation kit is used which can 
conjugate AF488 to proteins. However, each reaction varies slightly and as such the 
yield of labelled protein can differ between conjugations. The reaction can also produce 
proteins which have differing number of AF488 molecules conjugated to proteins; 
proteins with a high number of AF488 molecules conjugated to them fluoresce more 
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intensely than those with a low number of AF488 molecules. The ratio of AF488 
molecules bound to OVA and SpA was normalised for in this study, however, if the 
previous studies had a high ratio of conjugation this may account for the heightened 
binding of SpA to monocytes. One important control which should be used in future 
experiments with these reagents is the use of a naive mouse which would have allowed 
the identification of the baseline expression of fluorescence, thus allowing 
determination of the effects of OVA-488 and SpA-488. Another discrepancy in this study 
was that OVA-488 was found to highly interact with BM Ly6Clow and OCP populations. 
This interaction was unexpected; however, it may be due to OVA-488 deposition in the 
tissue and uptake by phagocytes which have not been gated out using our gating 
strategy. This may also represent a clearance of OVA from the system, and had the 
spleen been examined it is likely that OVA-488 would be found at a high concentration. 
However, to fully determine whether this is a physiologically relevant interaction or due 
to phagocytosis, these cells would need to be viewed under a confocal microscope to 
observe whether the fluorescence was on the cell surface or within intracellular 
vesicles. This would also allow observation of SpA-488 treated cells and could provide 
evidence to demonstrate that SpA-488 IgG complexes interact with surface receptors on 
these cells. The difference in OVA-488 and SpA-488 interactions in blood and BM could 
also be examined by measuring their protein concentration within the tissue. 
Examination of protein concentration using western blots could demonstrate the protein 
concentration present in the BM and provide insight into the pharmacokinetics and 
distribution of SpA in the mouse.  
In order to investigate whether monocyte subsets responded differently to ligation by 
FcγRs, Ly6Chigh and Ly6Clow monocytes were sorted from the blood and BM. Because the 
BM provides a limited supply of Ly6Clow monocytes, blood was also used as a source of 
monocytes to increase the yield. Unfortunately, the OCP population could not be 
isolated at the same time. Had this population been cultured in the same conditions, 
published research suggests that it would have been highly osteoclastogenic103. 
However, in comparison, Ly6Chigh monocytes were more osteoclastogenic than Ly6Clow 
monocytes, and were inhibited from differentiation by FcγR modulation. As previously 
demonstrated, OC cultures derived from BM could be inhibited by addition of IgG or IgG 
complexes. The addition of OpIg and SIC to cultures of Ly6Chigh monocytes was able to 
also inhibit OC differentiation. However, in vivo IgG is continually present and in its 
monomeric form has limited ability to influence cellular activity. Yet, IC have been 
shown to have a multitude of effects. In particular, IC have been shown to either inhibit 
or enhance osteoclastogenesis in vitro depending on the type of IC used262,317. IC are 
also known to directly induce disease pathology, an example of this is systemic lupus 
erythematosus in which antibodies against DNA form IC and propagate the autoimmune 
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inflammation resulting in dysfunction of the kidney and neurological issues394,395. 
Therefore, IC can have a multitude of effects in vivo and as SpA has been shown to be 
effective in reducing inflammatory derived OCs in vivo, the effect of SpA on pre-OC 
populations of the blood and BM was examined. 
Oestrogen deficiency was shown to have inconsistent effects on the monocytes of the 
blood and BM. Over the course of three treatment regimes, oestrogen deficiency had 
alternating effects on the total monocytes present in the blood, while not effecting BM 
monocytes. In the rat OVX model, Erben et al (1998) showed that the ED1+ BM cells, 
which represent CD68+ myeloid cells were increased in OVX animals compared with 
sham as well as observing enhanced B cell lymphogenesis396. In rats, ED1 is a membrane 
marker found on monocytes and is also expressed on OCs397,398. Research into the effects 
of oestrogen on monocytes is limited, however, the effects of oestrogen on other BM 
populations has been investigated. Katavic et al (2003) showed that in murine BM, 
CD45R+ B cells were increased two-fold following OVX compared to sham operated 
controls and that BM leukocytes were unaffected by OVX399. In the present study, 
CD45R/B220 was used in conjunction with CD3 to eliminate B and T cells from analysis 
of the monocyte subsets therefore analysis of the B cell compartment could not be done 
to verify this effect.  
This study showed that OVX increased the number of Ly6Chigh monocytes observed in the 
BM, but the OCP population was unaffected. The OCP population has been shown to be 
increased in a model of inflammatory bone loss103. However, this present study suggests 
that the OCP population is not affected by oestrogen deficiency. SpA treatment 
increased Ly6Chigh monocyte numbers in BM and Ly6Clow monocyte numbers in the blood. 
However these effects were not consistent across treatment regimes. One explanation 
for this inconsistency is that the dose of SpA given may not have been large enough to 
influence the disease progression. In the OVX models, SpA was injected i.p. at a dose of 
100μg while to observe SpA-488 binding to monocytes, a dose of 600μg was used. This 
allowed determination of how SpA interacted with cells in vivo, but it can also result in 
rapid clearance of circulating immunoglobulin. SpA immediately engages with IgG in 
circulation, but it continually dissociates and reforms complexes with free IgG with a 
half life of 9 hours299. As a result, SpA given at high doses is able to reduce the 
concentration of IgG present in the serum299. However, a dose of 100μg of SpA per 
animal per 48 hours was chosen for long term studies because previously this 
concentration had been effective in treating the inflammatory model of disease CIA316.       
The effect of oestradiol on the expression of FcγRs has received some attention. 
Previous work has shown that oestrogen and ERα signalling complexes engage the 
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oestrogen response element (ERE) on the FcγRIII promoter and removal of this signal 
up-regulates FcγRIII transcription beyond untreated controls382,400. Kramer et al (2004) 
also went onto demonstrate that direct ligation using mAb directed against the 
up-regulated FcγRIII resulted in heightened TNF-α, IL-6 and IL-1β secretion in human 
monocytes400. As mentioned, TNF-α, IL-6 and IL-1β are pro-OC cytokines which are 
up-regulated in the oestrogen deficiency model (Figure 4-1). Previous research on SIC 
showed that it can bind to the surface of MØ and increase the production of IL-10, while 
decreasing IL-12316,380. This switch from IL-12 production to IL-10 is believed to identify 
a regulatory phenotype instead of inflammatory phenotype276. However, production of 
TNF-α, IL-6 and IL-1β was not investigated as part of that study and as such it is 
unknown whether SIC affects production of these inflammatory cytokines316. This could 
have provided insight regarding the effect of SIC interactions with FcγRIII on monocytes 
and also indicate whether in the OVX model SIC could be interacting with monocytes to 
produce these inflammatory cytokines. In the OVX model, the concentration of TNF-a, 
IL-6, IL-1β and IFN-γ was examined in the serum of OVX and sham animals treated with 
SpA, however, the levels remained below the limit of detection. In order to fully 
evaluate the effect SIC exerts, SIC treated monocytes/MØ could have their production 
of TNF-a, IL-6 and IL-1β tested in vitro. This would be particularly interesting in 
FcγRIII-/- cultures, as SIC does not require FcγRIII to inhibit osteoclastogenesis but may 
have an effect on MØ cytokine production.  
The effect of the OVX model on the in vivo expression of FcγRs has not been previously 
addressed and so the present study examined whether oestrogen deficiency affected 
the expression of FcγRs. It was observed that in a state of oestrogen deficiency the 
expression of FcγRI and FcγRII/III remained relatively unchanged. However, the loss of 
distinction between FcγRII and FcγRIII due to use of an antibody which recognises both 
receptors could have masked any subtle changes that have been occurred in this model. 
The FcγRIII promoter is known to interact with the E/ER complex in human MØ and 
following removal of oestrogen from cultures FcγRIII transcription is up-regulated382. 
Removal of oestrogen has also been shown to enhance the response of FcγRIII ligation 
and cytokine production382. However, Kramer et al (2007) only used short term human 
cultures in vitro and there may also be species differences therefore this phenomenon 
must be verified in the murine system382. The results of this present study would suggest 
that any increase in FcγRIII expression on monocytes that Kramer et al (2007) observed 
is short lived and in a model of oestrogen deficiency the expression levels of FcγRs 
remains unchanged382. However, use of antibodies against FcγRII and FcγRIII would allow 
for distinct identification of changes in surface expression of these receptors. SpA 
treatment was also observed to have varied effects on monocyte subsets with the 
overall trend observed that FcγRI was down-regulated after SpA treatment and 
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FcγRII/III was up-regulated. The SpA IgG complexes may be interacting with FcγRI and 
thus masking its expression and increasing FcγRII/III in an attempt to clear IgG 
complexes from the system, however, these results were inconsistent across treatment 
regimes suggesting that overall long-term SpA treatment had no effect on the 
expression of FcγRs.  
To assess whether SpA could alter bone metabolism in the OVX model, the 
concentrations of both Osteocalcin and CTX-1 were measured in the animal’s plasma401. 
It was found that oestrogen deficiency or treatment with SpA had no effect on the level 
of Osteocalcin in animal’s plasma. Whereas animals undergoing oestrogen deficiency 
increased plasma CTX-1, which treatment with SpA did not effect. These results would 
indicate that bone resorption is increased in OVX animals, while bone formation remains 
unchanged. Published work has shown that due to the intimate nature of bone 
remodelling, an increase in bone resorption inherently results in an increase in bone 
formation402. Yet, in osteoporosis bone resorption occurs at a faster rate than bone 
formation resulting in bone loss. This data suggests that the ELISA used to detect 
Osteocalcin was not sensitive enough to detect changes in the plasma samples. The use 
of serum may have provided a more concentrated sample for analysis however due to 
the technical requirements serum could not be used. EDTA was used to collect blood to 
allow analysis of cells by flow cytometry and also collection of plasma. EDTA chelates 
Ca2+ to prevent coagulation thus plasma contains extra proteins compared to serum. The 
results of the CTX-1 analysis showed that bone erosion was increased in these models 
while bone formation, as measured by Osteocalcin, was unaffected by OVX and SpA was 
unable to impact on these bone remodelling.  
Three point bend testing was performed on the right femurs of sham and OVX operated 
animals. The results showed that there was no difference in bone strength, or quality, 
following OVX or treatment with SpA. However, this method of analysis is crude and 
destructive. Unfortunately, this experiment was underpowered with an ‘n’ of 4-6 which 
was too small to demonstrate any meaningful difference. Jämsä et al (1998) 
demonstrated that three point bend testing directly correlated with the cortical 
thickness and strength which requires up to 28 weeks following OVX to become notably 
altered387,403,404. The observed results would therefore suggest that the cortical strength 
of bone has been unaffected by six weeks of oestrogen deficiency or treatment with 
SpA. A more sensitive method of analysing the bone integrity was required to assess the 
effect of oestrogen deficiency on the micro-architecture of the tibial bone and to 
observe trabecular bone lost following oestrogen deficiency. 
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μCT was utilized to interrogate the micro-architecture of the trabecular bone in the 
proximal tibia and assess the presence of bone following oestrogen deficiency. A 
standardarized method for the assessment of bone loss by μCT was followed for each 
treatment regime405. As expected in all treatment regimes, OVX animals had less 
trabecular bone present than sham operated controls. The loss of oestrogen resulted in 
bone loss and treatment with SpA in OVX animals had no impact on the degree of bone 
loss. In this model of oestrogen deficiency an overall increase in pro-OC cytokines are 
produced which inadvertently drive monocytes to differentiate into OCs406. In this study, 
the data would suggest that SpA IgG complexes could interact with the monocytes but 
were unable to overcome the prevailing environment, which was driven towards 
osteoclastogenesis. Therapeutic treatments used to treat PMO, which have also been 
tested in OVX animal models, include denosumab (mAb direct to RANKL)407 and 
bisphosphonates (induce OC apoptosis)33. These therapies have a direct effect on 
reducing osteoporotic disease408,409, however, SpA had no effect on osteoporotic disease 
in the murine OVX model. Recently, SpA has been used in a safety trial, which provided 
evidence that SpA at low doses is safe for human use and could have beneficial effects 
in treating the disease410. This finding couples with the CIA model of disease where 
treatment with SpA could reduce disease progression316. Thus SpA appears to have the 
potential to become a therapeutic agent. However, the target diseases may remain 
inflammatory disorders as SpA could not alter disease progression in the OVX model of 
bone loss.      
In summary, SpA passes into circulation via i.p. injection, and can interact with blood 
and BM monocytes which act as the pre-OC pool in homeostasis. However, SpA can not 
intervene to prevent bone loss during from oestrogen deficient OVX model.  More 
research is required to determine whether SpA could be used as a therapeutic in 
treating PMO. 
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5 NF-κB inhibitor Bcl-3 modulates bone remodelling 
5.1 Introduction 
Bone remodelling refers to the dynamic and tightly regulated process by which OCs 
erode bone matrix and OB’s secrete new bone matrix13. OC’s are large multinucleated 
cells which secrete enzymes such as MMP9, Cathepsin K and TRAP to erode the bone 
matrix240,264,336. Cells of the monocyte/MØ cell lineage are pre-OCs366 and recent 
research has shown that certain subsets of monocytes found in the blood and BM are 
highly osteoclastogenic4,103,116. Fusion of pre-OCs occurs following commitment to the 
OC lineage after stimulation with M-CSF and RANKL, acting via CD115 and RANK, 
respectively, on the cell surface6,324. In fact animals deficient for M-CSF, CD115, RANKL 
or RANK develop osteopetrosis and fail to produce in vivo OCs102,119,137,411. For effective 
osteoclastogenesis to occur, CD115 provides the survival signal which also up-regulates 
RANK expression on the surface of pre-OCs6. RANKL can then engage RANK allowing for a 
number of signalling molecules to be activated. One of the most important of these is 
NF-κB, a ubiquitous signalling molecule vital for a variety of cellular functions. RANK is 
named for the receptor’s ability to drive osteoclastogenesis via NF-κB signalling145,156. 
NF-κB comprises of 5 subunits; p105 (p50), p100 (p52), p65, RelB and c-Rel158–162. These 
subunits can form 15 combinations of homo- and hetero- dimers which can translocate 
to the nucleus and engage NF-κB binding sites on the promoter regions of genes either 
activating/suppressing transcription163,164.  
In order to regulate this process, Inhibitor of κB (IκB) proteins sequester NF-κB dimers in 
the cytoplasm and nucleus and suppress activation. Of particular interest is IκBα which 
binds to the p65 subunit of the NF-κB p50:p65 heterodimer and prevents activation of 
the canonical NF-κB pathway169. Interaction between RANKL and RANK on the surface of 
pre-OCs results in activation of the canonical NF-κB pathway leading to rapid 
degradation of IκBα and translocation of NF-κB p50:p65 to the nucleus (Figure 5-1)172. 
There also exists a non-canonical NF-κB pathway which upon activation leads to a 
gradual degradation and processing of the IκB-like protein p100 into the NF-κB subunit 
p52 (Figure 5-1)160. p52 forms a heterodimer with RelB translocating to the nucleus for 
transcriptional activity173. Bcl-3 is an IκB-like protein which resides in the nucleus and is 
capable of binding homo- and hetero- dimers of p50 and p52170,171. p50 and p52 are 
unlike other NF-κB subunits because they lack transcriptional activation domains 
(TAD)167. This results in homo- and hetero- dimers of p50 and p52 occupying NF-κB sites 
on gene promoters suppressing transcription167. Bcl-3 selectively binds to these 
complexes, stabilizing the dimers on NF-κB binding sites, preventing their degradation 
and inhibiting activatory NF-κB binding and transcription167. The role of NF-κB has been 
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studied extensively and demonstrated that p50, p52, p65 and RelB but not c-Rel are 
essential for osteoclastogenesis (see Section 1.2.4)145,162,174–177.        
Studies investigating the atypical IκB protein, Bcl-3, have shown that in the absence of 
Bcl-3 MØ/DCs were highly responsive to TLR-4 stimulation as a result of aberrant NF-κB 
activity due to the lack of p50 or p52 dimers in the nucleus167. In addition, Bcl-3-/- 
animals have altered immune responses because secondary lymphoid organs do not 
develop412. These animals develop advanced diabetes compared to WT animals in both 
spontaneous and induced diabetes models which results from Bcl-3’s ability to control 
transcription of cytokine and chemokine mRNA in inflammatory conditions413. Thus in 
the absence of Bcl-3, there is higher production of inflammatory cytokines which 
worsens the progression of inflammatory diseases413. However, the role of Bcl-3 as an 
inhibitor of NF-κB in osteoclastogenesis has not been investigated. Furthermore, it 
remains to be elucidated whether Bcl-3 deficiency has any impact on in vivo bone 
remodelling. It is proposed that the absence of Bcl-3 will allow transcription of OC 
essential genes to continue without regulation and result in excessive osteoclastogenesis 
(Figure 5-1). Another, yet to be defined, aspect of interest is how Bcl-3 deficient 
pre-OCs respond to IC mediated inhibition of osteoclastogenesis. As previously shown, 
SIC is able to inhibit in vitro osteoclastogenesis by FcγR engagement and examination 
into the role of Bcl-3 in this inhibitory mechanism is required.  
The research presented in this chapter examines the role of Bcl-3 in osteoclastogenesis 
and phenotypes Bcl-3-/- animals for skeletal abnormalities. The principal aims were to: 
1. Investigate whether Bcl-3-/- pre-OCs could differentiate into OCs in vitro. 
2. Test the ability of SIC to inhibit osteoclastogenesis in Bcl-3-/- cultures. 
3. Determine whether Bcl-3-/- animals have osteoimmune abnormalities in 
vivo. 
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Figure 5-1: Schematic of Bcl-3’s hypothesised role in RANKL-RANK mediated signal 
transduction. 
Upon RANKL-RANK interaction, both the canonical and non-canonical pathways are activated by 
TRAF6 and TRAF3, respectively. Canonical signalling rapidly occurs and relies on TRAF6 mediated 
degradation of IκBα which allows for nuclear translocation of NF-κB heterodimer p50:p65 to bind 
NF-κB binding domains in the nucleus. TRAF3 is degraded following RANK activation which allows 
processing of the p100 to the p52 NF-κB subunit which dimerises with RelB and translocates to 
the nucleus. The non-canonical pathway requires hours to potentiate signalling and continues 
long term transcriptional processes after the canonical pathway ends. In this pathway, the 
proposed role of Bcl-3 is that it binds non-activatory homo- and hetero- dimers of p50 or p52 
blocking NF-κB domains on the promoters of essential osteoclastogenic genes (A). In the absence 
of Bcl-3 a shift in the ratio of non-activatory to activatory NF-κB binding dimers occurs resulting 
in excessive transcription of osteoclastogenesis (B). Thus Bcl-3 is hypothesised to be a regulator 
of osteoclastogenesis. 
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5.2 Results 
5.2.1 RANKL induces Bcl-3 mRNA transcription 
Bcl-3 is known to be under the transcriptional control of NF-κB414 and to verify that 
Bcl-3 is involved in RANKL mediated signalling, the level of Bcl-3 mRNA was measured in 
OCs. NA BM cells were cultured with 75ng/ml M-CSF and/or 50ng/ml RANKL for 5 days. 
mRNA was extracted from cultures and probed for the presence of Bcl-3 mRNA by qPCR. 
M-CSF and RANKL treated cultures were compared to M-CSF alone cultures, revealing 
that OCs had significantly more Bcl-3 mRNA than MØs (p<0.001) (Figure 5-2). This 
method of analysis shows that OCs have a higher level of Bcl-3 mRNA than MØ and 
provides evidence that Bcl-3 is involved in RANKL mediated osteoclastogenesis.     
 
 
Figure 5-2: RANKL stimulation up-regulates Bcl-3 mRNA.  
1x105 murine WT and Bcl-3-/- NA BM cells were cultured with 75ng/ml M-CSF (M) and/or RANKL 
(M+R) for 5 days at 37oC. Media was refreshed on day 4. Cultures were lysed, mRNA extracted, 
cDNA generated and qPCR performed on all samples which were run in triplicate. GAPDH was 
used as the housekeeping control and non-template controls were run for each gene. Fold 
Change (2(-ΔΔCT)) was measured by normalising samples of Bcl-3 primers to the housekeeping 
control (ΔCT). Subsequently M+R Bcl-3 ΔCT’s were normalised to the average M ΔCT to obtain the 
ΔΔCT. This was then used to obtain the fold change (2(-ΔΔCT)). To obtain the spread of M data, 
each M ΔCT was compared to the average M ΔCT and fold change calculated. Bcl-3 mRNA in M 
and M+R samples were compared using an unpaired two-tailed t test; p<0.001 (***).  Data 
represents mean ± SD, n=3. 
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5.2.2 Bcl-3 deficient osteoclastogenesis 
To investigate the effect of Bcl-3 deficiency on osteoclastogenesis, BM cultures were set 
up to differentiate non-adherent BM (NA BM) from C57Bl/6 (WT) or Bcl-3-/- animals on a 
C57Bl/6 background. OCs were differentiated as previously described in the presence of 
75ng/ml M-CSF and 50ng/ml RANKL. After 4, 5, 6 and 7 days of culture, cells were 
stained for the presence of TRAP. TRAP was used as an indicator of osteoclastogenesis 
and cells that were TRAP+ with 3 or more nuclei were considered as an OC. WT and 
Bcl-3-/- OCs were present at each day examined (Figure 5-3). Interestingly, in WT and 
Bcl-3-/- cultures the size of OCs appears to increase from day 4 to day 5, but then 
decrease on days 6 and 7 (Figure 5-3). Following the 5th day of culture there was 
evidence of cell death in the form of large cellular debris. The number of OCs was 
counted on each day which demonstrated that WT and Bcl-3-/- NA BM cultures were able 
to differentiate into OCs at the same rate up until 6 days of culture (Figure 5-4A). At 
day 7, WT cultures had significantly more OCs present than Bcl-3-/- cultures (p<0.01). 
Due to the multinucleated nature of OCs, the average size of OCs was calculated to 
ensure that the difference in number was not due to a discrepancy in the size of the 
OCs. The average size of OCs over the course of experiment remained equal between 
WT and Bcl-3-/- cultures, however, larger OCs were observed at day 5 compared to other 
days (Figure 5-4B). Differences between the numbers of OCs present over the course of 
this experiment may be due to differences in the pre-OC populations present in the BM. 
The BM contains a large number of myeloid precursors at a variety of differentiation 
stages and as such stimulation with M-CSF and RANKL could result in terminal 
differentiation to OCs occurring over a series of days. This could also account for the 
difference observed at day 7 between WT and Bcl-3-/-, as it is possible that there are 
differences between the progenitors present in the BM of each animal and this could 
ultimately affect the OC differentiation (Figure 5-4). However, WT and Bcl-3-/- NA BM 
cells are able to respond to RANKL and differentiate into OCs in vitro.   
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Figure 5-3: TRAP staining of osteoclast differentiation kinetics in WT and Bcl-3-/- cultures. 
1x105 NA BM cells from WT and Bcl-3-/- animals were cultured, in triplicate or quadruplicate, in 
the presence of 75ng/ml M-CSF and 50ng/ml RANKL. Cells were maintained at 37oC in 5% CO2 
with media refreshed on day 4. Cultures were stained for the presence of TRAP at days 4, 5, 6 
and 7. Representative images of WT and Bcl-3-/- OC cultures are shown at each of these days. 
Scale bars; 200μm.   
 
 
 
 
147 
 
 
Figure 5-4: Osteoclast differentiation kinetics in WT and Bcl-3-/- cultures. 
1x105 NA BM cells from WT and Bcl-3-/- animals were cultured, in triplicate or quadruplicate, 
alongside 75ng/ml M-CSF and 50ng/ml RANKL. Cells were maintained at 37oC in 5% CO2 with 
media refreshed on day 4. Cultures were stained for the presence of TRAP at days 4, 5, 6 and 7. 
Cells that stained positive for TRAP with > 3 nuclei were defined as an OC and counted. A) OCs 
were counted and the sum total of 4 fields of view per condition, in triplicate or quadruplicate. 
B) Each OC that was counted had their size measured using Image J software and the mean size 
of OCs (mm2) was calculated. Two-way ANOVAs with Bonferroni’s post-hoc tests were used to 
compare WT and Bcl-3-/- cultures on each day; p<0.001 (***). Data represents mean ± SD, n=3.   
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5.2.3 RANKL induced transcription in Bcl-3 deficient animals 
RANKL can induce the terminal differentiation of OCs in Bcl-3-/- NA BM. However, the 
transcriptional profile of Bcl-3-/- OCs was examined to confirm that differentiation of 
mature OCs. OCs present at day 5 were selected because this time point was the first 
point at which a significant degree of osteoclastogenesis is observed. This will also 
eliminate the possibly of the cell death observed at later time points influencing the 
results. 
In order to examine differences in transcriptional profile between WT and Bcl-3-/- OCs, 
mRNA was extracted from day 5 cultures. Bcl-3-/- OC culture mRNA was compared to 
that of the WT OC cultures. This revealed that at day 5 there was no difference in the 
transcription of CD115 or RANK, the two main inducers of osteoclastogenesis (Figure 
5-5A, B). The transcription of two anti-apoptotic genes were also examined; Bcl-2 and 
Bcl-XL are responsible for preventing apoptosis and modulating OC differentiation415,416. 
Both Bcl-2 and Bcl-XL were unaffected by the absence of Bcl-3 (Figure 5-5C, D). The 
effect of Bcl-3 deficiency on the levels of mRNA essential for osteoclastogenesis was 
also examined. mRNA for MMP9, Cathepsin K, DC-STAMP and TRAP, essential for 
multinucleation of pre-OCs10 and degradation of the bone matrix336, were all unchanged 
when Bcl-3-/- OC were compared to WT (Figure 5-6A-D). This data suggests that at day 5 
WT and Bcl-3-/- OCs have a similar transcriptional profile, however, further work may be 
required to fully determine if any differences exist in the transcription of other genes. 
Comparison between WT and Bcl-3-/- at day 6 and 7 in culture could also prove 
interesting as subsequent waves of osteoclastogenesis are evident from the kinetic 
experiments. Microarray analysis could provide insight into why there are less Bcl-3-/- 
OCs present in day 7 cultures. However, further work would need to be done to dissect 
possible differences. However, the data presented here shows that by day 5 Bcl-3-/- NA 
BM can differentiate mature OCs that are transcriptional similar to WT OCs. 
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Figure 5-5: Osteoclast survival signals are unaffected in the absence of Bcl-3.  
1x105 murine WT and Bcl-3-/- NA BM cells were cultured with 75ng/ml M-CSF and RANKL for 5 
days at 37oC to differentiate OCs. Media was refreshed on day 4. Cultures were lysed, mRNA 
extracted, cDNA generated and qPCR performed on all samples which were run in triplicate. 
GAPDH was used as the housekeeping control and non-template controls were run for each gene. 
Fold Change (2(-ΔΔCT)) was measured by normalising samples of each primer to the housekeeping 
control (ΔCT). Subsequently Bcl-3-/- ΔCT’s were normalised to the average WT ΔCT to obtain the 
ΔΔCT. This was then used to obtain the fold change (2(-ΔΔCT)). To obtain the spread of data, each 
WT ΔCT was compared to the average WT ΔCT and fold change calculated. WT and Bcl-3-/- 
samples were compared using an unpaired two-tailed t-test.  Data represents mean ± SD, n=3. 
 
 
150 
 
 
Figure 5-6: The transcription of osteoclast specific mRNA is unaffected in Bcl-3-/- osteoclasts.  
1x105 murine WT and Bcl-3-/- NA BM cells were cultured with 75ng/ml M-CSF and RANKL for 5 
days at 37oC to differentiate OCs. Media was refreshed on day 4. Cultures were lysed, mRNA 
extracted, cDNA generated and qPCR performed on all samples which were run in triplicate. 
GAPDH was used as the housekeeping control and non-template controls were run for each gene. 
Fold Change (2(-ΔΔCT)) was measured by normalising samples of each primer to the housekeeping 
control (ΔCT). Subsequently Bcl-3-/- ΔCT’s were normalised to the average WT ΔCT to obtain the 
ΔΔCT. This was then used to obtain the fold change (2(-ΔΔCT)). To obtain the spread of data, each 
WT ΔCT was compared to the average WT ΔCT and fold change calculated. WT and Bcl-3-/- 
samples were compared using an unpaired two-tailed t-test.  Data represents mean ± SD, n=3 
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5.2.4 Fcγ receptor mediated osteoclast inhibition 
To determine whether Bcl-3-/- OCs could be inhibited by engagement of FcγRs, cultures 
of NA BM were incubated in the presence of 75ng/ml M-CSF and/or 50ng/ml RANKL for 5 
days. SpA, OpIg and SIC were generated as previously described and cultured with OCs 
from day 1. When the number of TRAP+ OCs present in cultures were counted it was 
shown that with SIC treatment, WT and Bcl-3-/- OC differentiation was inhibited (63%; 
p<0.001 and 62%; p<0.001, respectively) (Figure 5-7 and Figure 5-8A, B). Bcl-3-/-, but not 
WT, cultures were inhibited by OpIg treatment (42% reduction; p<0.05) (Figure 5-8B). 
Previously, OpIg has been shown to inhibit the differentiation of WT OC cultures. 
However, OpIg contains monomeric IgG which is not capable of interacting with FcγRs in 
the same way as the IgG complexes which SIC generates. These results also demonstrate 
that the inhibitory potential of OpIg is not as consistent as SIC and as such shows that 
IgG complex interactions can consistently inhibit osteoclastogenesis. Overall, these 
results demonstrate that IgG and IgG complex interactions with FcγR do not require 
Bcl-3 to inhibit osteoclastogenesis.   
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Figure 5-7: Representative TRAP staining for WT and Bcl-3-/- osteoclasts.  
1x105 murine NA BM cells from WT and Bcl-3-/- were cultured with 75ng/ml M-CSF and/or 
50ng/ml RANKL for 5 days in 37oC with media renewed on day 4. Treatment with SpA, OpIg and 
SIC was given at day 1 and 4 alongside M-CSF and RANKL. Cultures were stained for the presence 
of TRAP and representative images of TRAP stained cultures are shown. Scale bar; 200μm.   
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Figure 5-8: Fcγ receptor modulation inhibits WT and Bcl-3-/- osteoclast differentiation.  
1x105 murine NA BM cells from WT and Bcl-3-/- were cultured with 75ng/ml M-CSF and/or 
50ng/ml RANKL for 5 days in 37oC with media renewed on day 4. Treatment with SpA, OpIg and 
SIC was given at day 1 and 4 alongside M-CSF and RANKL. Cultures were stained for the presence 
of TRAP (Figure 5-7). TRAP+ OCs with >3 nuclei were counted in A) WT and B) Bcl-3-/- cultures 
and the sum total of 4 fields of view per condition in triplicate. Mean values of each condition 
were compared using a one way ANOVA with Bonferroni’s post-hoc test; p<0.05 (*), p<0.001 (**). 
Data represents pooled mean ± SD of three individual experiments. 
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5.2.5 Bcl-3 is required for osteoclast precursor homeostasis 
To evaluate the pre-OC populations present in Bcl-3-/- animals we examined the 
monocyte subsets of the blood and BM from WT and Bcl-3-/- animals. Monocytes are 
known to differentiate into OCs, however recent research has shown that 
subpopulations of monocytes can respond with greater efficacy to M-CSF and 
RANKL4,103,116. Therefore, ex vivo analysis of blood and BM was done to examine these 
populations. 200μl of blood and BM from one femur were taken from WT and Bcl-3-/- 
animals and stained for FACS analysis with CD3, B220, Ly6G, Ly6C, CD11b and CD115. 
This panel allowed the total population of blood and BM cells to be interrogated for the 
percentage of total monocytes (Ly6C+Ly6G-) and neutrophils (Ly6C+Ly6G+) (Figure 5-9A, 
B and Figure 5-10A). This also allowed the examination of the monocyte subsets 
present; Ly6Chigh classical monocytes (Population 1 - Ly6Chigh CD11bhigh), Ly6Clow 
non-classical monocytes (Population 2 - Ly6Clow CD11bhigh) and osteoprecursors (OCPs – 
Population 3 Ly6Chigh CD11blow) (Figure 5-10B). All three subsets are able to differentiate 
to OCs, however, in the BM, the OCP population is considered the most proficient 
pre-OC, while in the blood the Ly6Chigh monocyte population is considered the most 
osteoclastogenic4,103,116.     
The percentage of cells obtained from FACS analysis was used to calculate the total 
number of cells present in each sample from cell counts. It was shown that the total 
number of monocytes present in the blood and BM was unaffected by the absence of 
Bcl-3 (Figure 5-10A and Figure 5-11A, B). Interestingly, the number of neutrophils in the 
blood and BM were significantly reduced in Bcl-3-/- animals compared to WT animals 
(Figure 5-10A and Figure 5-11C, D). This data suggests that Bcl-3 might play a role in 
neutrophil biology, however, this is outwith the focus of this study and merits separate 
investigation. 
The three monocyte subsets in the blood and BM of WT and Bcl-3-/- animals were 
examined. In the blood, Bcl-3 deficiency had no effect on the number of circulating 
monocyte subsets (Figure 5-12A). However, Bcl-3-/- had fewer Ly6Chigh and Ly6Clow 
monocytes in the BM (Figure 5-12B). In the BM, the OCP population is predominantly 
thought to be the main pre-OC4,103, however, it has previously been observed that 
Ly6Chigh BM monocytes can differentiate into OCs in vitro103. Therefore, Bcl-3-/- animals 
may have fewer pre-OCs present in vivo than WT controls.  
The examination of CD115 expression on these pre-OC populations was also examined 
because CD115 is essential in the up-regulation of RANK and thus osteoclastogenesis6. 
Populations of CD115+ monocytes and monocyte subsets were identified based on their 
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forward scatter and expression of CD115 (Figure 5-13) and the percentage CD115+ cells 
was used to calculate the total number of CD115+ cells in each population. This revealed 
that Bcl-3-/- animals had fewer CD115+ monocytes in the blood and BM, especially fewer 
Ly6Chigh CD115+ monocytes when compared to WT controls (Figure 5-14A, B). As CD115 
has an essential role in the differentiation of OCs in vivo, this data supports the idea 
that Bcl-3-/- animals may have fewer pre-OCs present in vivo.  
In order to ascertain whether the overall milieu of the BM was altered in Bcl-3-/- animals 
mRNA was extracted from whole BM. mRNA for RANK and RANKL was quantified and 
revealed to be unchanged in Bcl-3-/- animals compared to WT controls (Figure 5-15A, B). 
This would suggest that as an inducer of osteoclastogenesis the RANKL-RANK axis may 
be unaffected by Bcl-3 deficiency, however, further work needs to be done to validate 
this observation. At the same time, evaluation of the GM-CSF mRNA transcript level was 
examined. GM-CSF is a vital cytokine in the differentiation, chemotaxis and function of 
neutrophils417,418 and as such it was hypothesised that as the number of neutrophils 
present in the blood and BM are lower in Bcl-3-/- animals the GM-CSF production may be 
altered. However, examination of GM-CSF mRNA showed that in Bcl-3-/- BM had a slight, 
but significant, increase in the mRNA present compared to WT controls (p<0.01) (Figure 
5-15C). This increase could be due to any population present in the BM up-regulating 
GM-CSF mRNA and due to the large number of cells present this increase has become 
diluted. Therefore, dissemination of which population up-regulates GM-CSF mRNA is 
required. Examination of day 5 OC mRNA showed that GM-CSF mRNA from WT and 
Bcl-3-/- cultures were identical (Figure 5-15D). Thus, OCs are unlikely to be the cell 
responsible for this increase, however, further work will be required to determine if the 
increase in GM-CSF mRNA is physiologically relevant. An increase in GM-CSF is unlikely 
to induce the neutropenia observed in Bcl-3-/- animals therefore further work must be 
done to understand this phenotype.     
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Figure 5-9: Gating strategy to identify blood and bone marrow monocytes. 
A) Blood and B) BM cells were isolated from WT and Bcl-3-/- animals. Per animal, 1x106 BM cells 
and the cells present in 200μl of blood were stained with CD3, B220, Ly6G, Ly6C and CD11b for 
FACS analysis. Representative FACS plots of gating strategies employed to distinguish monocytes 
are shown. Doublets were isolated from single cells by exclusion of events which had a non-linear 
relationship with Side Scatter Area versus Side Scatter Height and T and B cells were excluded by 
their expression of CD3 and B220. Monocytes and Neutrophils could then be identified based on 
their expression of Ly6C and Ly6G. Neutrophils express Ly6G and Ly6C, however, monocytes do 
not express Ly6G and can express Ly6C at high or low levels. Representative FACS plots shown 
are based on WT blood and BM cells. Percentages shown in FACS plots are of the percentage of 
cells present in the current gate.   
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Figure 5-10: WT and Bcl-3-/- blood and bone marrow monocyte and neutrophil populations. 
FACS analysis was performed as previously described (Figure 5-9). A) A comparison of 
representative FACS plots depicting monocyte (Ly6C+/-Ly6G-) and neutrophil (Ly6C+ Ly6G+) 
populations of the blood and BM from WT and Bcl-3-/- animals. B) A comparison of representative 
FACS plots showing the three monocyte subset populations of the blood and BM based on their 
expression of Ly6C and CD11b. Ly6Chigh classical monocytes (Population 1), Ly6Clow non-classical 
(Population 2) and OCP (Osteoprecursor - Population 3). Percentages shown are of the 
percentage of cells present in the current gate. All FACS plots are representative of one 
experiment.  
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Figure 5-11: Number of total monocytes and neutrophils in WT and Bcl-3-/- animals. 
Blood and BM were taken from WT and Bcl-3-/- animals and prepared from analysis by flow 
cytometry. Cells were counted prior to staining for FACS analysis and a gating strategy previously 
shown (Figure 5-9) was used to isolate the number of total monocytes (Ly6C+/- Ly6G-) and 
neutrophils(Ly6C+ Ly6G+)  (Figure 5-10A). The % of monocytes or neutrophils defined by FACS 
analysis were used to calculate the absolute number of monocytes present in blood and BM. The 
number of monocytes from WT and Bcl-3-/- animals in A) Blood and B) BM are shown. The number 
of neutrophils from WT and Bcl-3-/- animals in C) Blood and D) BM are shown. WT and Bcl-3-/- 
animals were compared using an unpaired two-tailed t-test; p<0.05 (*). Data represents mean ± 
SD, n=3. Data representative of two separate experiments. 
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Figure 5-12: Monocyte subsets cell number in WT and Bcl-3-/- animals. 
Continuing on from the data shown in Figure 5-11, the expression of Ly6C and CD11b was used to 
identify monocyte subsets as described in Figure 5-10B. The % of cells in each monocyte subset 
was used to calculate the absolute number of monocytes present in both the blood and BM. The 
subsets of interest were the Ly6Chigh monocytes, Ly6Clow monocytes and the OCP population 
(Ly6Chigh CD11blow). The absolute numbers of cells constituting these subsets in A) Blood and B) 
BM for WT and Bcl-3-/- animals were calculated. Individual monocyte subsets from WT and Bcl-3-/- 
animals were compared using a Two Away ANOVAs with Bonferroni’s post-hoc test; p<0.05 (*). 
Data represents mean ± SD, n = 3. 
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Figure 5-13: Representative FACS plots of CD115 expression on monocytes and monocytes 
subsets. 
FACS analysis was performed on blood and BM from WT and Bcl-3-/- animals. Monocytes and 
monocyte subsets were identified as previously described (Figure 5-9 and Figure 5-10). 
Fluorsecence minus one (FMO) control was used to identify the CD115 expressing cells in each 
monocyte population. Representative FACS plots of CD115+ cells in blood and BM monocytes and 
monocytes subsets are shown from WT and Bcl-3-/- animals. Percentages shown are of cells 
present in the current gate. All FACS plots are representative of one experiment.  
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Figure 5-14: CD115 expressing monocytes in WT and Bcl-3-/- animals. 
Blood and BM taken from WT and Bcl-3-/- animals were isolated and prepared for flow cytometry. 
The gating strategy shown (Figure 5-9 and Figure 5-10) was used to isolate total monocytes and 
monocyte subsets for analysis of CD115 (Figure 5-13). The number of CD115+ cells in A) Blood and 
B) BM monocytes and monocyte subset populations was calculated from the % of CD115+ cells and 
the total number of cells isolated from each animal. Individual monocyte populations of WT and 
Bcl-3-/- animals were compared using a two way ANOVA’s with Bonferroni’s post-hoc tests; 
p<0.05 (*) and p<0.001 (***). Data represents mean ± SD, n=3. Data represents one experiment.  
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Figure 5-15: GM-CSF mRNA transcript is up-regulated in Bcl-3 bone marrow.  
A-C) 1x106 murine WT and Bcl-3-/- BM cells were lysed, mRNA extracted, cDNA generated and 
qPCR performed on all samples which were run in triplicate. D) NA BM cells cultured for 5 days in 
the presences of 75ng/ml M-CSF and 50ng/ml RANKL were lysed, mRNA extracted, cDNA 
generated and qPCR performed on all samples which were run in triplicate. For all samples, 
GAPDH was used as the housekeeping control and non-template controls were run for each gene. 
Fold Change (2(-ΔΔCT)) was measured by normalising samples of each primer to the housekeeping 
control (ΔCT). Subsequently Bcl-3-/- ΔCT’s were normalised to the average WT ΔCT to obtain the 
ΔΔCT. This was then used to obtain the fold change (2(-ΔΔCT)). To obtain the spread of WT data, 
each WT ΔCT was compared to the average WT ΔCT and fold change calculated. WT and Bcl-3-/- 
samples were compared using an unpaired two-tailed t-test; p<0.01 (**).  Data represents mean ± 
SD, n=3. 
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5.2.6 Bcl-3 deficiency results in perturbed bone remodelling 
Although we observed no overt difference in osteoclastogenesis, due to the previously 
described role of NF-κB signalling in bone remodelling the in vivo architecture of the 
tibial trabecular bone was examined. Tibias were removed from 12 week old WT and 
Bcl-3-/- male mice. The age of the animals was selected because at this point male mice 
have a fully mature skeletal system which removes any variance that younger mice 
might introduce into the study as their skeletal system develops at a rapid rate419. Male 
mice have higher bone mass than female mice and also less variance due to limited 
exposure to oestrogen which can influence bone remodelling41.  
μCT was used to interrogate the trabecular bone present in the proximal tibia (Figure 
5-16A). Analysis of the trabecular region revealed that Bcl-3-/- animals had significantly 
more bone present than WT, as measured by BV/TV (WT – 18.9% versus Bcl-3-/- - 23.1%; 
p<0.001) (Figure 5-16B). Further analysis of the trabecular bone showed that the 
number of trabecular structures was increased (p<0.05) and the space between 
trabeculae was decreased (p<0.05) when compared to WT controls (Figure 5-16C, D). 
Interestingly, there was no difference in the structural model index, thickness of 
trabeculae or the intersection surface (Figure 5-16E-G). Other parameters of trabecular 
structure were measured to examine the differences between WT and Bcl-3-/- animals 
(Table 5-1). These results revealed that Bcl-3-/- animals had normal trabecular structure 
compared to WT, yet the increase in bone volume suggests that there is an uncoupling 
in the bone remodelling process between WT and Bcl-3-/- animals.        
In order to test whether the increase in bone volume in Bcl-3-/- animals was due to a 
deficiency in in vivo OCs, histology was undertaken on μCT scanned tibias. Sections 
were stained with haematoxylin and eosin (H&E) which showed that WT and Bcl-3-/- 
tibias had a similar trabecular bone and growth plate structure (Figure 5-17A). TRAP 
staining was performed on these sections which revealed the presence of OCs in Bcl-3-/- 
tibias (Figure 5-17B). Therefore, the increase in bone present in the trabecular region of 
the tibia in Bcl-3-/- animals was not due to an absence of OCs. In order to fully examine 
the histomorphometry of these animals more research needs to be done to count the 
number of OCs and OBs present in the trabecular bone. This could provide insight in the 
in vivo differentiation of OCs and OBs in the Bcl-3-/- animals and using a larger sample 
size could definitively prove whether Bcl-3-/- animals have differences in bone 
remodelling. 
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Figure 5-16: μCT analysis of trabecular bone of proximal tibia from WT and Bcl-3-/- animals. 
The left tibias of WT and Bcl-3-/- animals were taken at 12 weeks of age. Tibias were fixed 
overnight in 4% para-formaldehyde before storing bones in 70% ethanol. To analyse the bone 
volume in the tibia, bones were scanned using a SkyScan 1172 μCT scanner. Trabecular bone was 
identified and analysed using SkyScan CTAn software. A) Representative images of trabecular 
bone reconstructions of WT (top panel) and Bcl-3-/- (bottom panel animals), B) % of Trabecular 
bone (BV/TV), C) Trabecular number (1/μm), D) Trabecular separation (μm), E) Structural Model 
Index (SMI), F) Trabecular thickness (μm) and G) Intersection surface (μm2). WT and Bcl-3-/- 
animals were compared using an unpaired two-tailed t-test; p < 0.05 (*), p < 0.001 (***). Data 
shown represents mean ± SD, n=6. 
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Table 5-1: All μCT analysis parameters of trabecular bone of the proximal tibia in WT and 
Bcl-3-/- animals. 
As previously outline (Figure 5-16), all μCT analysis parameters are provided. Unpaired 
two-tailed t-tests were used to compare WT and Bcl-3-/- animals; p<0.05 (*), p<0.01 (**) and 
p<0.001 (***). Data shown is the mean ± SD, n=6. 
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Figure 5-17: The presence of osteoclasts in Bcl-3-/- tibias. 
The left tibias of WT and Bcl-3-/- animals were taken at 12 weeks of age. Tibias were fixed 
overnight in 4% para-formaldehyde before decalcification in 14% EDTA pH 8 until bones were 
pliable. 20μm coronal sections of the proximal tibia were following paraffin wax embedding. A) 
Representative images of Haematoxylin and Eosin (H&E) staining of tibial sections. Scale bar is 
500μm. B) Representative images of TRAP staining of tibial sections (Purple – TRAP and Blue – 
Haematoxylin). Negative control for TRAP stain was included. 3-5 serial sections per tibia, n=3. 
Scale bar; 200μm. 
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5.3 Discussion 
NF-κB is an essential regulator of osteoclastogenesis via the roles of p50, p52, p65 and 
RelB145,162,176. These components bridge both the canonical and non-canonical NF-κB 
pathways which are essential in the in vitro and in vivo differentiation of fully 
functional OCs. Following stimulation of RANK by RANKL, these subunits translocate to 
the nucleus and initiate transcription of OC essential genes164. The role of the negative 
regulator of NF-κB signalling, Bcl-3, has not been examined as an osteoclastogenic 
regulator. Thus this investigation aimed to examine whether Bcl-3 influenced in vitro 
and in vivo osteoclastogenesis.  
In response to stimuli, various receptors can activate NF-κB signalling resulting in the 
transcription of a huge number of genes167. As Bcl-3 is under NF-κB control, 
transcription of Bcl-3 acts in a negative feedback loop to dampen the primary response 
and limit a possible secondary response from stimuli420. Therefore, the absence of Bcl-3 
can result in uncontrolled NF-κB mediated transcription. In the present study, RANKL 
was used as the activator of NF-κB and as such, was shown to induce Bcl-3 transcription 
(Figure 5-2). However, RANKL stimulation of WT and Bcl-3-/- NA BM induced the 
differentiation of OCs (Figure 5-4). This differentiation of OCs was also inhibited by 
stimulation of FcγRs by IgG alone and in IgG complexes with SpA (Figure 5-8). This 
suggests the mechanism used by FcγRs to inhibit osteoclastogenesis in response to IgG 
does not utilise Bcl-3 and that WT and Bcl-3-/- pre-OCs respond in a similar manner to 
stimulation. Evaluation of essential OC mRNA transcription failed to show any 
differences between WT and Bcl-3-/- in vitro cultures (Figure 5-5 and Figure 5-6). 
Importantly, WT and Bcl-3-/- cultures were not tested for OC activity on bovine bone, 
therefore it remains to be confirmed whether Bcl-3-/- pre-OCs differentiate into 
functional OCs.  
One noticeable difference between WT and Bcl-3-/- OC cultures was that by day 7, there 
were nearly twice as many OCs present in WT than Bcl-3-/- cultures (Figure 5-4). One 
possible explanation for this is the variety of progenitors present in the BM at different 
differentiation stages responding to M-CSF and RANKL over a series of days. This would 
suggest that Bcl-3-/- cells have a deficit in one of these progenitor populations and thus 
could not differentiate into OCs to the same degree as WT cells. Further work would 
need to be done to evaluate the effect of Bcl-3 on myelopoiesis and whether there was 
a defect in the BM progenitor populations. In order to do this, FACS analysis could 
investigate the populations of progenitors which are lineage negative and CD117 and 
CD135 positive. This would give a good insight into the progenitor populations present. 
These differences may also be caused by Bcl-3’s ability to act as a pro-survival factor, 
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as Bcl-3 can enhances adjuvant driven T cell proliferation and survival421. In the absence 
of Bcl-3, stimulated T cells have increased levels of the pro-apoptotic factor Bim, while 
over expression of Bcl-3 lowers the concentration of Bim present and enhances T cell 
survival422. Due to the availability of reagents examination of anti-apoptotic mediators, 
Bcl-2 and Bcl-XL, was done and showed that at day 5 there was no difference between 
WT and Bcl-3-/- OCs. However, examination of pro- and anti-apoptotic factors at later 
time points, day 6 and 7, could provide insight into Bcl-3’s role as a survival factor in 
OCs. Examination of Bim on these days could demonstrate whether there are 
differences in the ability of Bcl-3 to act as a survival factor in T cells and myeloid cells. 
Interplay may exist following OC stimulation, whereby Bcl-3 enhances the survival of 
OCs in long term cultures; however, this remains to be investigated.  
To fully evaluate the role of Bcl-3 in the differentiation of OCs it would be essential to 
investigate the early response of cells to RANKL. This is possible by culturing NA BM cells 
and examining the effect of RANKL induced p50:p65 nuclear translocation and the 
processing of p100:RelB to p52:RelB. ChIP analysis could also be conducted to examine 
the ability to Bcl-3:p50/p52 and NF-κB subunits to bind to NF-κB sites on the gene 
promoters of OC essential genes such as NFATc1 following RANKL stimulation. The 
transcription of mRNA at an earlier time point could indicate whether Bcl-3 acts as an 
osteoclastogenic regulator. Further examination gene promoters like nfatc1, rank and 
even OC specific genes like dc-stamp and trap may reveal potential Bcl-3:NF-κB binding 
sites and infer an activatory or suppressive activity of this complex423. This could be 
done using ChIP analysis to reveal which NF-κB subunits bind to amplified regions of the 
gene promoters. It should be appreciated that the view of Bcl-3 as an NF-κB regulator is 
evolving. Bcl-3 is capable of interacting with AP1 to drive expression of AP1 specific 
targets424. Deletion of c-fos, a component of AP1, results in osteopetrosis and 
prevention of RANKL induced osteoclastogenesis144. AP1 promotes cell survival425 and 
drives the differentiation of OCs144, thus Bcl-3 may have a role in this interaction. 
Examination of these interactions following RANKL stimulation would reveal whether 
Bcl-3 has a role in regulating the initial stages of osteoclastogenesis.                   
Monocytes serve as a pool of pre-OCs and can be used ex vivo to generate OCs366. 
Therefore, examination of Bcl-3-/- animals for defects in this population was 
undertaken. Blood and BM monocytes were identified on the basis of their expression of 
Ly6C+/- Ly6G- 384 allowing discrimination with Ly6C+ Ly6G+ neutrophils. Interestingly, 
identification of the neutrophil population revealed fewer blood and BM neutrophils in 
Bcl-3-/- animals compared to WT counterparts (Figure 5-11). Bcl-3 may also have an 
effect at an early stage of differentiation and influence the myelopoiesis of neutrophils 
from progenitors in the BM. As mentioned, identification of BM stem cells would allow 
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further comparison of the effects that the absence of Bcl-3 incurs. The presence of 
GM-CSF mRNA present in BM was examined, because of its pleitropic effects on 
neutrophils and bone biology. GM-CSF is involved in stimulating neutrophil 
differentiation from BM progenitors and acts as a chemotactic during inflammation417,418. 
It is also a known pro-OC factor and stimulates the differentiation and activity of OCs426, 
but it also increases the proliferation and activity of OBs427,428, enhancing bone 
remodelling. When examined there was an increase in GM-CSF mRNA in the BM of 
Bcl-3-/- animals was observed compared to WT animals. This is counter-intuitive as an 
increase in GM-CSF should result in the production of neutrophils. It could be speculated 
that the gene encoding GM-CSF, csf2 is transcribed under NF-κB or AP1 control and thus 
in the absence of Bcl-3, csf2 transcription becomes dysregulated leading to an increase 
in transcription. Cultured OCs do not alter expression of GM-CSF mRNA, therefore 
another cell type may be responsible for this increase in vivo. Protein concentration of 
GM-CSF needs to be examined to ensure that the difference in mRNA relates to a 
physiologically relevant change. Another cytokine that is known to influence neutrophil 
differentiation is G-CSF and this could also be investigated to further elucidate the link 
between Bcl-3 and neutrophil biology. 
However, following examination of neutrophils, the number of monocytes and monocyte 
subsets in WT and Bcl-3-/- animals was examined.  This revealed that there were fewer 
Ly6Chigh and Ly6Clow monocytes present in the BM of Bcl-3-/- animals (Figure 5-12). 
Following further examination of this population, the number of CD115+ monocytes were 
deficient in the blood and BM of Bcl-3-/- animals compared to WT controls. As the 
receptor for M-CSF, CD115 can be used as an identifier of pre-OCs4 and has been shown 
to be essential in driving RANK expression in pre-OCs6. With a decrease in the cells 
expressing this receptor there is the potential for an in vivo defect in the cells 
differentiating to OCs. This may itself provide an explanation for the difference in bone 
volume observed in WT and Bcl-3-/- animals’ trabecular bone and the difference in in 
vitro OC numbers at day 7. 
Following the observation that there was a defect in the CD115+ monocytes the 
micro-architecture of the tibial bone was examined to determine whether Bcl-3 had an 
effect on bone remodelling. This revealed that Bcl-3-/- animals had increase in bone 
volume in the trabecular region of the proximal tibia (Figure 5-16).  This increase in 
bone density would indicate that bone remodelling had become perturbed in Bcl-3-/- 
animals, suggesting that Bcl-3-/- may have roles in bone remodelling beyond OCs. 
Further work needs to be done to fully identify further changes in trabecular and 
cortical bone architecture, as well as the potential gender and age differences. 
However, this increase in bone volume was not due to an absence of OCs in vivo (Figure 
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5-17). Further work would need to be undertaken to determine the number of TRAP+ 
cells present in the tibial trabecular region of WT and Bcl-3-/- animals, this would have 
shown if Bcl-3-/- animals had a deficit in the number of in vivo OCs.  Bcl-3-/- BM also had 
similar levels of RANK and RANKL mRNA present compared to WT, suggesting that this 
axis is unaffected by Bcl-3 deficiency (Figure 5-15). However, the presence of OPG 
could be measured to ensure that there was no increase in OPG which would inhibit OC 
differentiation and could account for the increase in bone volume.    
The Bcl-3-/- animals have a global deletion of the bcl3 gene which will exert effects on 
all cell types. Therefore, to dissect the effect that Bcl-3 has on bone remodelling, OBs 
must also be examined. The role of NF-κB in the differentiation of OBs is complex as 
activation of NF-κB during differentiation inhibits maturation429. However, OBs require 
the NF-κB subunit p50 for TNF-α mediated secretion of M-CSF430. Yet, Yao et al (2014) 
demonstrated that RelB was a negative regulator of OB differentiation and function429. 
Indicating that the role of Bcl-3 in regulating OBs may be complex and the 
differentiation of OBs from WT and Bcl-3-/- animals would dissect the differences 
between these genotypes. The differentiation of OBs and OCs in co-cultures could also 
reveal if there are cell specific abnormalities. By using cultures of mixed genotype WT 
or Bcl-3-/- OBs could be co-cultured with WT or Bcl-3-/- pre-OCs. The level of 
osteoclastogenesis could demonstrate if the absence of Bcl-3 alters the relationship 
between these cell types. To further examine the capacity of OBs to function in vivo, 
bone formation can be measured by use of calcein double labelling, as calcein only 
binds to newly formed matrix. By administering two doses of calcein and visualisation of 
the bone matrix by histology the rate of bone formation can be measured by the 
distance between layers of calcein. This would indicate whether OBs from Bcl-3-/- 
animals can form bone at a higher rate than WT animals and may be the reason for the 
increased tibial bone volume in Bcl-3-/- animals.  
However, as a global gene deletion the Bcl-3-/- genotype is known to effect the activity 
of a number of other cells including B cells. B cells are known to be a major contributor 
to OPG production within the BM and if Bcl-3 were to influence B cell production of OPG 
there could be ramifications on bone remodelling. As such, the generation of two 
transgenic mouse strains with OC and OB specific Bcl-3 gene deficiencies would allow 
absolute observation of the effect of Bcl-3 in these cells in vivo. The use of Cre-lox 
technology to generate an OC specific Bcl-3 deletion under the control of the Cathepsin 
K promoter and osteocalcin promoter for OBs would be an excellent tool to examine the 
effects of Bcl-3 deficiency in an otherwise ordinary environment.  
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Studies have shown that Bcl-3 modulates NF-κB activation by sequestering p50/p52 
homo- and hetero- dimers on NF-κB sites and the absence of Bcl-3 can result in 
enhanced production of pro-inflammatory cytokines following stimulation with TNF-α or 
LPS167. This present study demonstrated that RANKL could induce Bcl-3 transcription and 
result in the differentiation of OCs in Bcl-3-/- cells. The role of Bcl-3 in vivo was shown 
to influence CD115+ monocytes and neutrophils numbers, however further work is 
required to examine this observation. Interestingly, Bcl-3 deficiency increased 
trabecular bone volume compared to WT animals. This confirmed that Bcl-3 had an 
impact on bone remodelling, however further work is required to understand the role of 
Bcl-3 in this process. 
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6 General discussion  
This thesis examined the potential for SpA IgG complexes as a novel therapeutic in 
osteoporotic disease. Osteoporosis is a condition resulting from a disruption between 
the immune and skeletal system due to menopausal oestrogen deficiency380. The animal 
model used to study this disease was the OVX model which was induced by the removal 
of the ovaries to simulate the menopause40. The result is a species and strain specific 
bone loss in the femur, tibia and vertebrae, emulating human disease39. Every second 
day following surgery animals were treated with 100μg SpA or OVA. We observed that 
SpA had no effect on the bone loss in the OVX model. Previous work had shown that 
100μg SpA was able to reduce inflammation and OCs numbers in inflamed joints of CIA 
animals316. A dose of 100μg SpA may have been optimal for treating inflammation in the 
CIA model, however, we hypothesis that a higher dose may be required to combat 
osteoclastogenesis in the OVX model. Further research is required to discover the 
optimal dose of SpA to exert an in vivo anti-osteoclastogenic effect. It has been shown 
that high doses of SpA (1.5mg) can reduce the serum IgG concentration299, thus the dose 
must be carefully monitored to ensure that there is no detrimental effects on serum IgG 
concentration following long term treatment. These pharmacokinetic experiments could 
inform the correct dose to test SpA’s ability to treat the OVX model of disease and 
determine whether SpA mediated FcγR modulation is capable of treating osteoporotic 
disease. 
The bioavailability of SpA is also an important factor as SpA can induce B cell apoptosis 
via the Fab VH3 domain of surface IgM271,308,309. However, SpA’s ability to interact with 
von Willebrand factor and, in particular, TNFRI is also important431,432. TNFRI is 
expressed on multiple cell types including epithelial cells, keratinocytes and 
OBS431,433,434. In animals models, S. aureus interacts directly with OBs in an SpA 
dependent manner435. This interaction can result in enhanced RANKL production and 
decreases OPG secretion by OBs435. It is currently believed that SpA triggers TNFRI NF-κB 
signalling, resulting in secretion of inflammatory cytokines and contributing to diseases 
like osteomyelitis435,436. However, this particular interaction requires the IgG binding 
domain and as SpA treated systemically co-opts circulating IgG, the interaction between 
SpA and OBs may not be physiologically relevant, but may require further 
investigation316,431.  
Recently, a highly purified form of SpA (PRTX-100) has been used in clinical trials410. In 
these safety trials, intravenous low doses of SpA (0.3-0.45μg/kg) were safe with only a 
small number of individuals presenting with adverse effects, while individuals given 
higher doses (5,10 and 20μg/kg) were more likely to suffer side effects410. Side effects 
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included headaches, myalgia and nausea410. At low doses, patients given SpA had a 
decrease in circulating lymphocytes, however, the effect on monocyte populations were 
not studied410. Clinical trials are on-going and aimed at determining the effect of 
PRTX-100 in RA patients410. It should be appreciated that this study observed the 
production of anti-SpA antibodies after treatment with PRTX-100, which resulted in 
enhanced clearance of SpA following administration410. To use SpA clinically a novel SpA 
mimetic needs to be developed that can engage FcγRs, while removing SpA’s 
immunogenicity.  
The inability of SpA to alter disease progression in the OVX model was not mirrored in 
vitro because SpA was able to form IgG complexes that inhibit murine 
osteoclastogenesis. The differentiation of OCs from BM cells isolated from mice and 
cultured with M-CSF and RANKL could be inhibited by treatment with SIC or OpIg. 
Importantly, SIC was able to inhibit osteoclastogenesis in an FcγRIII independent 
manner. Yet, OpIg required the presence of FcγRIII to inhibit osteoclastogenesis 
suggesting that aggregates are present in the OpIg preparation that have the capacity to 
interact with this low affinity receptor to inhibit osteoclastogenesis. Importantly, SIC 
but not OpIg, was able to limit in vitro OC-mediated bone erosion.  
Although in the murine system, both OpIg and SIC were able to inhibit 
osteoclastogenesis, previous studies have demonstrated that OpIg could not inhibit the 
differentiation of human OCs316. Why there is a difference between murine and human 
in vitro systems is not fully understood. The only constituents of OpIg are IgG and OVA, 
and OVA should be an inert protein in this system: unable to be bound by polyclonal IgG 
and unable to bind to any monocyte receptors. Given the unexplained result, even 
though the combination of OVA and IgG might seem to be the ideal control, further 
studies should be undertaken to categorically determine the effect of purified 
polyclonal IgG in the murine system. In addition, use of antibody:antigen complexes 
provide a more physiologically relevant method of FcγR engagement. Complexes 
consisting of OVA and anti-OVA IgG would have the ability to interact with FcγRs and 
the ratio of antigen to antibody would inform the FcγR binding affinity279. Therefore, 
studies using SpA IgG complexes, OVA immune complexes and monomeric polyclonal IgG 
(OpIg) to modulate OC differentiation would yield valuable insight into effect of FcγR 
modulation during osteoclastogenesis.  
FcγR modulation alters the mRNA transcription of pre-OC resulting in decreased levels 
of mRNA for genes such as Cathepsin K, DC-STAMP, OSCAR and TRAP which are required 
for the maturation of OCs7,154,242,336. Studies that examined siRNA mediated 
down-regulation of DC-STAMP mRNA revealed that DC-STAMP is essential for the fusion 
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of pre-OC220,363. Treatment with SIC and OpIg prevented RANKL induced DC-STAMP 
up-regulation and thus pre-OC fusion was inhibited. However, to confirm that the 
observed changes in mRNA transcription represented a physiological change the protein 
level of each corresponding mRNA transcript should be quantified. In this thesis, only 
OC specific mRNA transcription was investigated, yet, examination of MØ specific mRNA 
levels may identify the differentiation pathway FcγR modulated cells undertake. 
Previously, Grevers et al (2013) used heat-aggregated rabbit IgG to inhibit murine 
osteoclastogenesis while demonstrating that this form of FcγR modulation 
down-regulated mRNA transcription for DC-STAMP, TRAP and Cathepsin K, but also 
increased F4/80 mRNA317. F4/80 is a MØ marker associated with MØ maturation, 
suggesting that heat-aggregated rabbit IgG can skew the differentiation of progenitors 
from OCs to MØ317,437. Examination of this marker and others could identify similarities 
between SIC/OpIg and heat-aggregated rabbit IgG modulation of FcγRs. 
The final section of this thesis was an examination into the role of Bcl-3, a negative 
regulator of NF-κB, on bone remodelling. NF-κB is essential for osteoclastogenesis and 
the subunits p50, p52, p65 and Rel-B have been identified as mediators in OC 
differentiation145,162,176. Bcl-3-/- animals are highly responsive to TLR4 and cytokine 
stimulation and produce aberrant and excessive responses to stimulation167. We 
hypothesised that due to Bcl-3’s regulatory role in NF-κB signalling, it would regulate 
RANKL-RANK signalling and influence OC differentiation. Examination of day 5 OCs 
produced by WT and Bcl-3-/- animals showed that the OCs were similar in number, 
appearance and transcriptional profile, however, by day 7 there were fewer Bcl-3-/- OCs 
than WT OCs. There may be intrinsic differences in the progenitor populations present 
in the BM resulting in varied responses to M-CSF and RANKL. As such, examination of the 
BM monocyte subsets revealed that Bcl-3 deficient animals had fewer CD115+ 
monocytes. These cells are able to differentiate into OCs4 and may be responsible for 
the difference in OC numbers in vitro. Further examination of progenitor populations to 
identify HSCs, MDPs, and CMPs in Bcl-3 deficient animals would provide information 
regarding the involvement of Bcl-3 in myelopoiesis. This would not only help understand 
Bcl-3’s role in monocyte homeostasis but also our understanding of Bcl-3’s role in 
neutropenia, as Bcl-3 deficiency resulted in fewer neutrophils in the blood and BM. Due 
to the decrease in CD115+ monocytes in Bcl-3-/- animals, further studies were 
undertaken to assess the role Bcl-3 has in bone remodelling. The trabecular bone 
microarchitecture was examined by μCT and Bcl-3-/- animals were discovered to have 
increased bone compared to WT controls. This data suggests that there may be defect 
in OC erosion or OB bone formation that remains to be elucidated, however, Bcl-3 
appears to have a role in bone remodelling. 
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6.1 Future work 
It was shown in Chapter 3 that SpA IgG complexes are able to engage FcγRs and inhibit 
osteoclastogenesis. Yet, the signalling mechanism utilised by these complexes remains 
undefined. Activatory FcγRs signal via the FcRγ which has been implicated in OSCAR 
signalling along with the DAP12 adaptor protein. Classically, FcRγ and DAP12 signal via 
ITAM motifs and are regarded as an activatory signal enhancing osteoclastogenesis 
through Ca2+ responses and NFATc1154. Yet, TREM2-DAP12 ITAM signalling negatively 
regulates osteoclastogenesis and bone remodelling216, providing evidence that ITAM 
signalling can activate and inhibit cellular functions. Recently, ITAMi signalling has been 
shown to inhibit cellular abilities; one example of this is the interaction between 
monomeric IgG and FcγRIII which inhibits MØ Ca2+ responses, endocytosis and 
phagocytosis257. Typically FcγRIII-FcRγ signal via SYK which activates Ca2+ responses and 
NFATc1, yet, ITAMi signalling by FcγRIII-FcRγ can result in SHP-1 activation which is 
associated with the inhibitory FcγRIIB ITIM signalling257,330. In our system, SIC treatment 
is believed to act through FcγRI-FcRγ316. Examination of the molecular machinery 
associated with FcRγ following SIC engagement would reveal the initial signalling events 
resulting in the inhibition of OC differentiation. To do this, SIC treatment of pre-OCs 
followed by co-immunoprecipitation to ‘pull-out’ FcγRI would reveal the identity of 
receptors and signalling molecules associated with the FcγRI/SIC complex. Co-
immunoprecipitation allows a molecule to be targeted by antibody and subsequently 
removed from the sample. This isolated molecule can then be run on a gel and probed 
to determine which proteins it associates with. This could indentify whether SIC can 
induce FcγRI-FcRγ to signal via ITAM, ITIM or ITAMi pathways. This could reveal the 
signalling pathway used by SIC to inhibit osteoclastogenesis and also provide further 
targets which could be used to prevent osteoclastogenesis. 
The results from Chapter 5 demonstrate that in vitro WT and Bcl-3-/- OCs are 
fundamentally similar. However, these animals differ in their bone structure revealing 
that Bcl-3 has a role in bone remodelling. In order to continue this research further 
work must be undertaken to characterise the erosive potential of in vitro OCs. While in 
vivo examination of OCs could reveal whether there is a deficit in the number of OC 
present in the trabecular region. Examination of cortical and trabecular bone in the 
femur or vertebrae could be used to verify that the increase in bone is observed at 
other anatomical sites. As demonstrated, oestrogen has a marked effect on bone 
remodelling and its effect in Bcl-3-/- animals must be examined. Oestrogen deficiency 
has been shown to increase Bcl-3 mRNA and thus inhibit NF-κB activity438. The bone 
microarchitecture of Bcl-3-/- animals was only studied in male mice as female mice are 
exposed to higher levels of oestrogen. It is hypothesised that female Bcl-3-/- mice would 
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be more responsive to NF-κB activation than males, resulting in female Bcl-3-/- mice 
with more severe osteopetrosis. The examination and comparison of OCs and OBs 
produced from male and female animals would be useful in identifying interplay 
between oestrogen and Bcl-3 in bone remodelling. The use of OB maturation and nodule 
formation assays would provide insight in the role of Bcl-3 in osteoblastogenesis. 
Analysis of the secreted extracellular matrix would provide clues to the functionality of 
Bcl-3-/- OBs and thus allude to whether in vivo Bcl-3-/- OBs are dysfunctional. These 
studies would demonstrate the extent to which Bcl-3 is involved in bone remodelling 
and provide necessary information to determine whether Bcl-3 has therapeutic 
potential. 
6.2 Conclusion 
SpA IgG complexes and Bcl-3 were investigated to determine their potential as novel 
avenues of therapeutic intervention in osteoporotic disease. In vitro, SpA generating IgG 
complexes of a discreet size that interacted with FcγRs on the surface of murine 
pre-OCs inhibiting their differentiation to mature OCs in the presence of M-CSF and 
RANKL. Treatment of animals with SpA induced the formation of IgG complexes in 
circulation with the ability to interact with monocyte subsets in the blood. However, in 
the murine model of osteoporosis, therapeutic and prophylactic treatment of animals 
with SpA failed to prevent oestrogen deficient bone loss. Thus further work must be 
done to determine whether SpA at higher doses has the potential to prevent oestrogen 
deficient bone loss, yet, the data presented in this thesis demonstrates that SpA is 
unable to treat osteoporotic disease.  
The role of Bcl-3 in bone remodelling is yet to be fully elucidated; current observations 
demonstrate that Bcl-3 deficiency perturbs the intimate nature of bone remodelling 
resulting in increased trabecular bone. This novel target could potentially be used to 
treat osteoporotic diseases, however, whether the increase in bone in Bcl-3-/- mice is a 
result of increased bone formation or decreased bone erosion remains to be verified. 
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Appendix - Media, buffers and reagents 
Roswell Park Memorial Institute Medium (RPMI 1640) 
500 ml of RPMI 1640, 50 ml Fetal Bovine Serum (FBS), 5 ml L-glutamine and 5 ml 
Penicillin/Streptomycin. 
Complete Dulbecco’s Modified Eagle Medium (D-MEM) 
500 ml of D-MEM, 50 ml Fetal Bovine Serum (FBS), 5 ml L-glutamine and 5 ml 
Penicillin/Streptomycin. 
Complete alpha Minimum Essential Media (α-MEM) 
500 ml of α-MEM, 50 ml Fetal Bovine Serum (FBS), 5 ml L-glutamine and 5 ml 
Penicillin/Streptomycin. 
1x Phosphate Buffered Saline pH 7.4 (PBS)  
8 g NaCl, 0.2 g KCl, 0.2 g KH2PO4 and 1.74 g Na2HPO4  in 1 litre dH2O. 
Separation Media 
500 ml 1x PBS, 10 ml Fetal Bovine Serum (FBS) and 0.146g EDTA.  
PBS – 0.01% Tween-20 (PBST 0.01%) 
100 μl Tween-20 in 1 litre 1x PBS. 
FACS Buffer  
10 ml Foetal Bovine Serum (FBS, PAA Cell Culture Company), 2 g NaN3 and 1.68 g EDTA 
in 1 litre 1x PBS. 
0.5M EDTA Solution 
168.12 g EDTA in 1 litre dH20. 
Tris-Acetate-EDTA (TAE) pH 8 Buffer  
4.84 g Tris Base, 1.14 ml glacial acetic acid and 0.37 g EDTA in 1 litre dH20. 
TRAP Fixative Solution (Acid Phosphatase Leukocyte (TRAP) kit, Sigma-Aldrich) 
12.5 ml Citrate Solution, 32.5 ml Acetone and 4 ml 37% formaldehyde. 
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TRAP Staining Solution (Acid Phosphatase Leukocyte (TRAP) kit, Sigma-Aldrich) 
125 μl Fast Garnet GBC Base solution and 125 μl NaNO2 solution, mixed for 2 minutes. 
11.25 ml 37oC dH20 with 250 μl Fast Garnet/NaNO2 mixture, 125 μl Napthol As-Bi 
Phosphoric acid solution, 250 μl Acetate solutions and 250 μl Tartrate solution.  
Decalcification Solution (14% EDTA pH 8) 
140 g EDTA in 1 litre dH20 with pH adjusted to 8 using NaOH. 
ELISA Assay Diluent – 1x PBS (10% FBS) 
5 ml FBS in 50 ml 1x PBS. 
Sodium Carbonate Coating Buffer (pH 9.5) 
7.13 g NaHCO3 and 1.59 g Na2CO3 in litre of dH2O and pH to 9.5 with NaOH 
Sodium Phosphate Coating Buffer (pH 6.5)  
12.94 g Na2HPO4 and 15.47 g NaH2PO4 in 1 litre of dH2O and pH to 6.5 
Scott’s Tap Water Substitute 
2 g NaHCO3 and 20 g MgSO4 in 1 litre of dH2O. 
1% Acid/Alcohol Solution 
700 ml Ethanol, 10 ml concentrated HCl and 290 ml dH2O. 
2% Agarose Solution 
2 g Agarose in 100 ml 1x TAE, heated to dissolve agarose. 
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